var title_f12_36_12864="MAC long-axis";
var content_f12_36_12864=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral annular calcification: parasternal long-axis view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parasternal long-axis view showing MAC along the posterior mitral annulus.",
"    <div class=\"footnotes\">",
"     LA: left atrium; LV: left ventricle; MAC: mitral annular calcification; AV: aortic valve",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rosario V Freeman, MD, MS",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12864=[""].join("\n");
var outline_f12_36_12864=null;
var title_f12_36_12865="Anatomy of hand fractures - Scaphoid";
var content_f12_36_12865=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Anatomy of hand fractures - Scaphoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 488px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A precise anatomical description of the exact location of the fracture aids in localizing the fracture. The anatomical sites of scaphoid fracture are the tubercle, waist, proximal pole, and distal pole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12865=[""].join("\n");
var outline_f12_36_12865=null;
var title_f12_36_12866="Metatarsal stress fracture";
var content_f12_36_12866=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Metatarsal stress fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In panel A, there is mild narrowing of the medullary canal of the second metatarsal, one of the earlier signs of stress fracture. Callus formation can be seen as early as four to five weeks after symptom onset (panel B). After three months, there is well organized callus (panel C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eiff, MP, Hatch, RL, Calmbach, W (Eds). Fracture Management for Primary Care, 2nd Edition, W.B. Saunders Company, Philadelphia 2002. Copyright &copy; 2002 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12866=[""].join("\n");
var outline_f12_36_12866=null;
var title_f12_36_12867="Nodular sclerosis HL";
var content_f12_36_12867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular sclerosis Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 286px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEeAPoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDr9L8Tto0EvlNaLNcFGt1C7YS3Oc/7WMVylpc2Ns128qRwXE07z3C3SEzTtIDtY/3VUHiubN2YoIrdLqRgbhPMjmADF8t/Eeuf0xW9eW0ItXu0e5nnYN95gwcKwUlj6c8AVvyJfM+qUFBvzMnTYb6K7jlspcCHECygEFgWLEknrjPpWkswthdXdsZraNbnztpfAGB1A9TngdKuWeoBoo5bu4GxiCtuwJ4HAK46HjvxWMrRx3EkS+ZcPIm12XICxg8BuwPP3utVvuHNzPU3tL1KW2nbU9Xvbi9024g3Ld5EbxoRgow6EZOOg5rQtNZhgvLe5vx5QMsaI6fMNp+4zD2GK4S6Fu1i9q5guPMbaUhYLuGd5+mCOvc1Y/0X7HayRXIMdpyBNkeaD/AT6g9qlwRXKnuei+JrWbXr9RoyKY4EHmRqAu7PO4fgDxVFNHS18sWqTwxs3nRNejasjBeQOTwD+ZrG8J3n9mwA3DtfK8X7rcWEgJPEZ9h+VdwuqvcQ2trfrvMUgaUGMbCp5KJ349+9ZO8dETJyguVbFCDRlghkUXhDNGZJ9hAZd/XA7LxyOaqaNp8+n2X2GeN5ZZcytDb9Xz9xj6ZGaranq9vc3z3y6d9gkTzLCP7Tx5oOMeYB069evSsafVhAra3FqO1RMPNeFGBuD0CkY3YGeBimlJhGMnozRM72d3BNeiW0SSF0fym3JGQSCrcdMcVzF5eX3hZ4byPTmh066lP2mN496jPQp6KRyRWxcXN9qdrOkeovDbSSGGSMqF2KVyV5x94nH41pXWpWejadJZXsjTStNGq3DSbxbKwAzhuGAweKtadDfVaWucytpcyL5WiXVk+nyW/kBi2QVBBxg9cgYqe3vNRbX0fTp47S3tYUUSOAoWTAypT+IEcVY8X2lpc+IdmkPEukRlo3McQBmkwf3gxwfXrXNf2VcW1qL4TB5rZ1jGMM7Rnpkt3J9OlUrNalRtJep0uh2sd1JLGqfJAC0c0jZa3KZO0D3LHjmpdI1HItrmOeS3SRnPzR43ZUl1x371i6Nc6dNrVpBqLX9hLfSOqMM7FdQOueCDkcjOK0tM1iLUb21gMH2w2CefM4yAjZwBHuxyc9qTQpx3OhjDtAl9akNbOoEoDcqmcKD6n2rG1MtZWpt5vLmEchEsyD5t7dBjsMVdeUJcoI5T5ctwsqIQQwJPKN2OOtS67LFIhSzRSwG0TEBDvJ6MfwPWktzmaszkreWMQX8bzSO8S+XHCibmYHkspPTjkioIZmtfss7lrcWzq4FyNiuByGYc5Xnp6Vs3E0Zeb7QI48jOYo1J2+jj685qC/tDBbyxM8gLopXzgCjL7HoB2q7jvrqIqtqWq3REZd5HYRS7AQiEZ+X0AwfzpksMKWSf2ewmibdHuK4AcgqwHfAycfnTklWASyWcixQ7FVIFbOCQcjI6KaiiNzIqGRoxeKmGgC56/KPYnHFAXYyCGaRTePDIv2ZVSSVU3KMcbRz6YP41FZzwvcScT288n7tkB2xybSMl+vPoO9Xklie1EUyXEDOpX73KqP4ivfvUH2hJJDc2h8+BR5sZZvvJ0PPc/WmO2htyPcvDE1jdwyW0sjCR8gFQAWQ+xPArKkVruWCGzto4bmaHMu08y5JBx7cZz9ack+n2Si4slVIS+Gt3XcZSfmzz0AB7UW0nn3j3JEjHZuUhtjqOwHoDzwPSpWgjSjubKK5W0s5vtvlL5Udxt2IfXI7n3q6kE1oxmlSSFJVEQZ/nBQtjCr2H+129Ky4bN7i+jmdFiSNmUxxnJmUdgfXOOa1biV7W4jEcyB4gGlhck7FK8IAevrUPyM2+iJYJjJYyLZsIYVYgJMNxmI6MT3xzgCq17BdQSIY90l1kT+VcDKsCcNj88gVXfUoXu4J5Zo7eIKdkQXzJAg9CM7SSf0pmmzXGo2nnyXbxy28rsYZvm88AHJ3dQO/HpRZoXK0Q6q4e/1C4sbcxed+6Zs4VMKPu+lZ0ekxlFIvbLGB/y0I/pV2ENJJDcT3MZ8rOB92OXPOWz1GDj8K2H8O6/M7S/Y7xt53ZiMQQ57r83T0q1JR6icvkYV4LaSZ9PlSzvTO0bJJsJJDZIIIPB4P61o20c08YnsFhSBFaMx8kbRyAB34FUpr7TLG/WS9AW9R3Vk2YeSTAxjsSP60aqkcVpBczPfQiQYNrGAPLD87UIPLAdV7etBs79S9Hd2cl7DbmBbEQgPLHMMsmfu8+jGucjnlkO6NpFjZSA+P3eSeFyPoevSrs0l7rKW6398JEjHlxsBgeWOin6jjb655qgkVnvgub68ja2ZuEYYjLDOBn+HnGKaVhRVihptpcyXMzwWrb3by9nl7i+Ou3/Z3enetTUdPfT3tomeHUbuQ/PBB8y257/V8YH1FTpJqjR2v2u+jj1dczXAMQbyIR/Cpzzu68dKq6TvSW6SxaOGJt7oM4VsjJyTySfSndm129Tb0e8NpDJ9nliE0N2ki7iMycHcOfw4rrtNtZ9SS+1e8mbyELMqJhH3g5yO2DiuWsleHRbKa3skMzzuTIBlYUyOHz34rprbVbW50KeC6W6t9PWYssjDaJCTuOPbNYz8jOV3rEp+J7e3h0+K51eWJrG7Tz5IXckOR/DnqD+NYFnpsWo/Z4J9ttfK4nhYt8hQAktjuTxW/qYi1XUQ1jbtcwvGGteCS7L2JPaqF/fwpA0Ly7buG2y7omGwSNo9gBmhXtYcb9NzJ1G/ttXvIrya1AeBsz4bEUqr0LD1AGRjFTDX7B728s/JhlhhRYkLxb/MDZOf9kD3rUtDYyQtqum3IMtpHH9ohRNySAYwOcAE4/WsO7tbq+uLTUrdXt7a6l/0tFUbWOfuFc9hjJ+lUrPRmiaeg3Srm2027TTLuUWGnzRg4uTmNmyMEEcj3wazpreSWZrFbizmb7QZNsLbkO08FT1+7jOav6z4aOq3E7XOJFtwJI17SDH3QOx9u1NstOaa5+xPp0sYeNEhtA2SjHkZYdcAgmqTW5amnqL51g+srPBBHcPanyWgYtjJHOxmJCsKpSXWp6ZciN7xLiLTsvaPDECzr/ErEDDEdK0EsgzOjSSSWkb+QzLL8hb+707etZ+tJJpMsFrd2i27K/l27JJuRG6ruwORQtXYaavYuWk1zLFaAJ9r0+4fzZZ3bbMhc8AL/CVPP0rttPexuNGVbjy38ktGJhz8n94j+I+9cPLY3VpPHew3sMcjR+XMDHwJX4JK5+6RjB9e1bdhe3tlai4EJe8+7MUAAuIemMdAw9e9KSvsYzjdbl/VbdrbYba1tZhDH5qSdVuYiO+Ov0qGd4/OieJftdnHCrLHjdtzyQF9FJ75pt3cxtp0K2v2gRJK0arKcKhJxk4zxVtrqOCe2aGV5pbeRI1SADKj+JPTaeufeoMWnYwYTCZRaG3LXlzuKw7QiKeq8gdcA8VnxwzfamdJJIk+bzSwG5ueAvHHNbVwqzag9skjF/LdkXOQDkZVDxyKyZoobqVd025shMKduGAyTjtVplEd7eqtyzFGaeKILAy/fPqeeDjuKfPawppcL/2fuWXcrvE3lpKuRnbnoR6VFh4J1FvbRTmNzIIjyN46AH0Pem3l291cpbTOkDTN9p3sSQjjsPQn071Q79hkzwXBjhkDlIsKrxjcyLtx9Pl/XFXreNZprAxRc4IadwylnHb05GP1qO6eWPTDIkkjiM/vAQAzA8lN315A9O9QXZuBaLLLcKsDRExwckqO7Ajpijcls27LUJmLidmt5pVMfyIDtbqAgxx06mq8ciw6hIsqo/3ZFdpN7uw67iOhB6isK1kmewt1hkZN3/LXJAkQ9O3U1clmubSRIWAiQIzxuxyznpjp0B/Wlyme2xJZTW58zDRqvnM0rIACc9Amep9qvpHIYdyIhUMw8yRtmARypPSq1lLa/YN9uoXJBbdhtpXPO7qD83pRb7GjuYJXEdtHAQBL8qtIeQRjPYGhhfoUIltWgIe5SRShVCykjGSOOxUetdWGhUAJqV+EHA2zADHsMVg2UFzmGGacSBlDNwEjAP8Ad79OcetMl1S181/+JUOp6yc/yoepLetzrdZ0prO6a6ntUa1g8ycfaUQPCWwCCTxjgYK9c1zmrCCCaym2Jbyi3fZv/wCWZzvDuBz5jKCB3IJJrv8ASpXu18xgt0p2xFZBvDoMkbM9ueQc9Kx77S7m31S9ieOIJPIt35hTKyyAYBGeSRnsQB0xWUZW3Ki9dTndMgtE024+0X0DTmzklt7fzAJpZDltuRwDzz3xiuLtLR7oXWjANe2vlxXEe04B27txI7Y3YxXfXWnKyXmoSzaL/aOoyFIjJwVkChRsAPyg4wawvIhs7RptKuFt4riUoztwvn/xbW7L0wDmtYs1UrLRkenQC3tGu7m3VZFI+yuJWfyyRtxt+hyR2q7aY1iK1sbaG0jnkchG3sdpzhpGPTPHA9qkeOd57g3Mfk2EUXkyo5G6aYrtG1hwOTycdM10vh/TotHtJLWIRmRIVjIbBVSedydy2Tjn0pSlYV7a9SeHw3AGitrbUVmt4trXBeTdEyr/AA7P4mY+o4xUXiZIbiYS6gJobXcr2liW2LK2ernso/XFS3Xl2t7FJBHGJHXeAXGHY9mx1b2GMVl3UlzdXIm8TANbFwjBWDNtU8qoHQcYzWSu3ccU73bF0fVb2O5vI3uS8SqSQVZNh9FYfLg/XtXPXsc2rXyvHLZy7iDcy5KM4HG0eoXPHatnxHdJYfYrhCzwzS+bBpEJzgjhVdv7vc/WoL2zt55raBoEa+trdxIsUg+fOCWOP7uMY75q49zVWi+ZGZcnU47ZpIWhTS4HCPGUAFwkb53SKOCwIx7iooZ7uOKa4Eclw8yl0uC4WONM84ToMcVdheyGkQz3+pCGCEEFdpAYHp8vUmq6wwo8OlRH7Za3q5Ecj7H9QCey+1Wim+ljctr7Y92NQt7m83Ql/LQALID/ABLt6ZH64rO1FdW8O3NpNF58NvcKGi8sqrRBlH+sPoFOMnvUt5ZRXOmwRTQi0gS6SPzLiRlimPPy5BBY5wdqkdKz7jStQt3u55NRTyE3r5NwSFYZI25JOF7+wqVYiDV7BeXkUGlrLaP/AKVKMW1nbgNHI5PzMx6AnHQ+lPs0uRJHM9vcpZNKW805dCB2VDyCD7VlWum30sUFqQ8hkdpp7NSNkUYxh/MUDk+o6YqaJJbm7/s2WR0EKyT28ZZgOQcnOfxq7WKdtiW+NnfSHN1KFRygKxgSAk5IY9Twc4q/Ja3Md5aXZjxHHG8UttBIdr8DDEHox9DxxWBFDcQwQXFy8LJCgDPG2BGN2dxPdv6VvxSyw39xc3iwPD5m1545MwygAbSCO5z+lD02KejEsry6jdZVtmawjhEYdAW+ckN8w9MDHsK3w9rcWxvbMmJJ4z5tvgMFI/un+6a564u7uPTr5pUSK0kKFwjZeEDGDx2NTaRe6hc6jbaeTaXQWMyq1qQqup6E+/rUNdSZR6o17s2jR2yXEbpbeYFtpS2HjPc5+uKwdRtit1cyXawyXCgqsySECQbuvHt1JrrTHF5dwqQlo7pP31uSDtI9D/D61jx+H5xYXFrCFa2t080AOPnV++epIJ5qYuxi7W0OeMUMkSTXaSNLKuFSMqu9AeMY6LnP1qKTUJoYZRZLA64EQWVeT/tA/wB01duEMNrDtty1wsXlyCMErgEnIPbANZ63O4CS0uftEMaeVEoiG4Duf/r1qidtSsgvIJ1heKFY24chyRuPQD14rT057W5QqZ5kaHHlRcqQ2TyQO3tWcLbdZqY45JjGVZfLb5lGeTj171p21jHM9xHCji8GckH53dQCCp6FeeabsJSI7p777Nu3fZETeA0nzMhzyOfp1q7D5xsN5jVrkstwkhb5NoUZPPGCBk+uaztVinnVoWkElmY/ngkb5yTyX45wTx9DVu1nD6ZHYXNvIsTcqxPRMbcKO4BGKT2JsuUqQaZYxwMVIsprqQyBYX3FiPvdfu9RVi4dIriK3u/JEu3zVBbaEz3x3OOx4qq0yI8Bk2L9m482Ih3Ofu5Hb3FaEt5cR3ypcpbyys20GUA57EZ9cEn2xQ7g3fckhMFxGge2czgF/tQYfKg6KB03H+tc83h/UJWMhe8Bc7iC655/GugmFo63kUN35kUhCukZCqoXgZHUdOCDWWbeUnKq6qegDHgURbRDjfU7jwxc4gt/srxWqSqRcQAF3+zr/q+2GIOTnP8AFWLetrUUBuVEUUtyzqTESpbL5CkEfLnGT15rptM1ezlW0l8h9KljVoghIwp/i47dsela9kYEkW5urWS4hKMFil+dT3DEn+POP/11jzWd7Gl3DochYy+bpzia3s/PtpULeXJlw45CZI455z6mq1za+ZcxjSbwCKQiabHII53IfXtyK0bu0MalIYoPOuFaQRmPbJIw5JkI6ADoD1p5F3JpG2OzgYWnAMJCySn0x1Axnmnfqilvcjgt5YDHPavYy+VkgxJ5gyVJHPc98VK0+oJZXE0qRlkj3lU+R5H/AIct65pobTGt7eLTbeUNIy+WkchRpH3gcAdh3Jqtcyyw30kUomuJIXYlA4dWY99w7DoM9waW5pGN2T38qQ6fa3D3MME02IjHt3mIN0Bx0Y9qq6vbQ20tpZaDDFb21uxMrysGaeQjJye5B7VnslrNYROsotpUmEjREuHcc4D+/vV1fJUSXupJB+8XFtbxjcSSPm+Ucgk8kmnaxdrEd59rt5xHaXUFi4Ug4AlZ2IyQcZ9eT2qrZwrffbLa1d7u5SLzCYl2YdeoGe2fzrTGim3smuTaw6fOCEDQ53hG9ccKTU9xa+XYtPHLHOsoVMxKVYjuMjqfendC5/6/r/MzYZm1C2aaQLa3YgVJQoAaYKclc/w4Ppmq9zafb2le1jV7WdWXC8su0DcXPYDNdBPJaXcqwz2MRhjUN5ikBsY5GR396qW4Nld3Fykc9paSW+fli3gLk/eHUk0Ji5rdCPSrkXVnbWJMT2lohkREG1Yk6n5j3454rON/bG8F3qEcV/DqalbCSdi8XB2ttXHTA28+lbZdI7aWC5tobmV4ySjOEzkjP+8RVe4itVt2RJpEntYv3cbwoEjUjll42/lzQhxkjAkVrbT4rW2lkyFIkSQhMx55UHOMDPAJqpJBcTXeImiCRx7zJJGJXAzwuwkdfUE1tSQboSl3IFVwpiYwLJFKvdcYOWP/AOqq1xaR+cs8qzxPNl7fPylGJwpGORweh4q0y+cy76I2T29zbTxWj3MoGUg3/P8A88pE6EH1JHWr0YgupjJpFqkF+oBlsycfIv3mB6N1HyjpVqK0ktY2e4uLlUJw2QrCUg/MzL2x1qnD5VsBPKm6FJg1vJECWUnqV/LtQJWZfgv7hptt1YxRbiGjEafIysPunPfvjtUFvpllLq7wyfvoPJ86KW3k2xpJuIKEdwMdPXNWILqO2FzbxtLqEV8vnJ5/ytuU53cchtoI/nWfa2tq99JJYrOGFuZRbM4iVRkkkHj5s560hxbVzS0u6hs5dMSK3lijdmkk3tvLA8Zz3HtW/aXun6e8t02mw6lYSZhlWFsvbgdHH49q4jUJkAtp5t1od6o0e85UnIync/T3regt4tNuWsIpBHf28ZZnA2xOrH+L/a570pRJqRTL00Nte6bM9u8XnKrb43biQH7pC/3uxHtXM39iIo5JLW2IRCifuFzH0OSV6j8M10dvFby6iZ7q3CuIzujKkCZwOGX0x39aiSytLCSI3LSzG4BErW8hymTwyg9R2x2zRF2Isnc5CeyE6Q3FnJbh5HC+SzeXJIoONwPZQ3Hviq+mSYgRIEljWB3USqf42/hHcdK6DW9HkimmvEgW5tmkEWxiuQg52j69ay9QtIoHM1rOwcupeONclc9AQevvWiaaMmrFa3mku45pEkWaGP5JSi5K4OAoH8zWisltGzJbzxBdqgv5RDRt2B9QP5VREU1s0l39oEfBjXamx356FRxjv+FTQ3UKpbyyTpez3Ebr5URHDc7SW9M4znkU3qKLS0a1LMUQW9tbYy288SIy2+oQJ1LdHbuOcjpxipL/AE26uNPKPHb3iW5ZnKnLAqcEA+2enes+GFrZfOgdTLbDfdRocF4h1AB5J5+tXZ9quk0f2yzt5v8AVxENsJIyBjufp3qeoJ203KksEP2SdIZHMeEkklkf94B3VU7Vpw6rZmFDiQfKOCR/jVK/gtoJ1RVkWV9rFiCJGwASGJ9+h61myWNl5jb0AbJyN6HmmlchtJJHb28E+ry3ccq+bLckSySwrtX3K5zzwOPatNVukkMYuluY7UqZDO2JHIXPygcY45rnbXShPYpcQkQ2olNzbhxiRXOMKR6Dnj3FW/IupZri4vhJFqUzlRGmFVweOeeCRWTR0NJmxFcrqd3Jdw3VlAJPmkAfdtIHcdvWqst2ty8W8yvbxyFpZbb92/tvJzkH2ArBnhW1tmitonjj3eWkMafvI3PBwfr1NW7KHyJrb7UrQXMqN+6STIdeOCOmO5o5bajUUiV7mVIBOJEgsYy0ZwQsqluQDx6dx3qOHT5LjyvschlQH5NuUHHO0jqTk5/Gql6sFlfTW9xfTXV5PggrEQkR6AKBzuI6HHvXSw2hhgW4a0a3imGwEtuccYJY+vfik9EW5cuxUjtprmC4tZciSdvtEiFANoHcn+Qqa3sfsEl0wniEciqbIlh5jMSNxJxwRycVLMJbFPsyxpdtuVUZ2yCOceYe560l+kMlypcQB2iB85eNhB5yB39+tSQ2W53hgl+yLE1zsi3u8rbWZu4A/rWf5t5C0c8kRktyVEcLcLGOxyKtCW1a4tbfy3nttjZaHBduOrknhf1rPuZILm4vpRchltfligX5FQnoOOSM4polEguvt0X2l2Edok5DRlNpJB5H0zUc0rGVri1luJJHYFGdsBEHVduPfg1Kl1F9llkvL1oi0IDOjEtFJjDKidCD61CbuyjtGge8jlAj82RvvM/90E/geO1MV9TYsTDGtqJUt7y6kj+Q/dcr2ZeuPr3qGdDeajZrJeJcXJSSNLeaLaBgEFM9jjuc1hQ3sj6o8tt5luEAkBjG3z06HaepBzkCtCWbTtQQ2yQubdVJZZJMT7ictyeOnQ54pONgS6jk0u1XTGWeGW1tRIImVW5zz8x9G+lVbUT2d9dWRvUljfaVkkhOWixwh54wccjmtCW3dTBZ3t1bT5R1/fMQYk+XaJOMN9arTJvjnQ7YBBKpEsOSipuGS+cEY9euM00x3uZuqJcWvhyLV9Xv7ERteCD+zrf70mThTnOWGMZAxxVL7DBb6m4tbK8ikiZlV7r/AFSRtjKqe49D9aXU9K1TV7e4uFCRW1jcPcx3ErBGWNBlpI/VSB3xVSLUra8je/1GGaPUH2C2MrsVnQ5xKBjvg81oloVFWW9y6s8Vzfm1tIp7Ge1ZPMS7G1rhScEofx/Kp7qCy/f3Iu0trYL9wDesmwn7x69ap3u+/uhd3j3AaXyyI43/AHiquAryf7O3sMnFJqEjWelXP9nKRPEPPt5o8NE53HI2jrn8xSsaeQXOlFftAuJWS/u5CyvKNyKowU4/h71YLzWeixSajJJMWYia4KZxz2HU1Zt86ulpPdsz6iY1kW4ifKo2Dnepxg+xp00uj3ts1s19bxzQW5nW5YENK2eY8DPJ5ob7hd7MyRDNqDJcafcSbYQMQlvnIzyQT7YyK12u3spPt8lvBaJCoEyBSyiPpkHPX1qrYtFG9mzIwt2VmtQ8WCpI5B985/Srk0t3Y3rpYllkY7opbkBlkT+JSO/akxt9DZFvpgNvcWKi906XbIIAxfyiTnPGOCefxrC8YWj22oBTDONMdDIGVQWx6HHQA1s28ZtmubZbRnjuIwY44n2/NjllPdewFVtVnhMEPlW0x1GABDHCCXXPseG96iLaZztanJPAPkN5KIbSIlSxfAQnj884GKyLi0eDVPsAWB2ZC4kPyxKo9x1J7+9dFeRwq1wSheRvlktlBXfGxHzA9B9aybqyiguCLaFEmQq8RdyRCq9yfw69zW8WZyXQqTNE1tNZGOW21IkPHck+Yf8AcGMY+hzT11SW5mS31ua8ktbdyqLBgOs5ON7ccDt+NO0yWEz3MPmIJ5Q0kqyLtDLxwh7t9PWquoajBqmoTo9tJaJI/lRM7MEiZTlcjGRnHTFVYIp3uuh0etRXUcZjvn3SzbPJnYiRJWU/d3DGCByfasDytbH3I9y9jsByKtaff39syWNtNFJG+XHmnKyEH5gR2qZdWtVUA2yqQMELc4A+g7VKujSMovWSOwvJZrCwjtJIyYigmnaVTuaI9GBHQj0qpeNbadeW4v7j+05I4/8AXISCqqQNxXv+NYWrXlxJoVr9ukvDLCSi8ZRypGAV6kcnjPatOZ5JL6aO2s/s7IFknmZPlKlTyozwM4GPWo5bGvI1ub8jSuXMcwIuXUb8YPIGGHrxgmjyJDBbCKyE7wxFUfAGGJ6Envxk1kWc8jWLLbyXBkTd5DvHiMMwwVB9vvfjXSy5mCaZehBc3EYmBVsHcn3hnt1HOKzehD0JJreUW8xWZILpyP8AS1UM8jY+bn+EAZAxVGWaSOzS3imeWz3qUhaIs/mZ9em3v+JpuqyPHfwW9k7Nd+UJGjJyifLglR/EMcZyOcU6KWLTbUyvHKA7q08pT95jpkjPA9aSQkVL+x+7M9wyWkbeW5VSGdu+B6Djk1JcSW1reLIz7IZhsjEaAsMcNM5PAxzwfrVPW3nvNKDaZcJbOHJXzWyh5GVx34/KomtF1C0jkisnMh5ktw2efuqwb6cgetUl3G+7Kz3stlO/kESxyDELqu1iM8s+OD9TxWf9p220ymOM3wXIDH534OVwO/NSX1tb2t1KtjORGdqb5JMMMdQeOMkkfhWfbQSJA8tvNIWdjF+9+8nv9cZx61qkg16Fm3DjRlFq6KCdzySSBmQjnaB13dsUW85a4F1HbJAkvyHy8FJffa33T69qz76JfNItZxDLHGFBlXO0EdT2J5zntUunW4trVTAzuyfNHmXCMvcjjoDk/jVWFdmzcTRz39iLaa4AjPlJIvJhYA4CqOoB4J6YzT7a8vkiWN/sz3clwA6pFuVueeTyM9azLa1eytpLOG5iaSI7F8h9zMx/DjIzUktxMUEc8AWcE7MN90KMgt681NhJ3VjpH1iK+txNLaQw/ZX2/ZmYEmTuy55fOB8vOMVT1WG3SYzrNc3BVnluoZMorh2+7xjKjP1FYkt3s0s2s0sbwSjelvLETL5jHkEg8ngYPHWtRmt5rpVgkFvFbQR+eFf5hKB8y5Pdjx+NLlsVFWH2S6leafdWtzbKmnXEotxJM4IUkDaOOQhGFI9s1g/6OY4rOJzM9vFzHMxIRSedh67cgcDpWlqOpxy3WmG98+C0s8loI34k5J2njketYkOoxx+de+U0MpmM/nvIJElU8FBwNnbHXoaqKZrFNLY3lSRbdhCxd0iCysGG5JCuMqf4hnrnjFWLTRlXSLV9KjnukXJkt4m2+RKeDIzj5cH+6Kz9PvmvriGGRJ4lin3MQwBPGVUNjn5fmIx2rpFvtDXxDqEmjyXcI0+1WVreA/62ck5c9sLwT9ah3Qpcy0Rk6NZ+XpkyAqNTuWSacqrbY8EgBgeWJBP5Vam8PWGptcTR28ttcW7kL5K7RKF7nPTJFW4bVIb+5v8AUJRBCoFwGifLFyeVPHTkV0hjt7jUoNU061R4VjKXXnSFQw/vZxwR24qHOzIlUa1RgStLdrbNKn2eSycbbQKWaQ45O6qlta3MN3a2+otmEq8sLzj7rdMD1PPTrXRX93Ld2iRtdLaPCWKyTJvAH8I4wSPWpIomvdOX7S8nlovl7gflnf8A2ePlpKRPPZHH3MM0M72k85EahRFIz4VTu3ZB9G6e2a3Le7D2vl3DTQ3MEqPFMGw567lBPUdOvrV5tIiisj9pkhaPBLQSneuccAemfx5rnr60vdPQz2wSUzbY44Zmzled2fcDGKd1IfMplyaaO5sVY2u1pMmaVVJXA6LgdM9zXOaxpyKXnth5ivCCyuSAo9GHVlHSrthemxvEtrm1hgtZmMizrKfkU8Bjx79K3Pstldx+RciPzvNBEgfIcgYBB9xjNO/KTKNjg7exuLxXghaF3tMfZpbnbGvzdkJ4PTjPpWUJSwujcxzRzqC5MnzlsMBuY9mrrtesJYdUEeyW1W4TYyBwF9ipI6VzM0yYeCSF4L7cFeWQ9EI4BPpjj8a1i7mTVtzOs7mSWcyvbhpJG2B+AQBz+B/nV2TR8yMToVqSST81wc/jzWfqM7QXEYsIoktQ/wA0UYJDgAZUt6H+tZr2FozsRLdgE5Awf8a0SvqK56brTG8sBHdpFbajZW6RPsfepAP3yOrOat2eiNcr9ptdS/0xthu23kI8GOcL7tilgSGL7Pc3JQ3Fu8pV0TdlRjYxHcDLZq/pdhG2n2kvkAxs6MkwbbkkYxt7gsRj2rmbstDrbtoWdWkEWnxiCMxafY/NsJxIwboFz+ZPXmoSZZLzT5I8QyECS8k2ZGD0jBPb2qa6gV9dtzNcpNHGhDJjKvIWIwfTbjp7VA8ptxHbiVGDOWlljOVL/wAQAPpwM+9SZ7KxdS2RrWVLgxqzyGQzxLlxzkxgjovas/XLq3tke2kkcpjeYSxyy/3ePapJIAukiKxmkWecqfJ+6wxzjJ9hzWV4hMt7qsK2Jtlkmi8oFzkpIB958c4oitQjuYglm22lzDMkqRtsUzN1Zskj24HWtSaR0nhaO2laKElvJgudolymVLDPy84HtSfYTdadJeE2Ekwl8pkHEYRO6kdCc8Z54qO2+yzWluDEwnF0zRFEbdtCk4J6EnGADkZrTcqXkWphNObqK4CNOHUzCCMRqNwGFMg5Yj1NZ+mtp9zayEwyQahZsyzO5JWZn5GFHQYB5rQNhNcNcWMc50q4uVAhtGRnYtkkBm7k5+grPBt1CQ3ZvPnkEeLVQ5OQdwdgOQDjp0poixHqVmtvEttK0qrsEhHlZVjjdwWwOnORSy6abMhLMyTpwpj8oIzBh/yyI5C+/wBa6C9sjYxWkk108sdmPKS2k+4E+8fnbOdw+UUzWdRt0VBBBdJb3pH2aGN1MxDcbB3ABGQB6mjmfQPiRjSRKsE91cR/ZlZWWB4wVREjIySDj5s4GevPFW/7MuX00Xlrbs0c+2REu5uZGPORnr6YPcVnWkD69rJt727y+dsazNiNcfwgfxN7fWuvhNq7R2ck00l1G2JyhUrEAMKqKQTzx+JpN2Id4uxySw3FncwxoWgkkDSxyRPkH1HHQjuR6irVvMZbKaK5QmO5uVAaOIMYsqSWUDkgEAGn67bra+JoV+zTW6OhlmZ2Crk8YjPQf1z7VVt1lWOymSK6ifzJFIgOTGig4Jx0B6k1W6uaJ9RLr7Np2mtK0/m20LOrTxj/AFrEfwBsAntjrWBH/wASfUZDLbokW8jIIcyZxtDYyBGBnpzmutnjtE8DXukXULPbyXMN5FcH/lmxf5uexYdMVmXsYt/GNvpk0KQWF0jR+UmCTJgcqD8wByOvHWnGW5rGW6I7GC1v7oPHcO1usm7zIFeNfKHBbaQDjPcjpVvTzaCznbypoLh5iJWjUnemcIR74wSPTFS6j9u02ew0251NW1WRPIklt4w6xxqvKvgckgce3NO042d1Aps76aG6jxEW3q0MYLEblHUsRxjtSb6g5aXOntdXkTw4klzOi+dh8Ov71UT+Efw9x3zUd7rEl9Lb/bzMplUNsDquR1G1QcAbeveuFmuXk1EWs9vceTCfKdY0Yrsb+LHuQM9xV2K6urXULh1tkPllVLshcJgcIe/3fTHFR7Oxk0lqdZHrdrAxYW2GuHEcaqwIj/3fX6+tbXl3N8Xhiu5YYbcBdsjbhI3UZPQr15rg1uNllEkVzA0Dt5n7uPiMg52Bj6E9PerNj4hvpI722vGScyQeekq4QxhSOQBwR6gDipcOxPLfVHWx2ynUTJcz2lrDt2l9zMFOem0jlT39KW7ig1OyZLq1WdUmEjtbH5XYcYyf4cYrkZtbE1raXC5mS4lV5WdMvEQMHb/Cykj0romW01G0tpI725gD52oF2LKf7pA6Y/rUuLWrE01uYUxa0vpEuTIY9mI5o4A2ID03A8E9AT75qLRpooprnakTTxlGaB/kIViNpx9CORXRa1p6JYvGbsvPsAi+z/Pvj6hsd8Y6Vz01lHPdxTXBP2nywXu0ID4AyAQe3f2qk00aRkpI19VW21YfYdUjT7hwJnJVm/2fWuJ1HTW0toYpEItrxcjyzkyIBwAfUd+9dFa3UEk9xFISL+L95FHlSAD1OT3OBVZ5Pt12uxinlKMk8bWx99c8ZxkHHrTjdaA4dGcpBpS3F1CpuIpNOwQ0e7YHAHr/ABY9D3pbnwfP9pl8vUJwm87dsgxjPbnpWrqPlpOiBmcSEyhBEMM3Q7eOCQPoTVdbuHaNgRVxwGJyB7+9aqUuhm7LodmoVoYxIUWJZTlyvPGMK3tzW9aeVm/nezjt7yCZIIhzgRjuo6AACub0tbTT5r92DMsloUCByVMmV5wOnFeg+IrjT7u8tLeKQLAto4mJO1mAUndjrxjrXNJ9AqSaklYy7u3htbNxLbRkyDASbhpQzHLZ7Eisa4Nwskc9ti5XyyoZYwoAONqgZ5PByasW00t7YJJctujgKsGZvuRkAZOeuQB+NNtY3NnbyowYIy7gQQ0ajPzYHXtQtAStuZGptvWdAPKuspLMkb5CkkZVD29/euft54lvr2Sa7FvDMcidxkBV6oq9c9frWrrtwBYskdu8kstwX81PlkjLPn5COffmse32Jf288jwOyu8QaTKCLAyWI9TnHNaxWhojX0vUmn0e4EUTRi3LS7mUD5V6ZHpgk1Da281zDdXmmwfbrO7j8xC8oDT/AN/b/dIGQRT9Pjt7+7uLaxhWIXgF1dQXEm8LCvAfcedpz0HfFRzPJZ6ZbJpumI1qJnRGc7POGSctj+MNyGHUUegNli6ia/sbeGPz7aS3jRoyzZUbSTtJIBI569R6GnW2rQ25t9NvGeZJUeW1kZtkrHIzE3H3VGTmqaa5FLFKZxdNPCwEay72MDJzuCnhgM8mmXST6hrAbUIZTdtCNt/NGG80qD8ylMgAjI2nuRTt3J8maFlqU+nzTjV4InjRMRTxQeYJFK7kVhn5sDAplvNDHpawWMM9vKEM4AGEgcnlSOSoxyOT1oudU228dtYSmO0uBG06TqC9uVI/doeiuwGc5AGcdqVGXyvtFlc3ccVjNuxazBH46JISQXJycnkelIVtCvZxiWeS8tYi9jO5MV8g+cb/AOLy/pkZzxmrjQwaFFbGNJbuK1Bbzrn5FeVmOyMsM5XpgY/KqfiaFNP8JNdxyGJbedZgI5GVoizAggHHDDJ+Xvipbe0muIJEcCeOSTzba3jkKNJvQMSwbAJySS3QetPfUaV9WZviKBLK8sZLC6ubZWiHno67mZiSflbpjn8KIlCoLWadog3EhjQqjk8OrHPAyetWr5rcTWtq9wY4YOTAXMhHXnnjOfTgcY61j2c19LBHFcog35l8tZiFHzAYIPTGc++KpbFq5sm1iito7KKSNJLcq8G0FxGqncQfqOlVJ7i/bWQum26ebeXCTLdSoA+0AgrnPBb+laFvf6nFB52nAWyCUDzHAHn/AMO3Hpx16CmraR32vRi7jks4zbB5IS+w203OxgfTrkUr23KjpqzIv7hLB4J7iJ7Wd3kIkKbssuUIU59ahu4LK/AmkvHSe4Mf+qTKqqHJ3AYwc5I981Jdzz3Gm3Tai6zC2vDG8oVjEFCH94AR8uPXoTx3qhpt0JlLaWXN3djyw6pljEOpwOCT6dqpIbjp6Fk2s0V5HB9okjZdyIUG9scbXJyOTzSLp5h1F4bi2aaZceZKkuEQEcEehJwT19K0JLWWbWrLSoYY3haEGGZWb92yg4DHrjr0qxp9vMAzSI81yWC2yIMCRyOQ2fQZba3pzS5jF6GNZQ6oL3yJZrebT85CgbQJP4VUjqD745zUrXTySvftPdRoMpGWGGswvRiAD8p71oNdxRrqEqSwRwtKI2W3k+beQFfCrwo4GewqRdVlt9eimt3MdvcxeVLEsQ3ywkce5yep+lF/ITu2VPOuPtQuoYzdllXD2/CqThvlPqevToas6Dqt086W8sKiaQjM0xygJJwxHY9s+1Z1ys1i6TW5aGG5lEflscqdp5/3SAOvpVe3i+eSNULRytgbgd0y552nt9fai10P1PQ9HkHnyWz+TLMn3CVx5Q7xZ/ix2ar2qaMJ4vPgWPcHVLmBB1Q8Y+vaua0HUYBciyS1Km3Be3aSc7WTB3qzZ65wRnrity2ncaZNaZL7dtyUfGRH1+bP3sHpWLTTIaad0ZcHhww6lcWdvdrD8v2iKVh95P7mf6VziXd9aRzWjAyWyzK8czNyysfmVlxye/UV0rafe6rpt/cR3vmIkrR5kOxoGwCApHWsxBHclbO/ilW7eIuZY0wHZTwp7hqpPubJ33dxXiBeD7VBHJZXDsI5idjBxwAPbpWPLpmn+a/7qIcngPxWws9pf2SWStdRSSqwnG7cy+hwenPFRkRRnYLLTiF+UExjJxVJtEqKW5Zsg8iTz6czx7Im2uwDbzxw3bpXW6UJILAR3ELXHmoxjbZlo4SpYHnnGOMZ5zXL+HoVtrmK0swkhaWS6miR/mc4H3R2x6V0Xhma7trO9d2F1H9pcIwGDtbICZ74zn6Cs5hVEtPn0m2XzEFqAZJjj76jop/wrHtry7b+0DYTRRRSkMZcEsh/uDPQf4101pYfZrOzsREoUMXXc2Q7licMfT0FZGlPMwkNyY0kilS3YuuNwyTvHp6VKe5N73aMXXr7cbVkXyJkj2LEOu0N8xJ9RyAaw3ljj8i6gDOZCyNNKAx+gHY44Gc81t+J3le/naaWfBuGjjUgEpwfyz1zWFazK+niaT96gkZSxARt5G3AYE5GAOccHNbR2LitDasri1m+22sMES3NuRcW8ESnzZYwCPmPTbluV6Dis69vX1Vnniup4UsXiJjhXCMQgDogOenPPrVyxt4bfTdQs769dlhRA5s3O1pic+UTjJU4ztXP3etUNb0P+zbb+00mia0nJaUyu0j9OPLUDjB5OaFa4o2uaWo2VlP9pFrPPeJPkPKOWtvlB8tgMHJzz+FY9tFe6JOxjdYI2BtxDcz5WIAg7lPToCAOvJqpovid38Qf2TcBbmSRCltdN0UkfdHoD3ausudOjSXUY0tJTbXNwdkbkS7UUj58nGw4zzz1p/DowacHyyMzSJoG1CONUaQPunkNtIrW/l8hVkUgsDv75qdrcWtu6XDzeVJGY5pxEAN5OUz6J2z1461Ys410m61EGA3NrcxpI0ry7o1KtiMlcDJGBnp681TtdOmu7PVrhJxqtlPukSGC4yp24xgkDDZJwvTrzSFe92NvVvLi1UecltEYVWeOZ1lWTaRtVeOSP7w4xnipNKvtQFzDBdK8rDzYopDHuEZZMlRjBKkGrOnWEF/pJuLkSRGFdgZX+ZCw6rng469e1VN66DI1vJcWM0tvEskMkYJ84ngEcfeJ4I6d80eQX6CeMkM8cSWkRSNT5auyhQpONyN3zwOKxpZ22vtRFk3BWGQrFdpzgHrjpWjqqbry3kml+1RBElj3SsWQjOSeMd+ntWVLDcXVtISIzFIzbZS2Jo9vQn0BOAfrVx2Kj0NWCG5X7RbWuNqqshaY5WJSASQfXHHpmkhmkTUVvUjeGC9t2g3Ft/ngEdN2cYzyaoeHpLiPUfIlPli5VZRGD8sjDhvlOBxjPWpZQh1GRZvKFvb+bcSFizbAcZfaBjAIA6859qLalrV2Zpart0bT7e3ZFuYw5CJDmVJTI2RvI6gD+GsSVrm11uzMV1ZwwxFvMIYRCPdxtHovr3FaOoGS3stKhmtiRdRJPIpckLkD5wcfKR1NY0umx6jME8nypIWN01yeUdBwQfXOM5oiu4RS6nR+HmibTJbiF53mM5S3mB3FUX+HPYYJyT7Va0ucIZmuNOmNo8rBJNxjCRnrNk+g79xxVfTbe1SKGG7laycxkMoffuA5R07bye/pmm6nNbX8drbPIrOE868QOzQMe4Zsfd7k/pUPVmTV20S62v2GOI3ljbzRSOtxbyyReWzx5xlguMrgZ96jjuLR9X8q4aJgsYmWTOyTDffbB6KpwABjOavX8kF7YW32m2Js0KSALLsJUkgso/hUADA59e9R2d9pukwyR3jktJN5arGCwYj+JywGVNJbC6CXl1aWV0b11Ksi4ddnmKQRhWYfwlhgge9ZMtqzWCXFtkmGbchjmBEZPUEdcdPaujlmvJ7y4jsJRb2u1Z5/tKjy0wuFKdwOgxiqzJB9iuYI/Nwuxw6QAgFieeDzyDz9KE7EJ21OXNxNp1xbDUbR4WDNMUU5IIPyjH8QHU16LpFzHqV5HefaGM08Ya489AFfjnZjHbpXFR29wkufPSVLlMLOGAMB7L/TPvWhoEebaOC9mhiul8xizPjlQSqEfwknvzwac0mhuzR1E2mIi3NnFcosckG9Z1bIlCklSB0BGTnv0rNit5NIVrnzjJJOHaISnMZkIOHZu3GcVZglkZoL1Y5mt5FxMgG4x/n/AJNSXqA2l7bXNm4SU70yML8wwC3sCQay8mVF2VjgNVvU0a8uL+5uo7xfLiSZ7f7yEnt79jWQ2s6dKxkSRgjncBz0NdT4lEdvZ6Ta3NlGbBGW2eB1AwzH77N1JJOR7EVmtNo0LGJLJwqHaAI2wAPwreD8jojJbv8AA6TTiJZrU2Fqbe/ieR/PyPmyBlgR1A5/OrXh+WR444oCSRKN0cJJ2RqpwW/3gNwqO1tV1DU7aW182AxyOy7TjGQPNAPQKcJwc9aj02a4jW9nKCFlgDwBGCkAj7rD+Ilcr7ZrJ6mctUzpIdS/tO2uYXhMa2M5IYvtkLEAqSB9Rz0rOe5jvneGUSyXCHLKyZCr/CW9+v6U7V/IcWBs2+yw+VujhwWZ22gsn4e9UrS+iEzXlncR5e2j+dWw8vUBWBz78dfeoS7GdtLoz/Etysv2SKMLGIl8zzLnjzQR3b73Tg5rCuEhgsktGkhWONZJCgQqV3AbsE9eMY/PvWrqawQvsvGmdYl3rDImFZ933S/r3x6VkeTfz3caRQQulxl2ZJQxcjvgjkL0yMDit4rQvRIvaRDPFq1ubK8eO2W1E0e+LeZGJ+YREDAbHUj8K24oLgak/mXkiWrYmhMqMAAzbTkdWOD0PH4Vk2KLZJaT3c8E0tq7QhY8rHHGw4XOflAPU+uKePEZlitbENHcG3Ets8LcvIAC5de5HGc0mm3oQ1diR6JKmtMtrJaS3cksaRW9wEAml3NwqLyq429qVHL3l5pN3bXRu1WQPJFI4AJYMxbPO35eM8DtW9FMLZbZBFNcTCNGtNV2BnjkP8DoBnavfnOCOazrq21R76XU7yAQ2Uhdb5hcASyRjjzQuMqhYr64zRzX3Fdt6lS/s4dU037ObzbbpCWQRsfMOe7Y+Rkzzk8jvUN/a6fpmiWthp01zAigS+QiEySl+Pq+dp9QK0YpkhnjWwt4pmmhMIRznzOMkDGM4+9jvUaQu8GnRRuokRxIBE2WXk5WMnkPxwDkc07j5na3Q1dOMUWh/Y7e2STT1hkBhmJ4RhxJtPO76fKBmsmOFZ9DUGFTHBCoSYOka2jD5UiBOCwcgHd0AbA6UrES6hE6RFp/OPlJKD9xeCHwRuO3PTA68VILm0ivrmKWOPybrMaPCvmxRBhgNnooHfOcVOw7MyopLp2mLRSoQd3zlSqMOoUDt046ntVFZZZp7MXbwfaGldpo2DFpU5JIPY8ZxW5q2oXAvXtTt+0wpLCJ4mD7mAXD7QOhB6+1Z9iz2GkxxRSrFHJEGWY45k9dxBw2MjHvVp6DjqSxWVvczi5yJfO/d25mc7kkP3SI+y9s47Gq+qTvp+p36w+faxXKR2saBgY48Z8xWPdRwc+9WLC9Z5tXijtTbTiFFghQb3aQgYxJ0GT83TvTdfje0V44YrH7EtspBmc+Y8jEblU5xu4HbFC31LW9v66Gjc3MX2H7Egmkt12RqwGC6bfm5Pb+faszw/GsIlLK/kCNiEYBMspJCbjxsxjIPvmrE9okVszXbyCR2DIn3mLFx85A+7gcYqhf3PnzLbWTIiwXPmS5OUkjIAfavUkdSM96SXRC/unQuJUhltbHS7R7SdGeM7SzKWIJKd8cHrz0xVQS3cEd1HOZLe0aAtArQFVjCnkuMZy4GBnjBweakW5sYpfMju11HeUizawOxYL99AQ33M7TkYxio7mVI7qf7ZNMj30j+W0B80xkAja2eAueQMdcVJF9RYtTS4ZYb21ktmt2B89Y0lUsyjPqgAXb8tTWha91JIr3T5buwQMvnu6vJ5fUSKPuk5wCB0yMVXurdbLyld3+3CYW5mlt2HmKyjDYzgN15xVbT7+JdLmQmL7TFJJKY1k3MwYgKUAx8pGeaLaaD5b6omv7949iXMShrlxFEJLhXZ0XnbIQfkCj6ZxUVjeyCNrV7oW2nzTlkmt3O8jAAUn+5kHisvxKlnqMli+nkLO6fZpEkUhiV+b5V9gMFs889K2bK1tbbw/DLqKvBcwkPEblh5YGTuPAHHSqsrDaSiUr6A2jLI8UUgBEsyQ9DnqBj2yeO+Ktq1mNQtzZKkisTMDKcyP8uB8x6kLgEHnIqSe2ivLKK+jMMvlO6vtOPNb1P49O1ULOYBXt1t5JCSZGiVclWHO/d2I6ehx0o3Rnrsd7ZTzN4anhSVWZgImkGCVYkkcj0/rUd7cyLpsd1MAEWCMSruyv3cMcHjrWXoVwbmwcXSoFXIcI2GYH+M+uK1vIZx5M8CvayKY0ZT1cKQOO4rBqzFszl9etDcLc2WpQFo7m2YpI+Rsfb8m3P3iBg8Vu2Erx2Nuh8QuCsarhrKIngd8iqWrPKbjT7e2n3wIcNHKciBwo5U+h/Ss13g3t+6V+fvA5B96tao1SckXo/JMNpISUtUMg8wnHyNjk+rAj9RSpYXV3r1m0kES3BtyHwd2wKN4Rh3YhcH60yS8W50qZZo0WzijZhx8xZj8xx7FRV/SbqC40+WVVmZXAmuGgzu84DA2n/IpNtFtNJlpbiFI7m3SANaSRfaYlydwJHIHsDmsa8RoIQ0Ue6aNQBGmVVM+/dj/StWy1GJNMW7k8yS6jUxZjAIXcTxg+meT2qrI8t7cJaxmO4t/MZ4yJArSkDIOPbuPektGQctcafLp9qz3LOlq6jDIwLCYLk7++QAce9V7fVpBIZpYYDcFDGRM+JSpUfebuMYP41ua/LHqOkSS26xf2pHy0b/KrkHkBRz0yRXKTzWsc08i226RmRn80EfvCMHr04AGPato6rUHqtVqdPa20LzS213B9nhnPzMiA72I+Vn5wT1xnHrxiubvtLBZNMe6tUjhIikuJy4kkDNj5CFyxJOCe2e4q3aBrWxN3E0sMAkZ/K8wSCYj7272GRz71r6ZPdXcsIhYIfmlN26LK8MbL92IMDzk446daeqJfcs2Wpw6cJpbGKKGS3Vd+xfluEXhWJP3TnOe/HStA2CtEVkeOOaa2mD3RIkQq3zCIEkFQCowMY96wZhb3uqXFu1nPJDuEjRI21ZmUcc/wufQ1YsrfyrG/hvrWJ9QtbiMIkrsrLFznemeQpxgnrUtdSWZ+najJbyHU10v7S4to4jcrOMwkIFYlDj5hyeM4qKfTzfaZOs80EkabhEVkCgR8EPgc5BJ/Otm4h03Q9XuLaS2jkW7UHc6FwruMjaR90tn9cVjQaVI1zLcLY7ikgjhtoI8hw3DMJR1HHIzkYqk+qHp0L2oXRuLCBPKeJ0kETSRtukUgEnDnBLHG3HQhjXPytPPDc3MSizjH+rjiUqiqflcbf745wPWu0uNPs7W+uzFbm4jmEIW9iuUdUIUhv3eeGXtxnPWuTuJdS82Wyma4nSAlykUeye6jVi6yYx8pXjPfjNEGuhdOzWhLb3Cy3UYWeeObynhmvFhCGKNgNo68j5TkHGc0y5mlazKeREJL5gTuGAqgfw+gPTFX7eCK1mu5Zmmu7QBHkaUkZUA/eX723J6+1V7BHuo5IZSs1w8BuLZmOxQv3gRnoeApHcmncLJO5d0uaRLGzguXSPY2zfKownOQmB97Oevan+KIrya0tplj+z20oZLWNx/DxlZD1X1FZejXUr2iKWg+0wubh4Sp+8Rho2ZuAMDOR61vzXNxDp/2m2MkjXbkTWsrrJI5UfN1+7kEYHtUvRlLfQaIjp+kxeUjSwpEEnnADPtJzGxHuOcisyKSKBLO8uYY5L8NvhkHKFFJJdh05B2474pNMnh1bUpHP2uzFzbkCQMP3Yi+T7o6ZXIx75o0G2hvmNhcSyRovywmGLBZcnGVPb3HNFrbkyVty+q/Y7GaS1a4g2wZmFmf3nllhtCr0wcnK5549Ks3tqsVzpl9EwjKI1tPLJ80jMzYQFOwyQc+lZlpFMBb7md7Pm2uAr+XKsvO3gdTgHp0q1r15aQWMZljSC0SFE84OTM6bhwd3zElsYJ6fSk9xLcp6RfXc8kdnr1o7W8100EcqSlHAPDkD6AcUhsNNeHzDazR3UrCOO4aX5osH+M9NpGRjNT2trLFfafrkV9KtuAGlfyDKEOSBkkFQQAPmFRX7fbfJY2os7eW6aWUW7CRCV6sUOflbOcYp9dDTS9kaFx/Z8cS3F5PbzQQjyba1gxExbP8RXO4Y49cVc03yktkUyIyhg06vHvjwOTGB/dwRx3OazdM0q1itbmG3xLC9yLszpD++j5zuVSPlCj09K1bxLQ3kr6fcsunyrsIQiN1lH3Q6tyoY55PB5qHbYzl2Kt4lhYWrjyIHt7gCXZHMfPjz1BIHA9hmueitLmye4vbbMtmyDy0hcM6sTgFg2DkdfpW7cadE9peSS2LWlw7DfcRE7A/Uj/ZYY5AwKyLETT6k26W3R5FWNZX+UP8/wDEOoGO9XHYlO2h2OjJOLKHe1qxWIIV2gSOW6lh3PHWta51COR915EYbe1KQtOTjaw6n6Z4/GsPwxJaBrqJoP3drchYnZgHCt1PPJGRxV+8mZ7+e2KCWGYL9oSUEAnqMD8OlYyWpFtSh4hkhstHeXU40khy00Cxn55CCTjjP3unNc3DFpMkKOmszRqyhghQ/KD2rdeC3lfdbjM8hZWjLnCEdNo69Mcjiq0klxE7RvJZ7kJU4j4yKuOhrF8q3HiLy5ZInKS+XAzpIq8AHHzEdx7VZ05p7CwSYKyIbmWJ5FH+sXJKY9xgcVTtNSks7a9eQAixiRCQo+eM7snPUdgR7CnaXHLcqAJo7KK6tUkRZejuCAxC+x71L8za11qX5Nk2mXUcUKGIIrhWX5pAzEHGD97dnisw3g1TT1T7V5X2MiSRGTDnPBjB44PH5VfhtBd2pgupsSG4+zrcRjm0PUOB3IJzxRNoGoW8qT6hK17I7n7XOTzgD7wPvxQmkRpcyrxHe3wYkae2k+Uv8v7ojhlbvgVzU62p1JnSWYtLkiZhuVSRgNjv0roIriHIlee4ubdx5bRA5CKvzbR7Dbkn0GKwbjdFMLu5ZprN59q7RjGccgDqAMda2gKxuaPZaeUso2klNtIGS1nmcQkoRmQ5IIwGC9uc+1X9Qgi0jw95kMxsLiVcymSMuk64+VojkZJ4B6fSqbBDq6PfxpdWXlDy4VCugKkbfLGe2ec4/Srnim6iNlayl1e9E+JIoXLtjrlm6deABnAqXq0ZN2ZHa2n9kNC1/Jc7raPdJeMc/aCw3LhPbOCc54qKea3tbYyWtzJ5sWLi2byCwLE8KzE5Y4ySO2Km06acxtLMyKIZfOUyL5aqTwFC/dJOOefc9ahu5Lmy1oeQs0VtaM4850Co5I42A/Kc9+e1G71HuaWqQLNolyknlX2oLi68+N95VWXqwGPu9QB0x7VYsUjRYpFlebTIEJWedtjxx4BZto+8ck8cVz2mzPplvezLcGCQFZxGPn2928rtuxk4qnc30g0i8v7qAy77rfHdElZowQMDYOO3J6UcvQOXoa2mTMmqqF2tZuzRW7SrjyWwWz/tKcd++KoajBJDatcW6TPf7/JlnhOHkSXgqDzxzyccDip7eOOWK4XzJ8S2wcLgHeeuWB6e/eptDu40ura51CWe41SJltpGt0Cq6MOEViRuABAI9Ke2pSdldMp6usi29rHeSgMV/eupwHUfwhv4gO9ZupOJbeRLVQwZ/s4z0JwcsD6Air2pG1jvDZJ590Y907W8g5gTP+rU9AG+vaoXIn1Nrm3uB9mijGEjXah29ME89OCCKpBYmgjkto4n2IsdzbNCzn5wixrlpMcc+nrT5Ipori3lu5bl2vNwimTCmJxja2OeCM81EI5ZEhlaN5UjnEqhGO4KcMwUD2OOavX9xPLpYvNLQ29wWMZK4JCLzkE9zzn6UioblbSNVihv/ndZHcvFMQuA8r5w4Hvnke9RSWt3LZMzkpcW9wVjRGwOQAcH1AGfxqCy1UXQN8bOzCpNi3EsXzz59W6gg1tPBIbKa2tZ4zcswnjhMXLH+JCw646j60noxyVjPEi6hf2l0hAvGRY2lQ4QKPvAr/e6fNWhqc08dzFdwwR3cVuXi8yQBthIIKsegwpODWLd388LTG3tYIzHMI/lBaYNgj5eOMfrWl4ba6himsb2OD7LGwcWuRGC5X5XcrncSxGf7uaGupOyuXTG9hbSLOU+zMoi+yOxCWyP/EQOhb6njHSsnUmtLSXUZWllurhispkjGVhP/PMrxg5xz+lamh3MGjm0tLu7lksHSRZSrFmSTJJ2n+ADPHr3rNupXaFIrudry3mdmnNu2Jpih43S/jn04pLccdyPR7+5k3XOo2UK3CB2DkksFCn7wBGBj9K0m1Nbq6sIwlr9nv1JhCqWSR1+87v3xkbRgc5rMMtxJqFs1mkNxC7gSLIwUqvpIT6r1b1ree7WeayhlgW0FoCFuRHiKfqcBeuR0BxzQxT3Mm9ZE1RrbzLxXMLG4ZuY/vrzt75OMHOak0llv3u7VbVnuihRJ9m0cH7p56gdKq2tyo8yaCy8x5gZJNsnytngMe5JznGOKLVSl0lpH5qmNdjxoSdkhORhvUgjrTtoRqdNYCU6eFuIoCJiscUgl+cnnCHjrwa0bWMzXn2h3aNwGkZAeJH7/j3x6Vi2Ukl15aQgpc78LI6ACMjqMn19e1at75ccd6IbcywKimNVf1U5Ibr+dZMTI9e2Zt4UiEU7WzzJNHwJyCSUPpkVBbXFgltEtwJPOCAPgg/Njnt61PawrcWMRSSRIAiqsbAsy++7+9nj6Vy8tzZRyOgaQBSQB9qk4/SmlfQ0jDm0JoPPk0qW6vGgLyqUnVMjzEOMtj14HSpoHtxpllbqr7FH2fz3OSrswJOT0GRnFHh+zZLqWExxNNOrQkyLkCPGQEGeGOP0qHw/enV0tLDUUTdtaYsWwTu7Z9Q2B9M02dHR+RtaSrRXchkCyAsJEZzgSFW2uWH8J2gEfnVy4tjNYPc2cs5CK0TKWJDfQHqaxdpnuZ1lkdZFXCP/AHH+6Vz+GffNaSXiJpYMcrPK8SSYKEoRnnI7N61DXUyad7ow5tMZ7jThbl4RLblpFxhXYNgAehPf2zXOeKbua106+E9vJBEsiiRUYGNyP4UYdD3z+B6V6NfG3mn/ANG3i1kjZw0YztbsvuTXJ6rBDLBqqzWwdJFHmROS3loAPmC8Ybv1rSEiVe9zlbe5Fzbyy24njguXyLjGDCuODgdO444NdDbz2eoWWnebLHcPGpWUxMImb5MJhRjJHGfes6zZrYoLeGaOI5zOSPkX+FlH8PfHXvVu2/f2V89lO3KmOS5GI/LDcYJx8+Se2K1ZMjSs9StZLV1i+1+XbOHmuZ08xQT8u3A+X5sADjqDTdXe1ltLa2gmmeEOt29jM5VoHJG5gH6rnGFp0k0mjXs+nTXEbk2sNxM9tHuE78gKPTgD6dam0i6jRYRcxvLcIpc27HA56SO+D0BPGKjbVC2s0VLKW2n169spFeUt++NvENvzE8YB6FuB8uBzVG5KWl7Fd21750cUYjfz2GwZY5Qr1OOBntWve6Uz37gXsEM8h+02cs/zs7KvIV+MKAM8isy8ngSBFkVYpIWdI1WIjzkABeQ9dwy3sRTTvsFyLUltPPa9tQNPnhAMcf2gyJMysMkNnnjPyiuntrmK9kusWxtrNlSV3dDGp3Y5QtwBjnjkniuQ0d7HVb6QWVzPJKd0MkMkgKkHnAGP9nO7ParTP51pEILhY0tpQHSQ8unQZPsaJLoO19Ctf5t5NLWeMIYVkjMo3g3K5GN+TzjPH1qzfM8EfkhFDOpZnXjaCccZ+8xzTdTkvL25aea7S7df3flKu0RlscZ79Bj8aqRRPb3QtLuYtBGxiEQG75ycsxPoADVIpdzVsJU+0Ko1Bo53gWFGj+VvLLEEFeu7OenNa5ihmj1K03vdR+R+7NovERUgk46/n61lvbSRWiXljGv2fYyzXW3LbQxAK9yf5VeguGk0aFLO2SYSEFJANkxTuue+fWpYGdJcRz3Xl2lu6iZQYxIuXTK5KgDjO3LZ9qvwm9SeSzt0KwBYjKYmDFmLHaQ38JIwCOlV5BGty00oO2KZUzB/ANpASP0OOCec81Y1lP7JuVuNLRfss6IZY0GcYOdsnpSfYtq9kiG3WNriWa1Z4FWfaZeJG3IDgr3IOT05qta3aCPfLBbG8kO7d5nyy7uAuM5UZOc1uQW1nrMGq30Jf7BdKrIpPMcw6EHjA68Y/GssxvZCSa6sJpnYYZoFwxG7lyex74pJme7J4LZbaDfbvKgtSBLbeWGbYfvHbjcxBycnIIIq1caL5yRh2t1WaYREwMBFJjopUcoaoyxMs1o0cdzcQYYxTTLsZHxnc3Jz705bmQ3Xnpcy+YUG9kG2OcD727rg9KNRXfRlRLW7htbudrRVtoFdLqGP5vJXzCFLMc5O7BPYLVuS8mnjmaSdJhDF5QLA7hxkOo6A8/TFVZbtIb2R9OEQSfEqRZPBA5Yeozxg96ckzrcqbYR2if8ALWWZsmRj17cUx2e5DbrHd5jlmCyb12GNCohZVOR6ncM/0rSiE6pDJbMogaNmdWOGkYjAzj+ID16d6kN3aKbeJ4MSR/P8n3Vb7vzN368H9KryXVnZSXE1xHI8EYJkKt8pc8ZVu4I46deKTdyd2aOkX63Nu9vbCNwYv3bElsgHk56GtOzEcJJeU5XdvVsK0xHXC+lZWmN9t06CG4u7aGEB3klQbWjQYIGPXnsearveNfa1IIjCbuGMERjhVh3ADB/vYqGrsPI09F+2tq8UMc7bZIpJGifhY0OSG9SaWW1Mcrp5mn/KSOQM1PpV3DcSXF9O3lxyFom3jLkKPXsMfnUSWukzKJdzDeN2Nw4zzRfUqLszHv8A9zrkE4uLeAukc8hVyfl5GAO7c9KW0s7W4uLmKx2ReYZkiRvk8xoz8rbuwIHU+tGu29vamwjaFN2w4lzhsnkj2J/pVye4iurjSvJtzJvsnaWJV5QKcZJH5Y96p7aG93ZWMi8vLSLTru9ZpVuIowtzuY4UAcKvbl8gHqa2fDuuLc6DaXlrOT8h807cb1OeMH0x1rLjtLOSK5sUQHT5VQzCY7ud2VOf7oPX0rWjshYabZW9sII4N7ISCNuwY459M/rUytsKVrWZYZnbS4rt7loreRFV4UPzq24MDx0BA/Os3X1a5e7R3aZXTHDbX3EfLu/rmrfliZppX8q4NurRvHGdqMmc/if5VUitp76zuvsYt7l2jywjbOyMc7W75xxnNKOmpna2rOQv96X00UZt/N8tFYhiwdOfTpWrpU6wQRiGSO5kadVMEyqPLK8iUY6AY745qlfi1S8EtuYza+Zm1RVPmOACCPwJ6nINX0uRdaLIq26215gBpZQqrL9eM+2M1u9iGhbqea51DVZdOUzmObeZowWTJUAhwPpwTxVh2u7TR9Oiju4Yjebs3SRbxuLDcrHpuGO/NQ21hcWpvlglhgnFokJEEu1VJJO4n7rYz0xmtyWT7Fo9toJdEt4EW4KoyGNYwRumDEZ5JAJJPJFQ3skJtqxiai8NxrwhvZLhih8szgllY7fzBI6A8dq0Lb7YthFbtLBtuUlW5kkJRIduMkE8r8pXkdTn0qhNqCrNLcvLJ9mvHIQBB8oU4Qk49APmqnazteM8LPKtvJvRCw80gcYJxwec4FO10Kxk6VYafp5cO1r5HmESOshLnAPysf4ecdODWpaQvAitPNb/AGZ1LtGYS4UdQwGOu3FVILJ/t0jQJapbgedMsuAz4/hZf6jHNaEU77EgtmKyNIJRHkGJkP8AdJ5OB79eKtlq9yiyzJZzmSMfYVPy4PVj0Iz90D9M1pT7LWO1aVlceaGlA4HX5SQvRveoJxd3EDLNJiykkGEaIsYx3Jxg84qV4Lc3Ony3RuksHZnEir/e6cfxdeR1HtSuHmXbC2uptYt/7RaO2s5A6weW+1nUEsVVu/U5qVrqS3tnsLYmU7PMXylC5JJw4xycYxgevNVbeSx08JYtavqFwhd45FJ2Rx91GT8rH1ND6qiywJqSraXpTzYooYyw8tuAqsOmMUjRRLdnM9wkb3cMTAACdpAArMB0XH3T9KW41lmheTT4LaBkLj7OV2ljtHXuykfnVOa48y123JVJGVhGj/JG2xuv6Zz36VPNJc6laLcKLTzpo8QylxmMjh2JHRdoBpNdxuPVo0LJy+oTWs0aR+cI/MwAqqFBz5mOnXvzWzZ6fdW7rHZ3EP2bzC6SSsHLKeoZOhUdAK52BJL7TDKhjmEo8mS4hyDNIv3ceoPPzH0q5o2oCeGOGZysKs0YkZctC5blWA7k/his5LsZSQ24065vIruNBA6BimE3hzzwFQDGDWNMk5uYbX7Hc6ekg8xo0XDI69UYHqGznPtg9a6gv+4aOG4n35wjxoWPB6uy42L6E1cmuo5rWSUpcbZG2O+PMMZ6bl780KViL2OWtInuL6Dy4VQqry+XLDxtweflBGM84HSp7e3muJC0QOy5O3zS6sG9SBnp7n0raE8VncM9pdmEwfIuwA5yOSSc8eoFN1LTJ302KYTebHtMhdNqqfXBUD24p8wrmYyK2oPZRyi5miztFsNyrgjJfPB9MDNLf21rO0VvLHCQgLO0TAJGc85HQHuPQ1Dbm8t2tbZiEgl++YsZRc8ZxzmrGo3n9j2d3AqxG0mLCZZYtrw47ljxz79qOug3dspSziO+is4giWllLtLuQw6ZA/U9KgTUmXRhFdRxoHVjFcRooOc7ipI7cZ49Kn0yKeW1kE0J/eDzI5PLAMSD+I+vXqas6hJBYTrHFptvdwtaIkEjMQCjkEy7O3GR+NPrYfW25nwTF7qzLrLmX52uIcNHIoHy/hn161HLHE0jsYEBJJOI2x/KtMwRxXXm2ke+Z4SsUIyAT90BQONoABJ9c1cjurnYv+nOvA+XYvHt0ouWn2KPjJIriEPJKYPszCQsPuFfTFZN3bzwNYzWe8z3TsY3H3RFnmMCrfiHa9nJFHKjPGRyeckgBTz9DxTba5V7a2MUkoNkxWcqctIScYUdjk4prRHRC6igimkj07UFnVY4SywHy/vIdx5x344PsK1oZB9gttH0yS1WFm81FlH7uL6n3waz9KRUuZ2MmG5c7nI8tgcqPcnpUzL/AGekE1pp+6GOBm2O4CupI+ZvQjP61LIluWdKSaeO/h2xI0NwJkVDy0ZOF2n+7ggVryWsNtbS2kVu0KTZZ3jOCB6g+oOaxJJ/sOpRzaf9lkkjj8ltjloyrnJJI9M49K0d06w2MaeU1whkhMhPBVx2z2xUPczld6o5Oaxmssz3BiuIYJMM0cnzBD3Hrg4+uafdRwpYIRdby037xnGQCRnbjse+BnHrW5f2tndwSJB9lg2Ey+Qg5ZT3VffHGPT3rG1GFYbK1WLCLHOs8rz5Xy+MfKR6+h45rVSuTcmm+33VlbXU1y8rbGhjRxyg9Gx/CfX61l210R9oSEx2rSNhdseVQMcBgxOSmM8Y64rUutQupo47ezVQi/uTBgoDGSTnf+J4HFZkzWr22+5t5cjGxlUqysfurtPUcHIFNCXmYlytys88dzdlfLDxq0PzNEqkgY7ANj9av27eWJUi+W3KCaTcMMoIwCR7kHv+FOjNtcCVZJ9rlcFokKg45J2+/TNWYrZrlwYJbN/tWItn9zHRyDwQvPJ9au49dyA3o324UQx3cY8uTb/y13jdsb+6BiiwS6FtBI8RuJo5CoUnaMFsGPcf4R2GOanjhbUEC2EcVtLdfvLgod3Od2M98478Vakg22sEt5FLiNmYBwGPP8eOhI6+3ak30NUtNS0bMW+p7rOCW7mTaZIY32bkbopIzgZzyM1BPaQxyyRXVstuAGEyGUuizFhgA4657UiteabHBcPI0UUaocwS7SwJPykg52/X1p97LNaGS0aHyZr7d9pJwQoAIDBuit6EVOoct2U7vS76TUbyxeBLexkVFaUESAfKMhTkY5z9KhumuIw0tldFIWKxn94SuzoQOOD0qzbaIX8PCKGULpcUm3z5nH7yRuoI6n8OKrRWd5e3TTWcLpoVsQhuJmZA7Dpgj6mquXFLqblnbae+oRPdSsGhiw0TfKBlcAgenYYz1qXULO3hWG4l0+3F3HhRbsPujqoB/iJznoOtTSWVtd+WZYTO0K5icH5ox/eUtwTntUl0ZbRU80edcKRIl0uJAWxxk9cismzJu7JTYSmzvc30Sy4ClYwCoj/usMj5hxz2qjAkcdxM10ioRgbpI9jPju3OGHcYqY6VaRzC7nU3D3KmSdwwGDxlR2weOtSyQm6u4IfNlMMJV0srllYQjGThzzgD0+lK4ibT2FkWLwwSxiTAe2yH2MOv/wBarheSJnS3Zoo513xQXCjc5H3iOeG5rImDpcRPFfMd4Y24BKjr/EB1FSaffhJzeO1pLFhWW5upeXz94gHsOAO/NKxLRJbWjKj+QWkijJyJAGdN3Oc54POPanQymRILS3gRbLOSizEunr85HH+7j8a0VuoLmxeOMQAPIZY4UTaZh1OMcZ7n2rJvZYHWK6vkhiXIMcSZVWIPQ47/AF9qE77k7vUktrmKzUQp5FpcGVy9wqc4IPv1qgLbYsCM6TWryea00g3PuB4OP61LLfySQvN9kgjmaTLPNEcMT0/d4x+IFLJJ9q065knPkXUG2ITBgIQp9B0GPaqWgWsaFvOI9TnntZJQ4jLxLKcqWxjPuF9OnPWuavjcHVtOleFZ0eJlmYnDccnn0yOBWvDf21toM0azKrqnlTXTN5rMueTFnoDkZApmo2BuVD6UisvlqgDMU2KBlmz1PTntSWjLjaO5nae13c20bXwUy5aRWEmXjiycDHb3Fb091pInkH9pkfMeFXgc9qx73ydNvodUtJbR4pZR5kUfzGTCDP3e2B1rMn01LieSaGWbypGLplRnBORVWUikk3roXNfuYA1pCJVt9RkXy2bZu+Y5OPp71WiK22k3UznyjPIm8BTl1UYGB1Bzj+dY2nSb9TfZcjy/M2K7fOHJHB5+lbuvXsFrY2swke4uQixwtGvDyFCMH0561TVrI6uWzURxPlaNNIyK1vH5QVA2HI8wsck9epqzY3y6dCdR/s5rhnmM4SVyoII2krnjjPK9OlVbLTGt7SztVuVW5a1AZV+YK5Ylt2e3Napji0+3v7PyZhDMjbCFB8vdj5lGeCSO3FQ2jKdmrGTpGktbao8JuT5V0MaezMBzt5LLjoeuK19FvP3kQd3KhnaOZoyR0CEMP725W49MVg6ZCy3Kz3syXk1rbpFcIgCkYkVVkHPJUYyfTNdVcXBayRJpkuhLehVCPsHygFQpxyecnOOtEzKbu9SzJG4u42hSAhQWBZfl3Dqp7gHOevao0063vvNAVYRc4jmIGV2nuVOSDmntJNOI5LUvC6y4Ikb5onUcqQfr096svHFcWjyokQvY1MkBVsb+zAj2OcH2FZ3sZSRz+n6LdX+lyRySKseXDF2zJhThd2MccdvWtS4sLeR5Vv5PMvSAWtyMZXt83YYzg1ajuZLYRzSzTyybAJShwABznnqeeaj8v7fO/mgQyMGXeOrDHAPp7YzTu2TZ3MLVNMjDvcW/lK0bKuxMLJs6ANnIwOnvVaOzhvGVcukkMJM1zNgLHvJAOABz8uMe1bNosaPBAYpJiilT5fRB6sTjJzxxmqGom3ivUS7iCS3LCNDu34Yd2Hbr1rRN7GiXQbDp1rYWogDRXXmBmn8p/LCpnohPSppLfUbqezRI1aKKNo0h3DbtIzgnvwetNOmRTTTeQq3V7HAriZsxZ+XGQPXnipNNhNnAJCzRpLCA5dAXcZwcLnke5xSbNSvdWEEs8UGjlL2Vp44ftT5RYRzvJB4IHarN9apYLf3FvaSX0cOoNZ2sU6mJLoMrb5Cxz8inoRx0rITxNDdam2nJaLbrYFpprs7isynA2omOGPb8aTW55tStLC2t7K4tbG3gkghVpzNM0TuGIcEDJOP+A+tNJj5ZXSexs2dvp+l2No2oWryTtIfsYdSI5WXnjnDAHocc4qLx3rx8M+F206OCG123YmitHQyOZcc71z8q4PFaFrb3UcunQWdoGnt4RLaySyKwgZR0ck4I9q5jSbm11nWdTuNZeyl1O9t5JpbmIspIGAFRQCAxx1yKSV3dkqPM+Z62FXXVu7jTI9Hie3vnhQ3sd2CQjbd29AMYXjGPeup/e28cU8VnDJMQysVUhUBGeOcHOfTg1gaFNLcCaK707TIIUhRYmjh2uOPlyx6HHGaltTFeaotxdSS3AiVVgcSFGbBwyMoByOOCcU5K5Uktl0Ny/vI1neLylsc7UWErw7/j2PrWekdjqLSh4YWuIiQ7rNnZzgru6baWSG4u7FY4tRure3nRkbz8GZFBGF3Z/wAiqstpbRwCSC5it2jYi4nPysxzjGBnIqURFIfqZ0t55ZpJbkXcca20NvGv7ooOcqexGTn1pt1qmiWTJ+9ihkZtscdxGNu3uQD0Hp61Fc3sZsppLhvKgjUCFnAV2bPGR61kanpOqapIs+tQwNax7WEYk5yQePfGKpLuUodzrJEe/mRLWGaLA2pKV2MqEct6c9OKVLNvst3YywS27lw26R1cO3uccZ4rnnDSrZJYWUrkpsDXEmFPHJ4ztwfrW5Nrcdtoot763kju2K+Wlo5ZRID/ABZx2xUtNbEyi0ZFx/aUUE8Mrx+dExSZFfEiA9Cc5yPpilglW800pHbKLeAbZ5Z1KhuOmM4OfzqezntrjVrpbhWFyuGSa2b7j46v6ijxNLqtnPZf2NaPLNKMbBMW3ykcOFIA9DnPWq8hrV8qJzqsbJDHNZRC2EWy2jjUKWfsWz0FbOmLZ3DzLCPKuprJyts8mW6ZYY9PpXFNp0M9z9m1iSRblCr7mYqqMOcZGdxyTyK6WA3CXNqDp8BMUbSrO7EgxkfNyBkAn25qZJdCZRVtGYN3FPbwaY2kyzLJGhkmaSEKQh4IC459OKBreqIAkX9jiNeFBk5x2rRSG9ubqOaTHnNn+z4zgNt9CPTPc9q1k0ScIvmWp34+bb0z3x7VXMuom0tzhdI0Ge5fUDp01tBJawgTTzSDy42J+QD64YUupiCxmLi2lBgCQyRyTnYZgwMhQ5wV3DG70NR3Noz6fd6bdI8FnHIpuLo8B+cg/h/Wuihh0mGS0lmugbRllKyv86xyHlVU9+cdutU2+p1Sm077nMatcOIrcteL5k8UkqmFeAdxOzjnI/lW2/nnT9OvbdQG+zr5U00+9lHQFlz0PPyms1raS40mRmk23kLSBZFARjkZwOv3s46UaeUGgXNh4pjngknaFSEGHQjdncPf5eKGKTTSLWqRJc69DJcLBayPCIoguUYMo+csPQgHHbmtm1Xy47WRoY0meV3aNiXEwCgBht4VgAPu4qtaWenX9tJ/aAhCIy28ZmY7kVeCc9eSOD6VJr9nBY2b3mlyiW2JjjYxTZDfMQXXjjHQ+wqb3sjFtXsdPEVlmsZrySK6t5GJUMrLOzDoGbvjuTyeKq3VuRdENbhJgw2KkpCqpPOOeR346fSsu0uop4rNppZ2mPzxxt8qgj+I+mc1oAMJ7iOSJbSJz5g83Pl++xvXvis7WM7WJJlU3Vwl4GNxMuYxIHRWOOcMOACMcHrSWMYOnvPG7209vITFHKSdy9wD0xjpVm41DUYEWC2eBVIAS8fDMF/lk0yWMvZJNaLHJvJ+aT70Pb8KXQm1yrZ3qxXDlpE1CJEacwPiNgGY4XPB4z16VQihlt7X7VYWcUs10drW8gJ8sMeMMeSR7c81e8jVYrT7LZeTK6rtcvIvmsScggY+b6elUp98Oo2n9qRbiqljDCxwknqT2q0XHfQsi3njTztZ3LLb4Lqjhuh+Xb6Dtirs9nJcNlYrl45GWRkO0LA3UEuPnx/sE4z2rI0WVYleWbUT9ijkw0jpk7icqMfxe1aenaiskt5Je3NrCdrSbJSS85GckAY6AUncqV1oUoBeya5HIk8MzqT5v7sBQB0z9PUetEtpM7i+F88UxZ/Llt4gYSCcEKxG7HPrVae0uorBNMgEaWchFzsOY5JSTyjHJJzxgDFXL50/tRrcy3FtfuFfywR5cahTlWGOAO/rT9BOWuhQ1KyuLErHKYLqxTY62Af/AI+tzYYiQdD6DOPWtC0FyLW4eGy0mxEYXeZSsbRdfTG4n0PpUdrqiQnbEDcSghAsa4MgP9wHp7VNeaNss4L6CaQSMwd1vBu3tzlW6Y7UPzC/RleWOey8wTpcXyzxqeUBAwMgkr0B6Z96bA9sg2QXlvpsk52pGo81weuwHknB5yfWq0mv6hDpM76kA9q5YSBRkIM9OK0LiKUS2F9pkBWNkEsjOoG9QO2fun09aevUrVaMethBcW0GojXRfCfPmQraFT1xuBxjf9atq1nYysZNLnlRsJDPEA3mYPKnd0NR232vUNP+1/Z57S0J3eS8q7iR0DYHy5qtHh4nur6SaC4kbLxJJlY0AxwuOc9jx1qfUhN9f6+4peKf7O1Uumq6Td2rId6SIf4vfHtjjpVeKx0rULZZ7fUpoooShdZiS0pHcdh6H61txvKdDdFmw0h2/vVwqAng5OeajuNTlXS/J1PbFj5Vka3AyPRcdvemm9kWpdEV9Q1C0tdQijkS0tlHy+cWOwq3I2qOc5OD7U6S6U6o00/lyaY21ZJY9ohweGYMeh4GCa5c2Eep3MrW9vbwyt8kXmgsXOcAgZ61r2zapa6a+nNbmSCMlJLbI2tnHKnH6HNU4pFSgraM7mDw/wCFZrae5stWuLW6WEDzJ4AAVPXGBhz7jNc1zY6JdG4jd4oJTBBMzbmeM9W9Qcc460uhTzvYyXN3LJKLZ/8AUuA/ljvnGOavJeXsULTaRdhYZQdqGzJSM9g2SfmI4zWdrM5FFxbu7+v/AAxxCxm/Wa5h85LK1kKQWjP+8UDGZcn+Hn6V18s94l3a6TFLCEaDLvb/ALx32jlM9we5HSsVzcWF9/ZuoSWU89ym6OVEIEQY8g89f84qXUIUtYJY4prtY0cb3hwZYVboM/w57nmrlqbSdzbsILI6oLY20NtNcQYuA0rMY1P8KuTxkehzUM3kRzPGt7qxVWKjCnoK4tRqEGstfCa9wkySNJARNHGigDbJwMZA4PvXYRT6lNEko1WeMOA2z7PnbntScbdSNU7o5LVWl3wrnMoMdxdIVb5cZ3B8D3Uila3laS406E3S3M25beYEKZWLZd2JOVXr9KmjlmjcBZ3JPLM3JZeMA+pGD1puu28d0mELxSNI7SOGOSNjZx9e46Vpfodq6Ix9EnazjkS2X7Re3okSe4X51EUfAZSegyCM98V1UdmdRubHUtVBiZZPLlNycYyPl5GfTpXP+E9LSfUbF7VjDceUVliJJhMeTjA65746Zrr7aAalazvbyuZUmaVPtADKjdMADggds880pvXQzqOzGpbWlrqENyLpJPMhaB7kxbiZN+3aT1GBkZqprGnRtr+kW+nzTQW8Upie2ADRBgNw6dSxbrV3WZE0/QobW9kmeVm3AQqoUEjHU8981nWF3HNc/wBnRiSOV180SKcAYHPuCQO1Qr7mcW90bD6XepPM7W0tmslwztZsTIMMOGGOg4PT1rH1HVYBZOl/PPLYFhFCrfdR84Jfbkjb9O1X2iu8SywXs8bRgrK3msTsyAVT0zkVLd2TabN5LiFxsEruFGTGxxtxjrg9aF5kp9yKSxl03U2sLS6X7GqowIQuJQw++hAO7HoangtN6RjVFlun4V4SvylcH96v09DV4lv7PMzAWyxhliS2JAUKM7uejc9uKzYNWacW1tdz3E8eqQ77G4IVJYG6tv24B4BHGOtK7YczRoXC2S7/AN5aMkcYBigDwqVPRwMenB/OsWJYk8mZnuZbCbmDyQiu75+6zbs4+vPtUN//AGjC0Km8824lBKu6jG0HhTgdMDFPW1vrHTT5UttLcmUSCWSIAK/qFAxVJWK5WupNqcs2oPFi3trJgwV4U2soUg/OP9rOOaW8soDLbLcTwwxrtjRRJgl89guSAe/1rOfT4Ly4ixCsglkxKZHZS+OcfKcAA9MVoaHa2d1LdrpsH2KeM75JMiQkIeQpbJGcUPQppxQWmn3cF/eXk/lXt5IMTXkBDLbEfwgH7pxjpVTUNcuLVbu5gjMz27mKG1liB87I4aRj97jnHrXRanbWekamYgsn+lQByY8KOc4JHQt1yT7Vxttbi9EgyRaJMFIZiWx9/cP9riiLUtWZpqV2WTINVtfMh0662ziNpp7iTMkZU8iMfwjOeRzil1G4+3xrqAvbkxQyHzI95YTDgM79yBxxiql9dOz3MenPIqkNLGZjyu0ZIwOMGs4RXaiO6e58yzc5kixsbHsR/LpWijfUuLSdzqvO2zQcSSac0IISIgbx1CkdNpHY4rN1TVporZo7XTWtTEsgla7bIDEZRQoz8vNU5gY5iTLJFb/K7QR4KsrfKBk85wfz6UWqz2t4JLqRbhr6UwWsb5KKVAw0nQkAY4H40uXqDWly1Y6hdR/ZrRpWtVj3ZUFmdYyMqy8Yx1zz6Vq2mr77dvtN0ksgjH2chCjOw5IfHXoawU1WV47mOQB5DhVY8fMM88c468Co5dsNgftUkmyQfMkOAdo9GPIOf0ocTNI7K5v2ksmj+zQwxTlWmTd5jg9iAen+7WbruoIdIjYahJawr+6Fx8oLN2AXPHes21u7KaFIHglSOXksjfOXx8pJ9qp6uILLQ7S+W1hluvM3I0vzhkjP7xHByOcjBAyPWpjHUhSSehdjCajaifSyxvbUiKaQSFlCluQB6Hqc1fbX9YuUFjp4sL63VPNVWh8slQcN0HX6cVR8S202hamLvw7N9i0+9hg1E220NiORVJjOR2JOKzNC8ZPc66L0WwWSMSRkDCj5gBkYHA46VVrq6NdZJSWvU7prhImT7ArrdMN9zaRqMx++7ONvtmktNavUt5hHcLBayNmW4DgKST6Dnj1xXCteO2pGXTZZrXUbLfJOCd0My5wBj8e4rRhtU1O5MSRRKskQupGbILoOqYBwPmz07VPIupDp/MlurqJLyV7wSwLDydkhb7S38JYjJA68/SjRrGLVbho3jV9MBbZHMB8yk5+Zj95v5U5buLURYPLbIt3PG9vbsmVWJB13AfeP1qeHR7a4sY0vLy8VreTz2ESrtdOy4PvjmhuyKbstS1YxR217FptjAbnAKsgA5GeFPsOmfat59SvVdlOqpGQcbPJHy+1YXhq3Oo+IbyQ4heGLzY/LYjA9CRWRc6Fm5lP9oXn3z/EPX6VNk3qTy8zsf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prominent fibrous bands divide this lymph node into nodules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke RA, Weiss LM, Chan JK, et al. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12867=[""].join("\n");
var outline_f12_36_12867=null;
var title_f12_36_12868="Asymptomatic bacteriuria in patients with diabetes mellitus";
var content_f12_36_12868=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Asymptomatic bacteriuria in patients with diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12868/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12868/contributors\">",
"     Amy C Weintrob, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12868/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12868/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12868/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12868/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12868/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/36/12868/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term asymptomatic bacteriuria refers to the presence of a positive urine culture in an asymptomatic person. Most patients with asymptomatic bacteriuria have no adverse consequences and derive no benefit from antibiotic therapy. As a result, most episodes of asymptomatic bacteriuria are not detected since general screening is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42295?source=see_link\">",
"     \"Approach to the adult with asymptomatic bacteriuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to asymptomatic bacteriuria in patients with diabetes mellitus will be reviewed here. Diabetic patients have an increased risk of certain symptomatic urinary tract infections such as acute cystitis, emphysematous infections, renal and perinephric abscess, and Candida infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34278?source=see_link\">",
"     \"Emphysematous urinary tract infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14134?source=see_link\">",
"     \"Renal and perinephric abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/49/15128?source=see_link\">",
"     \"Candida infections of the bladder and kidneys\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=see_link\">",
"     \"Acute complicated cystitis and pyelonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term asymptomatic bacteriuria refers to the presence of high quantities of a uropathogen in the urine of an asymptomatic person. Initial studies showed that colony counts &ge;10(5)",
"    <span class=\"nowrap\">",
"     cfu/mL",
"    </span>",
"    more often predicted persistently high levels of bacteriuria compared with lower colony counts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2005 IDSA guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults recommend the following criteria for the diagnosis of asymptomatic bacteriuria [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For asymptomatic women, bacteriuria is defined as two consecutive clean-catch voided urine specimens with isolation of the same bacterial strain in counts &ge;10(5)",
"      <span class=\"nowrap\">",
"       cfu/mL.",
"      </span>",
"     </li>",
"     <li>",
"      For any asymptomatic patient, bacteriuria is defined as a single catheterized urine specimen with one bacterial species isolated in counts &ge;10(2)",
"      <span class=\"nowrap\">",
"       cfu/mL.",
"      </span>",
"      Although a count of &ge;10(2)",
"      <span class=\"nowrap\">",
"       cfu/mL",
"      </span>",
"      has been validated in research settings to be significant, many clinical laboratories do not routinely quantify counts in this range.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since screening for the presence of microalbuminuria is recommended in diabetic patients, these routine evaluations often lead to the incidental discovery of asymptomatic bacteriuria. The overall approach to this generally benign disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42295?source=see_link\">",
"     \"Approach to the adult with asymptomatic bacteriuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concern about asymptomatic bacteriuria in diabetic patients derives in part from three observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a roughly five-fold greater propensity toward UTI in diabetic women [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Asymptomatic bacteriuria often precedes symptomatic UTI in type 2 diabetes (relative risk [RR] 1.65, 95 percent confidence interval [CI] 1.02-2.67) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      UTIs are likely to be more severe in diabetic than nondiabetic women [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best estimate is an approximately three- to fourfold increase in risk of bacteriuria in diabetic women (eg, 18 versus 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/6\">",
"     6",
"    </a>",
"    ], 26 versus 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/7\">",
"     7",
"    </a>",
"    ]). The incidence is even higher in diabetic patients with advanced or severe disease as determined by end-organ damage or elevated levels of glycosylated hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective cohort study of 218 diabetic and 799 nondiabetic postmenopausal women examined risk factors for asymptomatic bacteriuria and UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/8\">",
"     8",
"    </a>",
"    ]. Increased risk occurred mainly in women taking insulin (relative risk 3.7) and those with a longer diabetes duration (&gt;10 years, relative risk 2.6) but not to glucose control.",
"   </p>",
"   <p>",
"    Genetic factors may also be involved. One Canadian study, for example, showed a higher rate of asymptomatic UTI in aboriginal diabetic women than in diabetic women of European heritage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ASSOCIATION WITH URINARY TRACT INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large cohort of diabetic women in the Netherlands was studied to determine the incidence of symptomatic UTIs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/9\">",
"     9",
"    </a>",
"    ]. In women with type 2 diabetes (but not with type 1), the presence of asymptomatic bacteriuria at baseline increased the risk of subsequent symptomatic UTI in the 18 month follow-up period from 19 to 34 percent. The rate of asymptomatic bacteriuria in this population was approximately 28 percent. By contrast, incidence of asymptomatic UTI was 6 percent in women who were not diabetic but attended other clinics in the same institution [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/7\">",
"     7",
"    </a>",
"    ]. Even in this cohort of diabetic women, there were more symptomatic UTIs in the women who had negative baseline urine cultures than in those with positive ones. Thus, screening for later UTI risk would not be very cost effective even in this high-risk population.",
"   </p>",
"   <p>",
"    A prospective study of 496 adult diabetics assessed the relationship",
"   </p>",
"   <p>",
"    between asymptomatic bacteriuria and subsequent hospitalization for urosepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/10\">",
"     10",
"    </a>",
"    ]. The prevalence of asymptomatic bacteriuria was 7.3 percent (14 percent females and 1 percent males). Twenty-nine patients were subsequently hospitalized with urosepsis. Asymptomatic bacteriuria was significantly associated with an increased risk of hospitalization for urosepsis (hazard ratio, 4.4; 95% CI 1.2-16.5). Further large scale studies are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bacteriology of UTIs is similar in diabetic and nondiabetic women with the preponderance being caused by E. coli and other gram-negative organisms. However, as in the subgroups described above, antibiotic therapy for asymptomatic bacteriuria does not affect the frequency of or time to symptomatic infection (including pyelonephritis), reinfection is common, and long-term prognosis is not improved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link&amp;anchor=H899949156#H899949156\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SHOULD YOU TREAT?",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <strong>",
"     not",
"    </strong>",
"    treating asymptomatic bacteriuria in diabetic women. This recommendation is based upon multiple studies which have shown that antibiotic therapy is associated with no reduction in symptomatic infection and a high rate of recurrent bacteriuria once antibiotics are discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. In addition, persistent asymptomatic bacteriuria is not associated with an adverse effect on renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best data come from a prospective trial in which 105 diabetic women over the age of 16 years with asymptomatic bacteriuria were randomly assigned to 14 days of antibiotics or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/11\">",
"     11",
"    </a>",
"    ]. At four weeks after the end of therapy, a significantly greater proportion of patients in the antibiotic group cleared the bacteriuria (80 versus 22 percent with placebo).",
"   </p>",
"   <p>",
"    After this six week period, the group assignment was revealed, and patients were followed for a mean of 27 months; bacteriuria was assessed at three month intervals and patients who originally received antibiotics were treated during subsequent episodes. Patients were also evaluated for symptomatic UTI, pyelonephritis, and hospitalization for UTI. There were no significant differences between the groups in the development of a symptomatic UTI, the timing of onset of such an infection, or any of the other parameters. Patients in the antibiotic treatment group had nearly five times the number of days on antibiotics compared to the placebo group.",
"   </p>",
"   <p>",
"    In a second report, 333 diabetic patients attending a clinic were screened for bacteriuria and followed for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/13\">",
"     13",
"    </a>",
"    ]. Forty-five of these patients were found to have bacteriuria; despite effective treatment, more than one-half had positive cultures within the year of the study. A similar study by the same authors tracked 45 diabetic women with bacteriuria [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12868/abstract/15\">",
"     15",
"    </a>",
"    ]. Despite six weeks of therapy for women with positive tests for antibody-coated bacteria (suggestive of parenchymal infection), there was a high rate (80 percent) of recurrent bacteriuria during a follow-up of up to several years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term asymptomatic bacteriuria refers to the presence of high quantities of a uropathogen in the urine of an asymptomatic person. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is an approximately three- to fourfold increase in risk of bacteriuria in diabetic women (eg, 18 versus 6 percent). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for UTI in diabetics includes those who take insulin (relative risk 3.7) and those with a longer diabetes duration (&gt;10 years, relative risk 2.6) but not glucose control. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      treating asymptomatic bacteriuria in diabetic women. Screening for bacteriuria is not necessary. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Should you treat?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/1\">",
"      KASS EH. Asymptomatic infections of the urinary tract. Trans Assoc Am Physicians 1956; 69:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/2\">",
"      Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005; 40:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/3\">",
"      Sharkey TP, Root HF. Infection of the urinary tract in diabetes. JAMA 1935; 104:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/4\">",
"      Geerlings SE, Stolk RP, Camps MJ, et al. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000; 23:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/5\">",
"      Baldwin AD, Root HF. Infections of upper urinary tract in diabetic patients. N Engl J Med 1940; 223:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/6\">",
"      Zhanel GG, Nicolle LE, Harding GK. Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. The Manitoba Diabetic Urinary Infection Study Group. Clin Infect Dis 1995; 21:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/7\">",
"      Geerlings SE, Stolk RP, Camps MJ, et al. Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Mellitus Women Asymptomatic Bacteriuria Utrecht Study Group. Diabetes Care 2000; 23:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/8\">",
"      Boyko EJ, Fihn SD, Scholes D, et al. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am J Epidemiol 2005; 161:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/9\">",
"      Geerlings SE, Stolk RP, Camps MJ, et al. Consequences of asymptomatic bacteriuria in women with diabetes mellitus. Arch Intern Med 2001; 161:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/10\">",
"      Karunajeewa H, McGechie D, Stuccio G, et al. Asymptomatic bacteriuria as a predictor of subsequent hospitalisation with urinary tract infection in diabetic adults: The Fremantle Diabetes Study. Diabetologia 2005; 48:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/11\">",
"      Harding GK, Zhanel GG, Nicolle LE, et al. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med 2002; 347:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/12\">",
"      Zhanel GG, Harding GK, Nicolle LE. Asymptomatic bacteriuria in patients with diabetes mellitus. Rev Infect Dis 1991; 13:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/13\">",
"      Forland M, Thomas V, Shelokov A. Urinary tract infections in patients with diabetes mellitus. Studies on antibody coating of bacteria. JAMA 1977; 238:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/14\">",
"      Meiland R, Geerlings SE, Stolk RP, et al. Asymptomatic bacteriuria in women with diabetes mellitus: effect on renal function after 6 years of follow-up. Arch Intern Med 2006; 166:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12868/abstract/15\">",
"      Forland M, Thomas VL. The treatment of urinary tract infections in women with diabetes mellitus. Diabetes Care 1985; 8:499.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8067 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12868=[""].join("\n");
var outline_f12_36_12868=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ASSOCIATION WITH URINARY TRACT INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SHOULD YOU TREAT?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=related_link\">",
"      Acute complicated cystitis and pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42295?source=related_link\">",
"      Approach to the adult with asymptomatic bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/49/15128?source=related_link\">",
"      Candida infections of the bladder and kidneys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34278?source=related_link\">",
"      Emphysematous urinary tract infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14134?source=related_link\">",
"      Renal and perinephric abscess",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_36_12869="Bedaquiline: Drug information";
var content_f12_36_12869=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bedaquiline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/2/44068?source=see_link\">",
"    see \"Bedaquiline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F15861179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15860479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitubercular Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15887643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use with &ge;3 drugs also active against the patient's",
"     <i>",
"      M. tuberculosis",
"     </i>",
"     isolate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Tuberculosis (multidrug-resistant), pulmonary:",
"     </b>",
"     Oral: Directly-observed therapy (DOT):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 1-2:  400 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     If a dose is missed during weeks 1-2, do not make up the missed dose, and continue the usual dosing schedule.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     Weeks 3-24: 200 mg 3 times weekly (total weekly dose: 600 mg).",
"     <b>",
"      Note:",
"     </b>",
"     Space doses at least 48 hours apart. If a dose is missed during weeks 3-24, administer the missed dose as soon as possible, and resume the 3-times-weekly schedule.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15887644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15887640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate renal impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe renal impairment: Use with caution; drug concentrations may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intermittent hemodialysis (IHD) or peritoneal dialysis (PD): Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15887641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe impairment (Child-Pugh class C): Use with caution (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15887598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15860482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sirturo&trade;: FDA approved December 2012; anticipated availability second quarter 2013.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15878132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM333729.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM333729.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15887645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Tablets should be taken with meals; swallow tablets whole. During weeks 3-24 of therapy, space doses at least 48 hours apart. Administer by directly-observed therapy (DOT).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15860481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pulmonary multidrug-resistant tuberculosis in combination therapy when other alternatives are not available; should not be used for latent, extrapulmonary or drug-sensitive tuberculosis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15883799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Chest pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (38%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Transaminases increased (9%; ALT increased &gt;3 x ULN: 11%; AST increased &gt;3 x ULN: 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Hemoptysis (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Anorexia (9%), amylase increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined: QT prolongation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15887604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15887605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Arrhythmias:",
"     <b>",
"      [U.S. Boxed Warning]: May prolong QT",
"      <sub>",
"       c",
"      </sub>",
"      interval.  Use with drugs that prolong the QT",
"      <sub>",
"       c",
"      </sub>",
"      interval may cause additive prolongation;",
"     </b>",
"     avoid use in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (including torsade de pointes, congenital long QT syndrome, bradyarrhythmias) or risk of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (hypothyroidism, uncompensated heart failure, low serum electrolyte levels). Baseline potassium, calcium and magnesium should be obtained and corrected, if abnormal. Also evaluate serum electrolytes if QT prolongation is detected during therapy.  Monitor ECG closely with concurrent administration of other medications known to prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval (including fluoroquinolones, macrolide antibiotics or clofazimine). Discontinue therapy if patient develops confirmed QT",
"     <sub>",
"      c",
"     </sub>",
"     F interval of &gt;500 ms or ventricular arrhythmia and monitor ECG to confirm return to baseline.  If patient experiences syncope, obtain ECG to assess potential QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic effects: Increased risk of hepatic reactions; avoid alcohol intake and other known hepatotoxic drugs, especially in patients with low hepatic reserve.  Monitor AST, ALT, alkaline phosphatase and bilirubin at baseline and during therapy.  Further evaluate patients with evidence of liver dysfunction (AST/ALT and/or bilirubin elevations, and/or symptoms [eg, fatigue, nausea, anorexia, hepatomegaly]).",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Should be administered by directly observed therapy (DOT). Should not be used for latent, extrapulmonary or drug-sensitive tuberculosis. Multidrug regimens (&ge;3 drugs) should be utilized against",
"     <i>",
"      M. tuberculosis",
"     </i>",
"     isolate; if failure/relapse occurs, test isolate for bedaquiline minimum inhibitory concentrations (MICs).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Treatment-related mortality:",
"     <b>",
"      [U.S. Boxed Warning]: Increased risk of death in clinical trials of bedaquiline versus placebo.",
"     </b>",
"     Only use if no other effective treatment regimen is available.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15976943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15976941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the hepatotoxic effect of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Bedaquiline. Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F15887618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: May increase risk of hepatic-related adverse drug reactions. Management: Avoid alcohol use during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Administration with a standard meal (~22 g fat; 558 calories) increases bioavailability by approximately twofold. Management: Administer with food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15887600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15887601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15887602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15887603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if bedaquiline is excreted into breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F15887647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets should be taken with meals.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15887648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG should be obtained at baseline and at weeks 2, 12, and 24 during therapy. Monitor ECG closely with concurrent administration of other medications known to prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval (including fluoroquinolones, macrolide antibiotics, or clofazimine). If QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation is detected during therapy, monitor ECG frequently to confirm QT",
"     <sub>",
"      c",
"     </sub>",
"     return to baseline. Baseline potassium, calcium, and magnesium should be obtained and corrected, if abnormal. Discontinue therapy if patient develops confirmed QT",
"     <sub>",
"      c",
"     </sub>",
"     F interval of &gt;500 ms or ventricular arrhythmia. Monitor AST, ALT, alkaline phosphatase, and bilirubin at baseline, monthly during treatment, and as needed. If AST or ALT &gt;3 x upper limit of normal (ULN), repeat test in 48 hours, test for viral hepatitis and discontinue other hepatotoxic medications. Further evaluate patients with evidence of liver dysfunction (AST/ALT and/or bilirubin elevations, and/or symptoms [eg fatigue, nausea, anorexia, hepatomegaly]).  Discontinue if AST or ALT elevations persist &gt;2 weeks, are &gt;8 x ULN, or if elevations also include total bilirubin &gt;2 x ULN.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15887621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a diarylquinoline antimycobacterial, inhibits the proton transfer chain of mycobacterial ATP synthase required for energy generation in",
"     <i>",
"      M. tuberculosis",
"     </i>",
"     .  It is not active against human ATP synthase.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15887623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Significantly increased with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~164 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4; forms N-monodesmethyl metabolite (M2) which has 4-6 times less antimycobacterial potency than parent drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Terminal: 5.5 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum: Oral: 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces; urine (&lt;0.001%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,&rdquo; 2003,",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 52(RR-11):3-5. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diacon AH, Donald PR, Pym A, et al, &ldquo;Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis:  Long Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2012, 56(6):3271-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12869/abstract-text/22391540/pubmed\" id=\"22391540\" target=\"_blank\">",
"        22391540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al, &ldquo;14-Day Bactericidal Activity of PA-824, Bedaquiline, Pyrazinamide and Moxifloxacin Combinations: A Randomised Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2012, 380(9846):986-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12869/abstract-text/22828481/pubmed\" id=\"22828481\" target=\"_blank\">",
"        22828481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diacon AH, Pym A, Grobusch M, et al, &ldquo;The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(23):2397-405.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12869/abstract-text/19494215/pubmed\" id=\"19494215\" target=\"_blank\">",
"        19494215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dooley KE, Park JG, Swindells S, et al, &ldquo;Safety, Tolerability and Pharmacokinetic Interaction of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy Volunteers: AIDS Clinical Trials Group Study A5267,&rdquo;",
"      <i>",
"       J Acquir Immune Defic Syndr",
"      </i>",
"      , 2012, 59(5):455-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12869/abstract-text/22126739/pubmed\" id=\"22126739\" target=\"_blank\">",
"        22126739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rustomjee R, Diacon AH, Allen J, et al, &ldquo;Early Bactericidal Activity and Pharmacokinetics of  Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2008, 52(8):2831-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12869/abstract-text/18505852/pubmed\" id=\"18505852\" target=\"_blank\">",
"        18505852",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Villemagne B, Crauste C, Flipo M, et al, &ldquo;Tuberculosis: The Drug Development Pipeline at a Glance,&rdquo;",
"      <i>",
"       Eur J Med Chem",
"      </i>",
"      , 2012, 51:1-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12869/abstract-text/22421275/pubmed\" id=\"22421275\" target=\"_blank\">",
"        22421275",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87509 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12869=[""].join("\n");
var outline_f12_36_12869=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15861179\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15860479\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887643\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887644\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887640\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887641\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887598\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15860482\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15878132\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887645\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15860481\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883799\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887604\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887605\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15976943\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15976941\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887618\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887600\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887601\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887602\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887603\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887647\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887648\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887621\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887623\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87509\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87509|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/2/44068?source=related_link\">",
"      Bedaquiline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_36_12870="Chlorhexidine gluconate: Drug information";
var content_f12_36_12870=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorhexidine gluconate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/1/40981?source=see_link\">",
"    see \"Chlorhexidine gluconate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/9/44180?source=see_link\">",
"    see \"Chlorhexidine gluconate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avagard&trade; [OTC];",
"     </li>",
"     <li>",
"      Bactoshield&reg; CHG [OTC];",
"     </li>",
"     <li>",
"      Betasept&reg; [OTC];",
"     </li>",
"     <li>",
"      ChloraPrep&reg; Frepp&reg; [OTC];",
"     </li>",
"     <li>",
"      ChloraPrep&reg; Sepp&reg; [OTC];",
"     </li>",
"     <li>",
"      ChloraPrep&reg; [OTC];",
"     </li>",
"     <li>",
"      Chlorascrub&trade; Maxi [OTC];",
"     </li>",
"     <li>",
"      Chlorascrub&trade; [OTC];",
"     </li>",
"     <li>",
"      Dyna-Hex&reg; [OTC];",
"     </li>",
"     <li>",
"      Hibiclens&reg; [OTC];",
"     </li>",
"     <li>",
"      Hibistat&reg; [OTC];",
"     </li>",
"     <li>",
"      Operand&reg; Chlorhexidine Gluconate [OTC];",
"     </li>",
"     <li>",
"      Peridex&reg;;",
"     </li>",
"     <li>",
"      periochip&reg;;",
"     </li>",
"     <li>",
"      PerioGard&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hibidil&reg; 1:2000;",
"     </li>",
"     <li>",
"      ORO-Clense;",
"     </li>",
"     <li>",
"      Peridex&reg; Oral Rinse",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Oral Rinse;",
"     </li>",
"     <li>",
"      Antibiotic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral rinse (Peridex&reg;, PerioGard&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Floss and brush teeth, completely rinse toothpaste from mouth and swish 15 mL (one capful) undiluted oral rinse around in mouth for 30 seconds, then expectorate. Caution patient not to swallow the medicine and instruct not to eat for 2-3 hours after treatment (cap on bottle measures 15 mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of gingivitis: Oral prophylaxis: Swish for 30 seconds with 15 mL chlorhexidine, then expectorate; repeat twice daily (morning and evening). Patient should have a re-evaluation followed by a dental prophylaxis every 6 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Periodontal chip: One chip is inserted into a periodontal pocket with a probing pocket depth &ge;5 mm. Up to 8 chips may be inserted in a single visit. Treatment is recommended every 3 months in pockets with a remaining depth &ge;5 mm. If dislodgment occurs 7 days or more after placement, the subject is considered to have had the full course of treatment. If dislodgment occurs within 48 hours, a new chip should be inserted. The chip biodegrades completely and does not need to be removed. Patients should avoid dental floss at the site of periochip&reg; insertion for 10 days after placement because flossing might dislodge the chip.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Insertion of periodontal chip: Pocket should be isolated and surrounding area dried prior to chip insertion. The chip should be grasped using forceps with the rounded edges away from the forceps. The chip should be inserted into the periodontal pocket to its maximum depth. It may be maneuvered into position using the tips of the forceps or a flat instrument.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cleanser:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Surgical scrub: Scrub 3 minutes and rinse thoroughly, wash for an additional 3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hand sanitizer (Avagard&trade;): Dispense 1 pumpful in palm of one hand; dip fingertips of opposite hand into solution and work it under nails. Spread remainder evenly over hand and just above elbow, covering all surfaces. Repeat on other hand. Dispense another pumpful in each hand and reapply to each hand up to the wrist. Allow to dry before gloving.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hand wash: Wash for 15 seconds and rinse",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hand rinse: Rub 15 seconds and rinse",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F149628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chip, for periodontal pocket insertion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     periochip&reg;: 2.5 mg (20s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral [rinse]: 0.12% (15 mL, 473 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peridex&reg;: 0.12% (118 mL, 473 mL, 1893 mL) [contains ethanol 11.6%; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PerioGard&reg;: 0.12% (480 mL) [contains ethanol 11.6%; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [surgical scrub]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betasept&reg;: 4% (118 mL, 237 mL, 473 mL, 946 mL, 3840 mL) [contains isopropyl alcohol 4%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dyna-Hex&reg;: 2% (120 mL, 480 mL, 960 mL, 3840 mL); 4% (120 mL, 240 mL, 480 mL, 960 mL, 3840 mL) [contains isopropyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hibiclens&reg;: 4% (15 mL, 118 mL, 236 mL, 473 mL, 946 mL, 3840 mL) [contains isopropyl alcohol 4%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Operand&reg; Chlorhexidine Gluconate: 2% (118 mL [DSC]); 4% (118 mL, 237 mL, 472 mL, 946 mL, 3785 mL) [contains isopropyl alcohol 4%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical [surgical scrub]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avagard&trade;: 1% (500 mL) [contains ethanol 61%, moisturizers]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [surgical scrub]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bactoshield&reg; CHG: 2% (120 mL, 480 mL, 750 mL, 960 mL, 3840 mL); 4% (120 mL, 473 mL, 960 mL, 3840 mL) [contains isopropyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sponge, topical [surgical scrub]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ChloraPrep&reg;: 2% (25s) [contains isopropyl alcohol 70%; 3 mL; clear]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ChloraPrep&reg;: 2% (25s) [contains isopropyl alcohol 70%; 3 mL; Hi-Lite Orange&trade; tint]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ChloraPrep&reg;: 2% (25s) [contains isopropyl alcohol 70%; 10.5 mL; clear]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ChloraPrep&reg;: 2% (25s) [contains isopropyl alcohol 70%; 10.5 mL; Hi-Lite Orange&trade; tint]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ChloraPrep&reg;: 2% (25s) [contains isopropyl alcohol 70%; 10.5 mL; Scrub Teal&trade; tint]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ChloraPrep&reg;: 2% (25s) [contains isopropyl alcohol 70%; 26 mL; clear]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ChloraPrep&reg;: 2% (25s) [contains isopropyl alcohol 70%; 26 mL; Hi-Lite Orange&trade; tint]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ChloraPrep&reg;: 2% (25s) [contains isopropyl alcohol 70%; 26 mL; Scrub Teal&trade; tint]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ChloraPrep&reg; Frepp&reg;: 2% (20s) [contains isopropyl alcohol 70%; 1.5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ChloraPrep&reg; Sepp&reg;: 2% (200s) [contains isopropyl alcohol 70%; 0.67 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sponge/Brush, topical [surgical scrub]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bactoshield&reg; CHG: 4% (300s) [contains isopropyl alcohol 4%; 25 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Swab, topical [prep pads]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlorascrub&trade;: 3.15% (100s) [contains isopropyl alcohol 70%; 1 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Swabsticks, topical [surgical scrub]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ChloraPrep&reg;: 2% (48s) [contains isopropyl alcohol 70%; 1.75 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ChloraPrep&reg;: 2% (120s) [contains isopropyl alcohol 70%; 5.25 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlorascrub&trade;: 3.15% (50s) [contains isopropyl alcohol 70%; 1.6 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlorascrub&trade; Maxi: 3.15% (30s) [contains isopropyl alcohol 70%; 5.1 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Wipe, topical [towelette]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hibistat&reg;: 0.5% (50s) [contains isopropyl alcohol 70%; 5 mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Oral liquid",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F149611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hand sanitizer (Avagard&trade;): To facilitate drying, continue rubbing hand prep into hands until dry.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Periodontal chip insertion: Pocket should be isolated and surrounding area dried prior to chip insertion. The chip should be grasped using forceps with the rounded edges away from the forceps. The chip should be inserted into the periodontal pocket to its maximum depth. It may be maneuvered into position using the tips of the forceps or a flat instrument. The chip biodegrades completely and does not need to be removed. Patients should avoid dental floss at the site of periochip&reg; insertion for 10 days after placement because flossing might dislodge the chip.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Keep out of eyes, ears, and mouth. Do not routinely apply to wounds which involve more than superficial layers of skin. Avoid contact with meninges (do not use on lumbar puncture sites). Solutions may be flammable (contain isopropyl alcohol); avoid exposure to open flame and/or ignition source (eg, electrocautery) until completely dry; avoid application to hairy areas which may significantly delay drying time.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F149610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skin cleanser for line placement, skin wounds, preoperative skin preparation; germicidal hand rinse; antibacterial dental rinse. Chlorhexidine is active against gram-positive and gram-negative organisms, facultative anaerobes, aerobes, and yeast. Chip, for periodontal pocket insertion: Reduces pocket depth in patients with adult periodontitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Orphan drug:",
"     </b>",
"     Peridex&reg;: Oral mucositis with cytoreductive therapy when used for patients undergoing bone marrow transplant",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F149646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Peridex&reg; may be confused with Precedex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F149637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;10%: Tartar on teeth increased, taste changes. Staining of oral surfaces (mucosa, teeth, dorsum of tongue) may be visible as soon as 1 week after therapy begins and is more pronounced when there is a heavy accumulation of unremoved plaque and when teeth fillings have rough surfaces. Stain does not have a clinically adverse effect but because removal may not be possible, patient with frontal restoration should be advised of the potential permanency of the stain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% to 10%: Gastrointestinal: Tongue irritation, oral irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Dyspnea, facial edema, nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Skin erythema and roughness, dryness, sensitization, allergic reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F149614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorhexidine gluconate or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F149598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral: Staining of oral surfaces (mucosa, teeth, tooth restorations, dorsum of tongue) may occur; may be visible as soon as 1 week after therapy begins and is more pronounced when there is a heavy accumulation of unremoved plaque and when teeth fillings have rough surfaces. Stain does not have a clinically adverse effect, but because removal may not be possible, patient with frontal restoration should be advised of the potential permanency of the stain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical: For topical use only. Avoid application over large surfaces or into open wounds. Keep out of eyes and ears. May stain fabric. There have been case reports of anaphylaxis following chlorhexidine disinfection. Not for preoperative preparation of face or head; avoid contact with meninges (do not use on lumbar puncture sites). Solutions may be flammable (contain isopropyl alcohol); avoid exposure to open flame and/or ignition source (eg, electrocautery) until completely dry; avoid application to hairy areas which may significantly delay drying time. Avoid use in children &lt;2 months of age due to increased absorption and/or irritation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F149605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (manufacturer specific) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13755159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies following use of the oral rinse; use of periodontal chip has not been studied. Chlorhexidine gluconate oral rinse is poorly absorbed from the gastrointestinal tract.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13755160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F149616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Betasept Surgical Scrub External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (946 mL): $16.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Chlorhexidine Gluconate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (118 mL): $4.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (473 mL): $10.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Hibiclens External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (236 mL): $5.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Misc",
"     </b>",
"     (Hibistat External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (50): $22.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (ChloraPrep One Step External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-70% (3 mL): $1.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Chlorhexidine Gluconate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (473 mL): $145.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Chlorhexidine Gluconate Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.12% (15 mL): $1.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Periogard Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.12% (473 mL): $7.50",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F149617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      AB Antiseptico (PY);",
"     </li>",
"     <li>",
"      Alcloxidine (IL);",
"     </li>",
"     <li>",
"      Alcosept (IL);",
"     </li>",
"     <li>",
"      Antiplac-B (CO);",
"     </li>",
"     <li>",
"      Antisek (EC);",
"     </li>",
"     <li>",
"      Blend-A-Med (DE);",
"     </li>",
"     <li>",
"      Bucoglobin (UY);",
"     </li>",
"     <li>",
"      Bucoxidina (PE);",
"     </li>",
"     <li>",
"      Cetavlex (FR);",
"     </li>",
"     <li>",
"      Cetavlon (FR);",
"     </li>",
"     <li>",
"      Chlorhex (TH);",
"     </li>",
"     <li>",
"      Chlorhexamed (CH);",
"     </li>",
"     <li>",
"      Chlorhexidine Obstetric Lotion (AU);",
"     </li>",
"     <li>",
"      Cleardent (IL);",
"     </li>",
"     <li>",
"      Clodine (IL);",
"     </li>",
"     <li>",
"      Corsodyl (IT, PT, ZA);",
"     </li>",
"     <li>",
"      Diaseptyl (FR);",
"     </li>",
"     <li>",
"      Dosiseptine (FR);",
"     </li>",
"     <li>",
"      Easy Antiseptic (TW);",
"     </li>",
"     <li>",
"      Exoseptoplix (FR);",
"     </li>",
"     <li>",
"      Fordenta (ID);",
"     </li>",
"     <li>",
"      Hibident (AT);",
"     </li>",
"     <li>",
"      Hibiscrub (FR, HK, NL, PK, TH);",
"     </li>",
"     <li>",
"      Hibisol (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Hibitan (KP);",
"     </li>",
"     <li>",
"      Hibitane (AE, BE, BH, CY, DK, EG, FR, HK, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SE, SY, YE);",
"     </li>",
"     <li>",
"      Hibitane Concentrate (MY, TH);",
"     </li>",
"     <li>",
"      Hibitane Cream (GR);",
"     </li>",
"     <li>",
"      Hibitane Dental (NO);",
"     </li>",
"     <li>",
"      Hibitane Solution (GR);",
"     </li>",
"     <li>",
"      Hidine (TH);",
"     </li>",
"     <li>",
"      Jiu Tai (CL);",
"     </li>",
"     <li>",
"      Klorhexidin (NO);",
"     </li>",
"     <li>",
"      Klorhexol (FI);",
"     </li>",
"     <li>",
"      Microshield (IN);",
"     </li>",
"     <li>",
"      Oradex (MY);",
"     </li>",
"     <li>",
"      Orahex (PH);",
"     </li>",
"     <li>",
"      Orinse (IN);",
"     </li>",
"     <li>",
"      Perio Chip (IL, PH);",
"     </li>",
"     <li>",
"      PerioChip (SG);",
"     </li>",
"     <li>",
"      Perioxidin (MX);",
"     </li>",
"     <li>",
"      Plaqacide Mouthrinse (AU);",
"     </li>",
"     <li>",
"      Savlon (IE);",
"     </li>",
"     <li>",
"      Septalone (IL);",
"     </li>",
"     <li>",
"      Septofervex (PL);",
"     </li>",
"     <li>",
"      Septol (IL);",
"     </li>",
"     <li>",
"      Xylodent (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F149597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The bactericidal effect of chlorhexidine is a result of the binding of this cationic molecule to negatively charged bacterial cell walls and extramicrobial complexes. At low concentrations, this causes an alteration of bacterial cell osmotic equilibrium and leakage of potassium and phosphorous resulting in a bacteriostatic effect. At high concentrations of chlorhexidine, the cytoplasmic contents of the bacterial cell precipitate and result in cell death.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F149613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical hand sanitizer (Avagard&trade;): Duration of antimicrobial protection: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral rinse (Peridex&reg;, PerioGard&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Absorption: ~30% retained in the oral cavity following rinsing and slowly released into oral fluids; poorly absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Time to peak, plasma: Oral rinse: Detectable levels not present after 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excretion: Feces (~90%); urine (&lt;1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      al-Tannir MA and Goodman HS, &ldquo;A Review of Chlorhexidine and Its Use in Special Populations,&rdquo;",
"      <i>",
"       Spec Care Dentist",
"      </i>",
"      , 1994, 14(3):116-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12870/abstract-text/7871472/pubmed\" id=\"7871472\" target=\"_blank\">",
"        7871472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12870/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Emerson D and Pierce C, &ldquo;A Case of a Single Ingestion of 4% Hibiclens&reg;,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1988, 30(6):583.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12870/abstract-text/3245128/pubmed\" id=\"3245128\" target=\"_blank\">",
"        3245128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferretti GA, Brown AT, Raybould TP, et al, &ldquo;Oral Antimicrobial Agents - Chlorhexidine,&rdquo;",
"      <i>",
"       NCI Monogr",
"      </i>",
"      , 1990, 9:51-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12870/abstract-text/2188158/pubmed\" id=\"2188158\" target=\"_blank\">",
"        2188158",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gonzales JR, Harnack L, Schmitt-Corsitto G, et al, \"A Novel Approach to the Use of Subgingival Controlled-Release Chlorhexidine Delivery in Chronic Periodontitis: A Randomized Clinical Trial,\"",
"      <i>",
"       J Periodontol",
"      </i>",
"      , 2011, 82(8):1131-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12870/abstract-text/21491990/pubmed\" id=\"21491990\" target=\"_blank\">",
"        21491990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenstein G, Berman C, and Jaffin R, &ldquo;Chlorhexidine. An Adjunct to Periodontal Therapy,&rdquo;",
"      <i>",
"       J Periodontol",
"      </i>",
"      , 1986, 57(6):370-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12870/abstract-text/3522851/pubmed\" id=\"3522851\" target=\"_blank\">",
"        3522851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson BT, &ldquo;Uses of Chlorhexidine in Dentistry,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1995, 43(2):126-32, 134-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12870/abstract-text/7590147/pubmed\" id=\"7590147\" target=\"_blank\">",
"        7590147",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Massano G, Ciocatto E, Rosabianca C, et al, &ldquo;Striking Aminotransferase Rise After Chlorhexidine Self-Poisoning,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8266):289.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12870/abstract-text/6120309/pubmed\" id=\"6120309\" target=\"_blank\">",
"        6120309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quinn MW and Bini RM, &ldquo;Bradycardia Associated With Chlorhexidine Spray,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1989, 64(6):892-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12870/abstract-text/2774629/pubmed\" id=\"2774629\" target=\"_blank\">",
"        2774629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yong D, Parker FC, and Foran SM, &ldquo;Severe Allergic Reactions and Intra-Urethral Chlorhexidine Gluconate,&rdquo;",
"      <i>",
"       Med J Aust",
"      </i>",
"      , 1995, 162(5):257-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12870/abstract-text/7891607/pubmed\" id=\"7891607\" target=\"_blank\">",
"        7891607",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusof ZA, &ldquo;Chlorhexidine Mouthwash: A Review of Its Pharmacological Activity, Clinical Effects, Uses and Abuses,&rdquo;",
"      <i>",
"       Dent J Malays",
"      </i>",
"      , 1988, 10(1):9-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/36/12870/abstract-text/3078144/pubmed\" id=\"3078144\" target=\"_blank\">",
"        3078144",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9244 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-9FDBE1AB85-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12870=[""].join("\n");
var outline_f12_36_12870=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149625\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149626\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149639\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149627\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149628\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149609\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149594\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149611\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149610\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149646\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149637\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149614\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149598\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299018\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149603\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149605\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13755159\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13755160\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149616\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149617\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149597\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149613\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9244\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9244|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/1/40981?source=related_link\">",
"      Chlorhexidine gluconate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/9/44180?source=related_link\">",
"      Chlorhexidine gluconate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_36_12871="Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes";
var content_f12_36_12871=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12871/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12871/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12871/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12871/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12871/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12871/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12871/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/36/12871/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overt hyperthyroidism (low TSH, elevated free T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T3) is relatively uncommon during pregnancy, occurring in 0.1 to 0.4 percent of all pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnosis of pregnant women with hyperthyroidism parallels that of nonpregnant women and men, but presents some unique problems. The clinical manifestations, diagnosis, and causes of hyperthyroidism during pregnancy are presented here. The treatment of hyperthyroidism during pregnancy and other aspects of thyroid disease during pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link\">",
"     \"Hyperthyroidism during pregnancy: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link\">",
"     \"Overview of thyroid disease in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H995335\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the nonspecific symptoms associated with pregnancy are similar to those associated with hyperthyroidism, including tachycardia, heat intolerance, and increased perspiration. Additional symptoms include anxiety, hand tremor, and weight loss despite a normal or increased appetite. Specific findings such as goiter and ophthalmopathy suggest Graves' hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pregnancy complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy complicated by poorly controlled overt hyperthyroidism (most often due to Graves&rsquo; disease) is associated with increased rates of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spontaneous abortion",
"     </li>",
"     <li>",
"      Premature labor",
"     </li>",
"     <li>",
"      Low birth weight",
"     </li>",
"     <li>",
"      Stillbirth",
"     </li>",
"     <li>",
"      Preeclampsia",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study of 180 pregnancies complicated by hyperthyroidism compared to 360 controls found a higher rate of maternal hypertension and a 1.3 to 1.4-fold increased risk of fetal growth restriction, low birth weight, and preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/7\">",
"     7",
"    </a>",
"    ]. The risk of early pregnancy loss also appears to be increased in women with thyroid hormone resistance if the fetus does not carry the mutation, presumably due to the transplacental passage of high levels of thyroid hormone to the fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=see_link\">",
"     \"Resistance to thyrotropin and thyrotropin-releasing hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Very rare cases of thyroid storm precipitated by labor, infection, preeclampsia, or cesarean section have been reported.",
"   </p>",
"   <p>",
"    In contrast to these findings in women with overt hyperthyroidism, in one report of 433 women with subclinical hyperthyroidism (low TSH, normal free T4), there was no evidence of adverse pregnancy outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H995354\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;To meet the increased metabolic needs during a normal pregnancy, there are changes in thyroid physiology that are reflected in altered thyroid function tests. These changes include the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'Thyroid adaptation during normal pregnancy'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TBG excess results in high serum total T4 concentrations, but not high serum free T4 concentrations.",
"     </li>",
"     <li>",
"      High serum hCG concentrations during early pregnancy and even higher concentrations in women with hyperemesis gravidarum or multiple pregnancies may result in transient subclinical or rarely overt hyperthyroidism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the changes in thyroid physiology during normal pregnancy, thyroid function tests should be interpreted using trimester-specific TSH and T4 reference ranges for pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/9\">",
"     9",
"    </a>",
"    ]. In several population studies, the lower limit of the reference range for healthy pregnant women during the first trimester ranged from 0.03 to 0.1",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. In one of the largest population-based studies (over 13,000 pregnant women), the reference range (2.5 to 97.5",
"    <sup>",
"     th",
"    </sup>",
"    percentile) for TSH in the first trimester was 0.08 to 2.99",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. Total T4 and T3 levels during pregnancy are 1.5-fold higher than in nonpregnant women due to TBG excess. Reference ranges for free T4 are method-specific and trimester-specific reference ranges should be provided with the assay kits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link&amp;anchor=H1156384#H1156384\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'Trimester-specific reference ranges'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most pregnant women with significant overt hyperthyroidism in the first trimester have a serum TSH below that which is seen in asymptomatic healthy pregnant women (ie, &lt;0.01",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    associated with an elevated free T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    free T3 (or total T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    total T3) measurement that exceeds the normal range during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H994499\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hyperthyroidism during pregnancy is based upon clinical manifestations and laboratory findings. Specific findings on physical examination such as goiter and ophthalmopathy suggest Graves' hyperthyroidism. (See",
"    <a class=\"local\" href=\"#H3166170\">",
"     'Graves' disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When there is a clinical suspicion of hyperthyroidism, serum TSH should be measured. If the TSH level is &lt;0.1",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    free T4 (or free T4 index) should be obtained. If the free T4 is in the normal range for pregnancy, a free T3 should also be measured. In the event that free thyroid hormone levels are discordant with serum TSH and clinical findings, total T4 should be measured. The diagnosis of hyperthyroidism during pregnancy should be based primarily upon a suppressed (&lt;0.1",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    or undetectable (&lt;0.01",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    serum TSH value and also a high serum free T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    free T3 (or total T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    total T3) measurement that exceeds the normal range for pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12186870\">",
"    <span class=\"h1\">",
"     ESTABLISHING THE CAUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of hyperthyroidism is established, the cause of hyperthyroidism should be determined. Although hyperthyroidism from any cause can complicate pregnancy, Graves' (occurring in 0.1 to 1 percent of all pregnancies) and hCG-mediated hyperthyroidism (1 to 3 percent of pregnancies) are the most common causes of hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. Other causes of hyperthyroidism (including silent or subacute thyroiditis, toxic adenoma, toxic multinodular goiter, and factitious thyrotoxicosis) are rare during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link\">",
"     \"Disorders that cause hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the primary objective is to differentiate Graves&rsquo; disease from hCG-mediated hyperthyroidism. Although the clinical symptoms are similar, the presence of goiter or ophthalmopathy on physical examination favors the diagnosis of Graves&rsquo; disease. Goiter is not a classical clinical feature of hCG-mediated hyperthyroidism, but it may be present. Graves&rsquo; disease usually becomes less severe during the later stages of pregnancy due to a reduction in TSH receptor antibody concentrations or, rarely, mediated by a change in the activity of TSH receptor antibodies from stimulatory to blocking [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. hCG-mediated hyperthyroidism may occur transiently in the first half of gestation and is typically less severe than Graves&rsquo; disease. (See",
"    <a class=\"local\" href=\"#H3166170\">",
"     'Graves' disease'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12187099\">",
"     'hCG-mediated hyperthyroidism'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In situations where the clinical diagnosis is uncertain, thyrotropin (TSH) receptor antibodies (TRAb), using a second-generation thyrotropin-binding inhibitory immunoglobulin (TBII) assay, should be measured. TSH receptor antibodies are positive in 95 percent of patients with Graves' disease and, therefore, the presence of TSH receptor antibodies confirms the diagnosis of Graves' disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, measurement of total T3 can sometimes help distinguish T3 toxicosis caused by Graves&rsquo; disease from hCG-mediated hyperthyroidism (both T4 and T3 elevated).",
"   </p>",
"   <p>",
"    Thyroid radionuclide imaging is typically performed in nonpregnant patients to distinguish Graves&rsquo; disease from thyroiditis. However, radionuclide imaging is contraindicated in pregnant women. In experienced hands, thyroid ultrasound with Doppler flow may be useful to distinguish Graves&rsquo; disease (high blood flow) from painless or postpartum thyroiditis (low blood flow) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/20\">",
"     20",
"    </a>",
"    ]. However, its utility in diagnosing hCG-mediated hyperthyroidism is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3166170\">",
"    <span class=\"h2\">",
"     Graves' disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graves' disease is a syndrome that may consist of hyperthyroidism, goiter, eye disease (orbitopathy), and occasionally a dermopathy referred to as pretibial or localized myxedema. The terms Graves' disease and hyperthyroidism are not synonymous because some patients may have orbitopathy but no hyperthyroidism, and there are many other causes of hyperthyroidism in addition to Graves' disease. Hyperthyroidism is the most common feature of Graves' disease, affecting nearly all patients, and is caused by autoantibodies to the thyrotropin (TSH) receptor (TRAb) that activate the receptor, thereby stimulating thyroid hormone synthesis and secretion as well as thyroid growth (causing a diffuse goiter). The presence of TRAbs in serum and orbitopathy on clinical examination distinguishes the disorder from other causes of hyperthyroidism. The thyroid gland is usually, but not always, diffusely enlarged. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis of Graves' disease\", section on 'The thyroid gland in Graves' disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis of Graves' disease\", section on 'Autoantibodies to the TSH receptor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of measuring maternal serum TSH receptor antibodies (TRAb) for prediction of fetal and neonatal Graves&rsquo; disease is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link&amp;anchor=H13#H13\">",
"     \"Hyperthyroidism during pregnancy: Treatment\", section on 'Fetal hyperthyroidism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/97?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation and management of neonatal Graves' disease\", section on 'Measurement of antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12187099\">",
"    <span class=\"h2\">",
"     hCG-mediated hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;During normal pregnancy, serum human chorionic gonadotropin (hCG) concentrations rise soon after fertilization and peak at 10 to 12 weeks gestation, after which time the levels decline. There is considerable homology between the beta-subunits of hCG and TSH. As a result, hCG has weak thyroid-stimulating activity and may cause hyperthyroidism during the period of highest serum hCG concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link&amp;anchor=H994022#H994022\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'hCG and thyroid function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a number of examples of hCG-mediated hyperthyroidism:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12187126\">",
"    <span class=\"h3\">",
"     Gestational transient thyrotoxicosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the time of peak hCG concentrations (10 to 12 weeks), total serum T4 and T3 concentrations increase. Serum free T4 and T3 concentrations increase slightly, usually within the normal range, and serum TSH concentrations are appropriately reduced. Thus, in some women, the high serum concentration of hCG during early pregnancy can lead to subclinical or mild overt hyperthyroidism characterized by slightly low serum TSH concentrations and high-normal or mildly elevated serum free T4 concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/21\">",
"     21",
"    </a>",
"    ]. This phenomenon is called gestational transient thyrotoxicosis (GTT). It occurs near the end of the first trimester and symptoms (if present) and thyroid hyperfunction subside as hCG production falls (typically 14 to 18 weeks gestation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link&amp;anchor=H994022#H994022\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'hCG and thyroid function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12187133\">",
"    <span class=\"h3\">",
"     Hyperemesis gravidarum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperemesis gravidarum is a syndrome of nausea and vomiting associated with weight loss of 5 percent or more during early pregnancy that occurs in 0.1 to 0.2 percent of pregnancies. Women who develop hyperemesis gravidarum have higher serum hCG and estradiol concentrations than normal pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/22\">",
"     22",
"    </a>",
"    ]; in addition, their hCG has more thyroid-stimulating activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Therefore, their serum TSH concentrations are often lower than those in normal pregnant women (60 versus 9 percent had a low serum TSH in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. A few of these women have high serum free T4 concentrations and therefore have overt hyperthyroidism.",
"   </p>",
"   <p>",
"    Features that distinguish the transient hyperthyroidism of hyperemesis gravidarum from hyperthyroidism of other causes (which in a pregnant woman is most likely due to Graves' disease) are the vomiting, absence of goiter and ophthalmopathy, and absence of the common symptoms and signs of hyperthyroidism (tachycardia greater than 100",
"    <span class=\"nowrap\">",
"     beats/minute,",
"    </span>",
"    hyperdefecation, muscle weakness, tremor). In addition, serum free T4 concentrations are only minimally elevated and serum T3 concentrations are frequently not elevated in women with hyperemesis gravidarum, whereas both are usually unequivocally elevated in pregnant women with true hyperthyroidism from Graves&rsquo; disease.",
"   </p>",
"   <p>",
"    The thyroid hyperfunction in women with hyperemesis gravidarum usually does",
"    <strong>",
"     not",
"    </strong>",
"    require treatment because it is mild and subsides as hCG production falls (as does the vomiting). Like the thyroid hyperfunction, the vomiting is also proportional to the elevation in serum hCG and estradiol concentrations, and it is thought to be caused by estradiol [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/22\">",
"     22",
"    </a>",
"    ]. If overt hyperthyroidism persists for more than several weeks or beyond the first trimester, it is probably not hCG-mediated.",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, and treatment of hyperemesis gravidarum are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41207?source=see_link\">",
"     \"Clinical features and evaluation of nausea and vomiting of pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29002?source=see_link\">",
"     \"Treatment and outcome of nausea and vomiting of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12187140\">",
"    <span class=\"h3\">",
"     Trophoblastic hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthyroidism can also occur with gestational trophoblastic disease. A hydatidiform mole (molar pregnancy) is benign, but may give rise to choriocarcinoma. Both are associated with high serum hCG concentrations and abnormal hCG isoforms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13816?source=see_link\">",
"     \"Gestational trophoblastic disease: Pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, approximately 55 to 60 percent of women with trophoblastic disease had clinically evident hyperthyroidism at the time of diagnosis, which could be severe. However, in a review of 196 patients from the UK treated for gestational trophoblastic disease between 2005 and 2010, biochemical hyperthyroidism was present in 7 percent and clinical hyperthyroidism in only 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/27\">",
"     27",
"    </a>",
"    ]. The difference in prevalence is likely related to earlier diagnosis of trophoblastic disease due to ultrasonography and monitoring of serum beta-hCG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with hyperthyroidism caused by trophoblastic disease have a normal thyroid gland and few symptoms of thyroid hormone excess. However, some patients have more typical clinical findings of hyperthyroidism and a diffuse goiter, but ophthalmopathy is not present. Nausea and vomiting may predominate, as in hyperemesis gravidarum.",
"   </p>",
"   <p>",
"    The treatment of women with symptomatic moderate to severe hyperthyroidism due to trophoblastic hyperthyroidism is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link&amp;anchor=H21852089#H21852089\">",
"     \"Hyperthyroidism during pregnancy: Treatment\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12187147\">",
"    <span class=\"h3\">",
"     Familial gestational hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent gestational hyperthyroidism has been described in one family due to a mutant thyrotropin receptor that is hypersensitive to physiologic concentrations of hCG [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12871/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/58/13219?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"       \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many of the nonspecific symptoms associated with pregnancy are similar to those associated with hyperthyroidism, including tachycardia, heat intolerance, and increased perspiration. Additional symptoms may include anxiety, hand tremor, and weight loss despite a normal or increased appetite. Specific findings such as goiter and ophthalmopathy suggest Graves' hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"       \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of hyperthyroidism during pregnancy should be based primarily upon a finding of a suppressed (&lt;0.1",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      or undetectable (&lt;0.01) serum TSH value and elevated thyroid hormone levels (serum free T4",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      free T3 or total T4",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      total T3) that exceed the normal range for pregnancy. (See",
"      <a class=\"local\" href=\"#H994499\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although hyperthyroidism from any cause can complicate pregnancy, Graves' (occurring in 0.1 to 1 percent of all pregnancies) and hCG-mediated hyperthyroidism (1 to 3 percent of pregnancies) are the most common causes of hyperthyroidism. In situations where the clinical diagnosis is uncertain, thyrotropin (TSH) receptor antibodies, using a second-generation thyrotropin-binding inhibitory immunoglobulin (TBII) assay, should be measured. TSH receptor antibodies are positive in 95 percent of patients with Graves' disease and, therefore, the presence of TSH receptor antibodies confirms the diagnosis of Graves' disease. (See",
"      <a class=\"local\" href=\"#H12186870\">",
"       'Establishing the cause'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=see_link\">",
"       \"Pathogenesis of Graves' disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperthyroidism mediated by the effects of hCG include gestational transient thyrotoxicosis, hyperemesis gravidarum, and trophoblastic hyperthyroidism. Only the latter requires treatment of the hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H12187099\">",
"       'hCG-mediated hyperthyroidism'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link\">",
"       \"Hyperthyroidism during pregnancy: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/1\">",
"      Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev 2010; 31:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/2\">",
"      Davis LE, Lucas MJ, Hankins GD, et al. Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol 1989; 160:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/3\">",
"      Sheffield JS, Cunningham FG. Thyrotoxicosis and heart failure that complicate pregnancy. Am J Obstet Gynecol 2004; 190:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/4\">",
"      Phoojaroenchanachai M, Sriussadaporn S, Peerapatdit T, et al. Effect of maternal hyperthyroidism during late pregnancy on the risk of neonatal low birth weight. Clin Endocrinol (Oxf) 2001; 54:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/5\">",
"      Millar LK, Wing DA, Leung AS, et al. Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol 1994; 84:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/6\">",
"      Kriplani A, Buckshee K, Bhargava VL, et al. Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. Eur J Obstet Gynecol Reprod Biol 1994; 54:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/7\">",
"      Luewan S, Chakkabut P, Tongsong T. Outcomes of pregnancy complicated with hyperthyroidism: a cohort study. Arch Gynecol Obstet 2011; 283:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/8\">",
"      Casey BM, Dashe JS, Wells CE, et al. Subclinical hyperthyroidism and pregnancy outcomes. Obstet Gynecol 2006; 107:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/9\">",
"      Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/10\">",
"      Dashe JS, Casey BM, Wells CE, et al. Thyroid-stimulating hormone in singleton and twin pregnancy: importance of gestational age-specific reference ranges. Obstet Gynecol 2005; 106:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/11\">",
"      Stricker R, Echenard M, Eberhart R, et al. Evaluation of maternal thyroid function during pregnancy: the importance of using gestational age-specific reference intervals. Eur J Endocrinol 2007; 157:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/12\">",
"      Gilbert RM, Hadlow NC, Walsh JP, et al. Assessment of thyroid function during pregnancy: first-trimester (weeks 9-13) reference intervals derived from Western Australian women. Med J Aust 2008; 189:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/13\">",
"      Fitzpatrick DL, Russell MA. Diagnosis and management of thyroid disease in pregnancy. Obstet Gynecol Clin North Am 2010; 37:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/14\">",
"      Lambert-Messerlian G, McClain M, Haddow JE, et al. First- and second-trimester thyroid hormone reference data in pregnant women: a FaSTER (First- and Second-Trimester Evaluation of Risk for aneuploidy) Research Consortium study. Am J Obstet Gynecol 2008; 199:62.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/15\">",
"      American College of Obstetricians and Gynecologists.. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001). Thyroid disease in pregnancy. Obstet Gynecol 2002; 100:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/16\">",
"      Patil-Sisodia K, Mestman JH. Graves hyperthyroidism and pregnancy: a clinical update. Endocr Pract 2010; 16:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/17\">",
"      Salvi M, How J. Pregnancy and autoimmune thyroid disease. Endocrinol Metab Clin North Am 1987; 16:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/18\">",
"      Kung AW, Lau KS, Kohn LD. Epitope mapping of tsh receptor-blocking antibodies in Graves' disease that appear during pregnancy. J Clin Endocrinol Metab 2001; 86:3647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/19\">",
"      Vos XG, Smit N, Endert E, et al. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study. Clin Endocrinol (Oxf) 2008; 69:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/20\">",
"      Ota H, Amino N, Morita S, et al. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. Clin Endocrinol (Oxf) 2007; 67:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/21\">",
"      Glinoer D, de Nayer P, Bourdoux P, et al. Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab 1990; 71:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/22\">",
"      Goodwin TM, Montoro M, Mestman JH, et al. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab 1992; 75:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/23\">",
"      Yamazaki K, Sato K, Shizume K, et al. Potent thyrotropic activity of human chorionic gonadotropin variants in terms of 125I incorporation and de novo synthesized thyroid hormone release in human thyroid follicles. J Clin Endocrinol Metab 1995; 80:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/24\">",
"      Kimura M, Amino N, Tamaki H, et al. Gestational thyrotoxicosis and hyperemesis gravidarum: possible role of hCG with higher stimulating activity. Clin Endocrinol (Oxf) 1993; 38:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/25\">",
"      Hershman JM. Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Thyroid 1999; 9:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/26\">",
"      Yoshimura M, Pekary AE, Pang XP, et al. Thyrotropic activity of basic isoelectric forms of human chorionic gonadotropin extracted from hydatidiform mole tissues. J Clin Endocrinol Metab 1994; 78:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/27\">",
"      Walkington L, Webster J, Hancock BW, et al. Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease. Br J Cancer 2011; 104:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/28\">",
"      Rodien P, Br&eacute;mont C, Sanson ML, et al. Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. N Engl J Med 1998; 339:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12871/abstract/29\">",
"      Smits G, Govaerts C, Nubourgh I, et al. Lysine 183 and glutamic acid 157 of the TSH receptor: two interacting residues with a key role in determining specificity toward TSH and human CG. Mol Endocrinol 2002; 16:722.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7868 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12871=[""].join("\n");
var outline_f12_36_12871=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H995335\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pregnancy complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H995354\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H994499\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12186870\">",
"      ESTABLISHING THE CAUSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3166170\">",
"      Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12187099\">",
"      hCG-mediated hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12187126\">",
"      - Gestational transient thyrotoxicosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12187133\">",
"      - Hyperemesis gravidarum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12187140\">",
"      - Trophoblastic hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12187147\">",
"      - Familial gestational hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41207?source=related_link\">",
"      Clinical features and evaluation of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/97?source=related_link\">",
"      Evaluation and management of neonatal Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=related_link\">",
"      Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13816?source=related_link\">",
"      Gestational trophoblastic disease: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=related_link\">",
"      Hyperthyroidism during pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=related_link\">",
"      Pathogenesis of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=related_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/58/13219?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=related_link\">",
"      Resistance to thyrotropin and thyrotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29002?source=related_link\">",
"      Treatment and outcome of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_36_12872="Nitric oxide, other hormones, cytokines, and chemokines in heart failure";
var content_f12_36_12872=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nitric oxide, other hormones, cytokines, and chemokines in heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12872/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12872/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12872/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12872/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12872/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12872/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/36/12872/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of heart failure (HF) are in part due to compensatory mechanisms utilized by the body in an attempt to repair the primary deficit in the cardiac output. Well-recognized neurohumoral adaptations, such as activation of the renin-angiotensin-aldosterone and sympathetic nervous systems and antidiuretic hormone (vasopressin) by the low output state, can contribute to maintenance of perfusion of vital organs in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance of systemic pressure by vasoconstriction, resulting in redistribution of blood flow to vital organs",
"     </li>",
"     <li>",
"      Restoration of cardiac output by increasing myocardial contractility and heart rate and by expansion of the extracellular fluid volume",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed below, HF is also associated with alterations in a host of autocrine and paracrine signaling systems, many of which are involved in mediating inflammation, including nitric oxide (NO), inflammatory cytokines, chemokines and cyclooxygenase. The physiologic and clinical significance of these changes is complex and less well understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NITRIC OXIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide is enzymatically formed from L-arginine by three isoforms of nitric oxide synthetase (NOS): neuronal-type (nNOS, NOS1), cytokine-inducible NOS (iNOS, NOS2), and the endothelial-type (eNOS, NOS3) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/1\">",
"     1",
"    </a>",
"    ]. These enzymes differ markedly in their localization and function. Many cell types, most notably endothelial cells, constitutively express eNOS, generating relatively low levels of NO that are under tight control by regulatory factors. In contrast, iNOS is normally not expressed, but when induced by inflammatory cytokines can generate large amounts of NO far in excess of those made by eNOS. There may be alterations in all three isoforms of NOS in HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     NOS in the endothelium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic HF is associated with arterial endothelial dysfunction and impaired endothelium-dependent, flow-mediated dilation; the mechanism is probably a reduction in NO synthesis via eNOS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/2\">",
"     2",
"    </a>",
"    ] as well as a decrease in endothelial release of and response to NO [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In contrast, venous endothelial function and tone and basal and stimulated NO release from the venous capacitance bed is preserved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link\">",
"     \"Endothelial dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is evidence for increased free radical formation in HF, and it is possible that these species inactivate NO. Support for this hypothesis comes from one study in which vitamin C improved endothelial function in patients with HF in association with an increased availability of NO [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Myocardium and skeletal muscle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level of NOS activity in the failing human myocardium is variable, likely reflecting the multiple types of NOS and the heterogeneity of myocardial failure. Increased levels of activity of eNOS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/7\">",
"     7",
"    </a>",
"    ] and nNOS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/8\">",
"     8",
"    </a>",
"    ], and increased NO production, have been observed within myocytes from patients with HF due to either an ischemic or nonischemic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. The expression of iNOS, in particular, appears to correlate with the level of tumor necrosis factor alpha (TNFa) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nitric oxide may exert either beneficial or detrimental effects in the myocardium:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an animal model of myocardial infarction, the presence of eNOS limits left ventricular dysfunction and remodeling, in part by decreasing myocyte hypertrophy in the noninfarcted myocardium [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=see_link\">",
"       \"Cardiac remodeling: Basic aspects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another animal study found that nitric oxide production lowers myocyte energy production by directly affecting mitochondrial function [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/13\">",
"       13",
"      </a>",
"      ]. While this effect may limit energy availability, it may also reduce the generation of reactive oxygen radicals in the mitochondria.",
"     </li>",
"     <li>",
"      Nitric oxide can also affect basal myocardial function and can impair the inotropic response to beta-adrenergic receptor stimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/10,14-17\">",
"       10,14-17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The localization of NOS within the myocyte may also be disrupted in HF. In a study of nNOS expression in human hearts explanted at transplantation, there was a significant increase in sarcolemmal nNOS and a concomitant decrease in nNOS associated with the sarcoplasmic reticulum [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/8\">",
"     8",
"    </a>",
"    ]. This translocation of nNOS within failing heart muscle cells could contribute to the pathogenesis of HF by reducing calcium stores in the sarcoplasmic reticulum and increasing inhibition of the cell membrane L-type calcium channel, both effects that would reduce the availability of calcium to the contractile apparatus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inducible nitric oxide synthase gene expression and local nitric oxide production may also be increased within skeletal muscle of patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/19\">",
"     19",
"    </a>",
"    ]. This response could contribute to a reduction in contractile performance and muscle wasting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CYTOKINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure is often characterized by increases in circulating proinflammatory cytokines (TNFa, interleukin [IL]-6, IL-1-beta, and IL-2) and their soluble receptor or receptor antagonists that become more pronounced as myocardial function deteriorates [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/20-25\">",
"     20-25",
"    </a>",
"    ]. In addition, increased production of proinflammatory cytokines and other inflammatory markers may identify patients at increased risk of developing HF in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical significance of elevated cytokine levels in HF remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. A cause-and-effect relationship may contribute since, as will be described below, excess TNFa and IL-6 may have a deleterious effects on cardiac function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tumor necrosis factor-alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma TNFa concentrations are often elevated in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/20-22,29\">",
"     20-22,29",
"    </a>",
"    ]. Plasma TNFa increases with disease severity, being directly correlated with NYHA functional class (",
"    <a class=\"graphic graphic_figure graphicRef67957 \" href=\"UTD.htm?15/43/16061\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/20,29\">",
"     20,29",
"    </a>",
"    ]. An increase in TNFa may predict both the prognosis in patients with HF and the development of HF in patients without the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with HF, the source of TNFa may in part be the heart itself [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Although the nonfailing heart does not express TNFa, significant amounts are expressed by the failing human heart [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/31\">",
"     31",
"    </a>",
"    ]. The stimuli for cardiac TNFa expression are not well understood. Passive stretch alone can increase expression in cardiac myocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/32\">",
"     32",
"    </a>",
"    ], and, in humans, pressure and volume overload due to aortic stenosis or mitral regurgitation are associated with increased plasma TNFa and other cytokine concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/29\">",
"     29",
"    </a>",
"    ]. However, inflammation is also likely to be important since increased TNFa production by peripheral blood mononuclear cells is also predictive of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/26\">",
"     26",
"    </a>",
"    ]. Cytokine activation may be a marker for chronic inflammation. One possible mechanism is increased exposure to endotoxin due to altered gut permeability in patients with edema [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental studies suggest that local production of TNFa may have toxic effects on the myocardium, which could explain the association of TNFa with an adverse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transgenic mice with myocardial expression of TNFa developed severe cardiac disease including transmural myocarditis and ultimately biventricular fibrosis, chamber dilatation, and left ventricular dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/34\">",
"       34",
"      </a>",
"      ]. The rate of progression and severity of left ventricular dysfunction correlated with the degree of TNFa overexpression [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/35\">",
"       35",
"      </a>",
"      ]. The administration of an anti-TNFa antibody both preserved cardiac function and partially reversed the pathologic changes in heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results can be achieved by a continuous infusion of TNFa, which produces a time-dependent depression of left ventricular function and chamber dilatation that are partially reversible after discontinuation of the infusion or treatment with a TNFa antagonist (",
"      <a class=\"graphic graphic_figure graphicRef50390 \" href=\"UTD.htm?2/47/2814\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The deleterious actions of TNFa may be mediated in part by the generation of reactive oxygen intermediates, an effect that might be inhibited by antioxidants [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these observations, three randomized trials of anti-TNFa therapy in patients with HF failed to show an improvement in clinical HF or morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link&amp;anchor=H18#H18\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Role in prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated levels of TNFa and other proinflammatory cytokines may have prognostic importance in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. This issue was best addressed by a study of 1200 patients with advanced heart failure enrolled in the VEST trial who were followed for a mean follow-up of 55 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/23\">",
"     23",
"    </a>",
"    ]. With respect to TNFa, higher plasma levels at baseline were associated with increased mortality. The relationship was influenced by age, sex, and the cause of heart failure. The plasma concentration of soluble TNFa receptors was also an adverse prognostic predictor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Role in prediction of HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;TNFa also may predict the development of HF in at least two settings: elderly patients and those who have undergone a heart transplant. The role in elderly adults was evaluated in a prospective review of 732 elderly subjects from the Framingham Heart Study who had no history of myocardial infarction or HF at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/26\">",
"     26",
"    </a>",
"    ]. At a mean follow-up of 5.2 years, 56 patients (7.7 percent) developed HF. After adjustment for risk factors, there was a 60 percent increase in HF risk for each tertile increment in spontaneous production of TNFa by peripheral blood mononuclear cells.",
"   </p>",
"   <p>",
"    Right ventricular failure after heart transplantation is an important problem that can result from either elevated pulmonary vascular resistance in the recipient or myocardial dysfunction of the donor heart. The possible role of TNFa was assessed in a report of 26 donor hearts in which transesophageal echocardiography and right ventricular biopsy were obtained immediately prior to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/40\">",
"     40",
"    </a>",
"    ]. TNFa was expressed in the donor heart of seven of eight patients who developed right ventricular failure after transplantation compared to 4 of 18 who did not (88 versus 22 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=see_link\">",
"     \"Prognosis after cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Interleukin-6",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with TNFa, IL-6 production is increased in patients in HF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/20-22\">",
"     20-22",
"    </a>",
"    ] and may contribute to disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/23,41,42\">",
"     23,41,42",
"    </a>",
"    ]. This issue was best addressed in the VEST trial cited above in which 1200 patients with advanced heart failure were followed for a mean follow-up of 55 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/23\">",
"     23",
"    </a>",
"    ]. Higher plasma levels of IL-6 at baseline were significantly associated with enhanced mortality.",
"   </p>",
"   <p>",
"    The increase in plasma IL-6 is at least in part derived from the peripheral circulation, where the rate of production varies with the severity of the heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/41\">",
"     41",
"    </a>",
"    ]. The rate of cytokine activation can be reduced by optimal medical therapy but persistently high IL-6 levels are associated with increased mortality. It is possible that elevated IL-6 contributes to the decline in cardiac function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with TFNa, plasma IL-6 also may predict the development of HF. This was illustrated in the above report of 732 elderly subjects from the Framingham Heart Study who had no history of myocardial infarction or HF at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/26\">",
"     26",
"    </a>",
"    ]. At a mean follow-up of 5.2 years, 56 patients (7.7 percent) developed HF. After adjustment for risk factors, there was a 68 percent increase in HF risk for each tertile increment in plasma IL-6. Plasma IL-6 was related to C-reactive protein levels, which could reflect the central role of IL-6 in the acute phase response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CHEMOKINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemokines (chemotactic cytokines) are a family of low molecular weight proteins that are potent chemoattractants of monocytes and may modulate the formation of reactive oxygen species and cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/44\">",
"     44",
"    </a>",
"    ]. As an example, one study of 44 patients with HF and 21 healthy control subjects found that those with HF had significantly elevated levels of all chemokines, including MCP-1, macrophage inflammatory protein-1 alpha, and RANTES (regulated on activation normally T-cell expressed and secreted) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/45\">",
"     45",
"    </a>",
"    ]. The levels were not related to the cause of HF but were inversely associated with left ventricular ejection fraction and were highest in patients with NYHA class IV functional status.",
"   </p>",
"   <p>",
"    Chemokines specific for neutrophils, called CXC chemokines, are distinguished from other chemokines by a protein motif in which the first two cysteines are separated by one amino acid. CXC chemokines are produced by many different cell types, including endothelial cells, platelets, neutrophils, T lymphocytes, and monocytes. The CXC cytokines include IL-8 (previously known as neutrophil activating peptide 1), neutrophil activating peptide-2 (NAP-2), and GRO-alpha. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17048?source=see_link\">",
"     \"Determinants of neutrophil movement\"",
"    </a>",
"    .) One report found that levels of all three CXC cytokines were significantly elevated in 47 patients with heart failure compared to 20 normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/46\">",
"     46",
"    </a>",
"    ]. The levels were directly related to the severity of heart failure evaluated both clinically and hemodynamically. Activated monocytes and platelets may contribute to the elevated levels of CXC chemokines.",
"   </p>",
"   <p>",
"    Treatment with intravenous immunoglobulin reduces the level of chemokines and chemokine gene expression, explaining, in part, the possible beneficial effect of this therapy in heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18809?source=see_link\">",
"     \"Possibly effective emerging therapies for heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CYCLOOXYGENASE-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclooxygenase-2 (COX-2), which is induced in many cells in response to cytokines, such as TNFa, and ischemia, is an enzyme that catalyzes the conversion of arachidonic acid to prostaglandins and thromboxane A2.",
"   </p>",
"   <p>",
"    COX-2 may play an important role in myocardial inflammation and injury. In one study, myocardial tissue from patients with end-stage heart failure had significant expression of COX-2 in myocytes and inflammatory cells within the area of fibrotic scar, but not in areas of normal myocardium; COX-2 expression was not seen in the myocardium of normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MYELOPEROXIDASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myeloperoxidase (MPO) is a leukocyte-derived enzyme that can produce a cascade of reactive oxidative species, which may lead to lipid peroxidation, scavenging of nitric oxide, and nitric oxide synthase inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Plasma MPO levels are elevated in patients with chronic systolic HF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/51\">",
"     51",
"    </a>",
"    ]. Elevated plasma MPO has been associated with an increased likelihood of more advanced HF and may be predictive of a higher rate of adverse clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ADRENOMEDULLIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenomedullin is a peptide that was originally isolated from human pheochromocytoma cells; it has an amino acid sequence that is similar to human calcitonin gene-related peptide, a potent vasodilator [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition to vasodilatory effects on the vasculature, adrenomedullin and its binding sites have been found in the heart and adrenomedullin enhances myocardial contractility via a cyclic AMP-independent mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/54\">",
"     54",
"    </a>",
"    ]. This suggests that adrenomedullin may play a role in the compensatory mechanisms in HF.",
"   </p>",
"   <p>",
"    Supporting this hypothesis is the observation that circulating levels of adrenomedullin are elevated in patients with HF and are correlated with the degree of left ventricular function and elevation in pulmonary artery pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/55\">",
"     55",
"    </a>",
"    ]. Levels are especially increased in those with evidence of diastolic dysfunction and a restrictive left ventricular filling pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/56\">",
"     56",
"    </a>",
"    ]. An infusion of adrenomedullin causes rapid and long-lasting arterial vasodilation in normal subjects; these actions, which are mediated by a nitric oxide-dependent mechanism, are attenuated in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/57\">",
"     57",
"    </a>",
"    ]. However, even this lesser degree of arterial vasodilation is sufficient to increase the cardiac index and reduce the pulmonary capillary wedge pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An elevated plasma adrenomedullin concentration is an independent predictor of a poor outcome in patients with ischemic cardiomyopathy. As an example, the Australia-New Zealand Heart Failure study of 297 patients found that patients with supramedian baseline serum adrenomedullin concentrations had, compared to those with inframedian levels, an increased risk of all-cause mortality (risk ratio 3.92), heart failure mortality (risk ratio 4.87), and hospital admission for heart failure (risk ratio 2.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/59\">",
"     59",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    reduced the risk of death or heart failure only in those with supramedian levels of serum adrenomedullin to rates comparable to those with inframedian values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COTRANSPORT INHIBITORY FACTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cotransport inhibitory factor (CIF) is a nondigitalis-like natriuretic factor that acts like loop diuretic drugs and inhibits the furosemide-sensitive sodium-potassium-chloride cotransport system. In contrast to ANP, CIF seems to regulate long-term renal sodium excretion. CIF plasma and urinary activities are increased in patients with HF and while they change in parallel with ANP and are correlated with the decrease in LVEF, the increase in plasma CIF is twice as great as those of plasma ANP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12872/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13275185\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heart failure (HF) is associated with alterations in a host of autocrine and paracrine signaling systems, many of which are involved in mediating inflammation, including nitric oxide (NO), inflammatory cytokines, chemokines, and cyclooxygenase. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nitric oxide is enzymatically formed from L-arginine by three isoforms of nitric oxide synthetase (NOS): neuronal-type (nNOS, NOS1), cytokine-inducible NOS (iNOS, NOS2), and the endothelial-type (eNOS, NOS3). There may be alterations in all three isoforms of NOS in HF. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nitric oxide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic HF is associated with arterial endothelial dysfunction and impaired endothelium-dependent, flow-mediated dilation; the mechanism is probably a reduction in NO synthesis via eNOS as well as a decrease in endothelial release of and response to NO. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'NOS in the endothelium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Heart failure is often characterized by increases in circulating proinflammatory cytokines (TNFa, interleukin [IL]-6, IL-1-beta, and IL-2) and their soluble receptor or receptor antagonists that become more pronounced as myocardial function deteriorates. In addition, increased production of proinflammatory cytokines and other inflammatory markers may identify patients at increased risk of developing HF in the future. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cytokines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/1\">",
"      F&ouml;rstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/2\">",
"      Katz SD, Khan T, Zeballos GA, et al. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 1999; 99:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/3\">",
"      Kubo SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991; 84:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/4\">",
"      Katz SD, Krum H, Khan T, Knecht M. Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium-derived nitric oxide. J Am Coll Cardiol 1996; 28:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/5\">",
"      Nightingale AK, Blackman DJ, Ellis GR, et al. Preservation of venous endothelial function in the forearm venous capacitance bed of patients with chronic heart failure despite arterial endothelial dysfunction. J Am Coll Cardiol 2001; 37:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/6\">",
"      Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 97:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/7\">",
"      Stein B, Eschenhagen T, R&uuml;diger J, et al. Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failure. J Am Coll Cardiol 1998; 32:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/8\">",
"      Damy T, Ratajczak P, Shah AM, et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 2004; 363:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/9\">",
"      Haywood GA, Tsao PS, von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996; 93:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/10\">",
"      Drexler H, K&auml;stner S, Strobel A, et al. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 1998; 32:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/11\">",
"      Comini L, Bachetti T, Agnoletti L, et al. Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor-alpha. Eur Heart J 1999; 20:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/12\">",
"      Scherrer-Crosbie M, Ullrich R, Bloch KD, et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001; 104:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/13\">",
"      Tatsumi T, Matoba S, Kawahara A, et al. Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J Am Coll Cardiol 2000; 35:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/14\">",
"      Hare JM, Loh E, Creager MA, Colucci WS. Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. Circulation 1995; 92:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/15\">",
"      Yamamoto S, Tsutsui H, Tagawa H, et al. Role of myocyte nitric oxide in beta-adrenergic hyporesponsiveness in heart failure. Circulation 1997; 95:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/16\">",
"      Hare JM, Givertz MM, Creager MA, Colucci WS. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. Circulation 1998; 97:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/17\">",
"      Shinke T, Takaoka H, Takeuchi M, et al. Nitric oxide spares myocardial oxygen consumption through attenuation of contractile response to beta-adrenergic stimulation in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/18\">",
"      Hare JM. Spatial confinement of isoforms of cardiac nitric-oxide synthase: unravelling the complexities of nitric oxide's cardiobiology. Lancet 2004; 363:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/19\">",
"      Riede UN, F&ouml;rstermann U, Drexler H. Inducible nitric oxide synthase in skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 1998; 32:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/20\">",
"      Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/21\">",
"      Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996; 28:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/22\">",
"      Mohler ER 3rd, Sorensen LC, Ghali JK, et al. Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. J Am Coll Cardiol 1997; 30:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/23\">",
"      Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/24\">",
"      Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/25\">",
"      Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102:3060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/26\">",
"      Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003; 107:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/27\">",
"      Murray DR, Freeman GL. Proinflammatory cytokines: predictors of a failing heart? Circulation 2003; 107:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/28\">",
"      Kelly RA, Smith TW. Cytokines and cardiac contractile function. Circulation 1997; 95:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/29\">",
"      Kapadia SR, Yakoob K, Nader S, et al. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 2000; 36:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/30\">",
"      Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000; 35:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/31\">",
"      Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/32\">",
"      Kapadia SR, Oral H, Lee J, et al. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 1997; 81:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/33\">",
"      Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999; 353:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/34\">",
"      Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998; 97:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/35\">",
"      Franco F, Thomas GD, Giroir B, et al. Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1999; 99:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/36\">",
"      Kadokami T, Frye C, Lemster B, et al. Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 2001; 104:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/37\">",
"      Kubota T, Bounoutas GS, Miyagishima M, et al. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation 2000; 101:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/38\">",
"      Bozkurt B, Kribbs SB, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/39\">",
"      Nakamura K, Fushimi K, Kouchi H, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998; 98:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/40\">",
"      Birks EJ, Owen VJ, Burton PB, et al. Tumor necrosis factor-alpha is expressed in donor heart and predicts right ventricular failure after human heart transplantation. Circulation 2000; 102:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/41\">",
"      Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998; 31:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/42\">",
"      Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/43\">",
"      Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev 2001; 6:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/44\">",
"      Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines. Adv Immunol 1994; 55:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/45\">",
"      Aukrust P, Ueland T, M&uuml;ller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998; 97:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/46\">",
"      Dam&aring;s JK, Gullestad L, Ueland T, et al. CXC-chemokines, a new group of cytokines in congestive heart failure--possible role of platelets and monocytes. Cardiovasc Res 2000; 45:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/47\">",
"      Dam&aring;s JK, Gullestad L, Aass H, et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure--modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 2001; 38:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/48\">",
"      Wong SC, Fukuchi M, Melnyk P, et al. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation 1998; 98:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/49\">",
"      Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005; 25:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/50\">",
"      Galijasevic S, Saed GM, Diamond MP, Abu-Soud HM. Myeloperoxidase up-regulates the catalytic activity of inducible nitric oxide synthase by preventing nitric oxide feedback inhibition. Proc Natl Acad Sci U S A 2003; 100:14766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/51\">",
"      Ng LL, Pathik B, Loke IW, et al. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J 2006; 152:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/52\">",
"      Tang WH, Tong W, Troughton RW, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 2007; 49:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/53\">",
"      Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/54\">",
"      Szokodi I, Kinnunen P, Tavi P, et al. Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation 1998; 97:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/55\">",
"      Nishikimi T, Saito Y, Kitamura K, et al. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 1995; 26:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/56\">",
"      Yu CM, Cheung BM, Leung R, et al. Increase in plasma adrenomedullin in patients with heart failure characterised by diastolic dysfunction. Heart 2001; 86:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/57\">",
"      Nakamura M, Yoshida H, Makita S, et al. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation 1997; 95:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/58\">",
"      Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2000; 101:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/59\">",
"      Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001; 37:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12872/abstract/60\">",
"      Dubois-Rand&eacute; JL, Montagne O, Alvarez-Guerra M, et al. Endogenous sodium-potassium-chloride cotransport inhibitor in congestive heart failure. J Am Coll Cardiol 1996; 28:1464.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3460 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12872=[""].join("\n");
var outline_f12_36_12872=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13275185\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NITRIC OXIDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NOS in the endothelium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Myocardium and skeletal muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CYTOKINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tumor necrosis factor-alpha",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Role in prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Role in prediction of HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Interleukin-6",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CHEMOKINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CYCLOOXYGENASE-2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MYELOPEROXIDASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ADRENOMEDULLIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COTRANSPORT INHIBITORY FACTOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13275185\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3460\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3460|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/43/16061\" title=\"figure 1\">",
"      Levels TNF and NYHA class",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/47/2814\" title=\"figure 2\">",
"      Tumor necrosis factor LV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=related_link\">",
"      Cardiac remodeling: Basic aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17048?source=related_link\">",
"      Determinants of neutrophil movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18809?source=related_link\">",
"      Possibly effective emerging therapies for heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=related_link\">",
"      Prognosis after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_36_12873="Aspartoacylase deficiency (Canavan disease)";
var content_f12_36_12873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Aspartoacylase deficiency (Canavan disease)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12873/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12873/contributors\">",
"     Alan K Percy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12873/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12873/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12873/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12873/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12873/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/36/12873/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspartoacylase deficiency (Canavan disease; MIM #271900) is an autosomal recessive spongiform leukodystrophy that is prevalent in, but not restricted to, Ashkenazi Jewish individuals. The disease typically begins in infancy and is marked by relentless progression.",
"   </p>",
"   <p>",
"    Canavan disease was first described in the early 20th century as spongy degeneration of central nervous system myelin in infancy. The linkage of Canavan disease with abnormal N-acetylaspartic acid (NAA) metabolism was not made until 1989 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/1\">",
"     1",
"    </a>",
"    ]. Elevated urinary NAA excretion and aspartoacylase deficiency had been reported two years previously, but without a direct association to spongy degeneration of myelin in infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/2\">",
"     2",
"    </a>",
"    ]. The aspartoacylase gene was cloned in 1993, and numerous mutations have been identified since then [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the Canavan disease eponym is widely used, aspartoacylase deficiency is preferable. Of interest, Canavan's own report was linked to Schilder disease or Krabbe disease (galactocerebrosidase deficiency) and not spongy degeneration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspartoacylase deficiency is caused by mutations in the ASPA gene that encodes the enzyme aspartoacylase. The resulting deficiency of aspartoacylase leads to accumulation of N-acetylaspartic acid (NAA) in the brain and to oligodendrocyte dysfunction, spongiform changes, and absence of myelin. However, the precise mechanisms causing spongiform degeneration are uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspartoacylase deficiency is transmitted in an autosomal recessive fashion. The gene encoding aspartoacylase (ASPA) is located on chromosome 17pter-p13 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/4\">",
"     4",
"    </a>",
"    ]. Several mutations have been defined in ASPA, but just four of them account for &gt;99 percent of aspartoacylase deficiency cases in Ashkenazi Jews [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/3,5,7-10\">",
"     3,5,7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In non-Ashkenazi individuals, a broad range of distinctly different mutations, including large deletions, has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/8-15\">",
"     8-15",
"    </a>",
"    ]. Unique ASPA mutations have been identified in the Japanese and Scandinavian populations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Biochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The linkage of aspartoacylase deficiency (Canavan disease) with abnormal N-acetylaspartic acid (NAA) metabolism was made in 1989 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    N-acetylaspartic acid, formed from acetyl-CoA and aspartic acid, is the second most prevalent free amino acid in the brain. It is localized to neurons, where it is synthesized within mitochondria, and to oligodendrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/18\">",
"     18",
"    </a>",
"    ]. In neurons, NAA is converted to N-acetylaspartylglutamate (NAAG) and is taken up by astrocytes, where it is hydrolyzed to NAA and glutamate. The NAA is then taken up by oligodendrocytes, the primary location of aspartoacylase [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aspartoacylase catalyzes the conversion of NAA to aspartate (aspartic acid) and acetate. By mechanisms that are largely unknown, deficiency of aspartoacylase leads to oligodendrocyte dysfunction, the prominent spongiform changes, and absence of myelin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Levels of NAA are markedly increased in plasma, urine, and cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Loss-of-function mutations of the ASPA gene lead to structural changes, including decreased thermal or conformational stability, which result in diminished or nearly absent enzymatic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal myelination, with associated prominence of swollen, vacuolated astrocytes, is a fundamental hallmark of aspartoacylase deficiency. However, the specific role of N-acetylaspartic acid (NAA) in the pathogenesis of this disease is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One suggestion is that a reduction in aspartic acid as a result of aspartoacylase deficiency adversely impacts the recycling of aspartate for NAA synthesis and the availability of aspartate for intercellular signaling [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another plausible hypothesis is that of a cytotoxic mechanism involving NAA or its metabolic product, N-acetylaspartylglutamate (NAAG) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It has been proposed that the extracellular concentration of NAA increases up to 1000-fold secondary to absent or markedly decreased aspartoacylase activity, resulting in disruption of the oligodendrocyte-axon interface and interruption of myelination [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. In an animal model, deficient aspartoacylase expression resulted in altered oligodendrocyte maturation, markedly reduced myelination, and increased levels of GFAP protein, a marker of gliosis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/37\">",
"       37",
"      </a>",
"      ]. In addition, NAA is taken up by astrocytes, producing the prominent vacuolization within their cytoplasm, and leading to macrocephaly. In this model, NAA is cytotoxic for astrocytes and not oligodendrocytes. The turnover of NAA is regarded as highly dynamic [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/38\">",
"       38",
"      </a>",
"      ]. As such, failure of NAA degradation could provide a profound osmotic force, resulting in the observed vacuolar changes in the brain [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/39\">",
"       39",
"      </a>",
"      ]. The disruption of mitochondria in astrocytes may be a secondary phenomenon, but a primary alteration in mitochondrial metabolism has been proposed as potentially related to the prominent cellular alterations.",
"     </li>",
"     <li>",
"      A further potential pathogenetic mechanism involves NAAG as a trigger of glutamate excitotoxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/40\">",
"       40",
"      </a>",
"      ]. The possibility of an acetate deficit secondary to low or absent aspartoacylase activity (NAA is hydrolyzed to acetate and L-aspartate) also has been suggested [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. This seems less likely, as alternate acetate sources are readily available via other metabolic pathways.",
"     </li>",
"     <li>",
"      Finally, oxidative stress may play a role in the pathogenesis of aspartoacylase deficiency, based upon evidence that NAA produces lipid peroxidation and protein oxidation and reduces antioxidants in rat brain [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspartoacylase deficiency is highly prevalent among Ashkenazi Jewish individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. It has been described in other populations as well, including a large series from Saudi Arabia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/45\">",
"     45",
"    </a>",
"    ]. The carrier frequency among the Ashkenazi ranges from 1:37 to 1:57, yielding a range of approximate prevalence rates between 1:6000 and 1:14,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The disorder is much less common in non-Ashkenazi populations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. However, sufficient data are not available to calculate a prevalence rate in groups other than Jewish people.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial presentation of aspartoacylase deficiency, generally at about age three months, features lethargy and listlessness, weak cry and suck, poor head control, and hypotonia with a paucity of extremity movement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/48\">",
"     48",
"    </a>",
"    ]. However, poor feeding, irritability, and visual inattention have been described in neonates.",
"   </p>",
"   <p>",
"    Macrocephaly becomes prominent by three to six months, and thereafter hypotonia progresses to spasticity, hyperreflexia, extensor plantar responses, and tonic extensor spasms. The extensor spasms may occur in response to noise, but infants with aspartoacylase deficiency do not exhibit the hyperacusis noted in Tay-Sachs disease.",
"   </p>",
"   <p>",
"    By age six months, neurologic abnormalities are invariant in those with the typical form of aspartoacylase deficiency. Little subsequent development is noted, although visual fixation may be acquired later only to be lost.",
"   </p>",
"   <p>",
"    Blindness in association with optic atrophy occurs between 6 and 18 months. Seizures, usually generalized tonic-clonic, are noted in about 50 percent. Unlike most leukodystrophies, the cerebrospinal fluid protein is usually normal. Fair complexion has been described, but this is of dubious significance.",
"   </p>",
"   <p>",
"    Pseudobulbar signs and decerebrate posturing dominate the end stage of aspartoacylase deficiency. Feeding is a major issue with prominent swallowing dysfunction and gastroesophageal reflux. Death may occur in childhood, although survival into the teens is typical as the result of enhanced medical management, particularly alternative feeding strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Variant forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of variant forms of aspartoacylase deficiency is controversial. A suggested juvenile-onset form, beginning after age five, is characterized by spasticity, cerebellar dysfunction, and blindness, with death occurring by the age of 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/49\">",
"     49",
"    </a>",
"    ]. Onset in adults, clinically resembling multiple sclerosis, also has been reported.",
"   </p>",
"   <p>",
"    Whether these variants represent aspartoacylase deficiency is unclear, as they were described prior to the availability of biochemical and molecular diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/49\">",
"     49",
"    </a>",
"    ]. At that time, the diagnosis was based upon the characteristic clinical features and demonstration of spongiform degeneration of the brain. However, this is a nonspecific pathology shared by a number of other unrelated conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Later studies have not found evidence supporting a distinct juvenile form of aspartoacylase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/24\">",
"     24",
"    </a>",
"    ]. Rather, they suggest that the disease typically begins in infancy but progresses at a highly variable rate.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study reported 22 Ashkenazi infants with Canavan disease and typical onset in infancy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/50\">",
"       50",
"      </a>",
"      ]. There were 14 patients younger than age 6 who were clinically stable. Two patients died before the age of 5. Survival beyond age 5 was noted in six patients, with ages at death ranging from 6 to 17 years.",
"     </li>",
"     <li>",
"      Another series of 60 children, mainly Ashkenazi, with onset prior to 10 months of life demonstrated high variability in survival, including significantly different longevity in two siblings from two families [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors in both studies concluded that despite variable survival, these children did not represent variant forms of aspartoacylase deficiency. In subsequent reports, milder disease expression has been associated with specific ASPA gene mutations that may produce a relatively benign phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with aspartoacylase deficiency, cranial imaging by CT and MRI reveal diffuse and symmetrical white matter involvement. CT shows marked reduction of white matter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]. MRI demonstrates white matter that is hypointense on T1 and hyperintense on T2 (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51056 \" href=\"UTD.htm?40/52/41807\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83743 \" href=\"UTD.htm?10/36/10824\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. Diffusion-weighted MRI sequences reveal restricted diffusion in deep white matter and brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/59\">",
"     59",
"    </a>",
"    ]. In individuals with delayed onset and slower progression, brain MRI may show less prominent white matter changes and increased signal intensity in basal ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance spectroscopy (MRS) typically shows markedly increased levels of N-acetylaspartic acid (NAA) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83741 \" href=\"UTD.htm?31/51/32562\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/57,58,62,63\">",
"     57,58,62,63",
"    </a>",
"    ]. MRS is also being studied to track the natural progression of metabolite changes and could serve as a measure for monitoring therapeutic interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/64\">",
"     64",
"    </a>",
"    ]. In some instances, NAA levels are normal, but other metabolites are reduced, yielding elevated ratios of",
"    <span class=\"nowrap\">",
"     NAA/choline",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     NAA/creatine",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neuropathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain weight is increased significantly in aspartoacylase deficiency, reflecting the prominent macrocephaly noted in early infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/49\">",
"     49",
"    </a>",
"    ]. However, by age 30 months, brain weight may be normal, reflecting the progressive white matter loss [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gross pathologic findings are dominated by spongy degeneration of deep cortex, subcortical white matter, and cerebellum. The spongiform changes reflect vacuolated astrocytes in deeper cortical layers and in adjacent subcortical white matter. Grossly enlarged Alzheimer type II astrocytes are seen in gray matter.",
"   </p>",
"   <p>",
"    Ultrastructural studies reveal disruption of mitochondria in astrocytes. Myelin is markedly reduced and may be virtually absent in some areas. Myelin lamellae within subcortical white matter are separated by vacuoles. With prolonged survival, white matter is depleted and vacuolization is present throughout the cortex.",
"   </p>",
"   <p>",
"    Unlike galactosylceramide lipidosis (Krabbe disease) and sulfatide lipidosis (metachromatic leukodystrophy), peripheral nerves are generally uninvolved in aspartoacylase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/49\">",
"     49",
"    </a>",
"    ]. An early report, prior to biochemical or molecular diagnosis, did identify peripheral nerve changes including axonopathy and demyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As affected individuals are unlikely to reproduce, no information is available regarding pregnancy in patients with aspartoacylase deficiency.",
"   </p>",
"   <p>",
"    Findings from the knock-out mouse model suggest reduced reproductive health in the homozygous affected females and heightened fetal lethality (50 percent fewer",
"    <span class=\"nowrap\">",
"     pups/litter)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis of aspartoacylase deficiency is relatively straightforward. In symptomatic infants with compatible clinical features (eg, hypotonia, poor head control, macrocephaly) and neuroimaging findings, the diagnosis is supported by elevated levels of urine N-acetylaspartic acid (NAA) and deficient aspartoacylase activity in cultured skin fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/24\">",
"     24",
"    </a>",
"    ]. Genetic testing is not required if elevated urine NAA and skin fibroblast testing are diagnostic, but may be obtained for purposes of genetic counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with clinical features and cranial imaging findings suggesting aspartoacylase deficiency, one should request measurement of N-acetylaspartic acid (NAA) in urine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/68\">",
"     68",
"    </a>",
"    ] or, more specifically, aspartoacylase activity determination in cultured skin fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urine levels of NAA are increased up to 200 times normal in aspartoacylase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/25\">",
"     25",
"    </a>",
"    ]. This measurement is determined by gas",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectrometry. In one report, the mean concentration of urinary NAA in patients with neonatal or infantile (severe) aspartoacylase deficiency was 1441",
"    <span class=\"nowrap\">",
"     micromol/mmol",
"    </span>",
"    creatinine, versus 24",
"    <span class=\"nowrap\">",
"     micromol/mmol",
"    </span>",
"    creatinine in controls [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/24\">",
"     24",
"    </a>",
"    ]. Occasional patients with aspartoacylase deficiency have lower levels of urine NAA excretion, but the levels are still approximately five- to ten-fold higher than normal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In affected infants, levels of NAA are also increased in plasma (up to 20 times normal) and in cerebrospinal fluid, but elevated urine NAA is sufficient to support the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aspartoacylase activity can be measured reliably in cultured skin fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/1,69,71\">",
"     1,69,71",
"    </a>",
"    ]. This test is used to confirm the chemical diagnosis and to rule out false positives, particularly for patients who have an elevation of urine NAA that is lower than usual for aspartoacylase deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Molecular genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients diagnosed with aspartoacylase deficiency by elevated urine NAA levels, targeted molecular genetic testing of the patient and family members can be useful for purposes of genetic counseling, particularly in Ashkenazi children where the number of possible mutations is small, or in families with a previously affected sibling whose mutation is known. In non-Ashkenazi families with their first affected child and no previously identified mutation, complete molecular testing may be required in order to provide genetic counseling, especially when the family may wish to consider a future pregnancy.",
"   </p>",
"   <p>",
"    Targeted mutation analysis can identify specific alleles that cause most cases of aspartoacylase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Ashkenazi Jewish cases, two mutations &ndash; p.Glu285Ala and p.Tyr231X &ndash; are found in approximately 98 percent of disease-causing alleles [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/12\">",
"       12",
"      </a>",
"      ]. Two other mutations &ndash; p.Ala305Glu and c.433-2A&gt;G &ndash; each account for approximately one percent of alleles [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In non-Jewish patients of European origin, the p.Ala305Glu mutation accounts for 40 to 60 percent of disease-causing alleles [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/8,10\">",
"       8,10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sequence analysis of the ASPA coding region can be performed when targeted mutation analysis fails to identify disease-causing alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/24\">",
"     24",
"    </a>",
"    ]. Complete or partial deletions of the entire ASPA gene in aspartoacylase deficiency are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/14,72\">",
"     14,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis is possible, but must be approached cautiously [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. Aspartoacylase activity in cultured chorionic villi and amniocytes is measurable, but is often too low to discriminate affected from carriers reliably [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Thus, prenatal diagnosis by biochemical markers is best accomplished by measuring N-acetylaspartic acid (NAA) levels in amniotic fluid using stable isotope dilution coupled with gas",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectrometry and by molecular analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For pregnancies at 25 percent risk (ie, the parents are each carriers of a disease-causing mutation in the ASPA gene, or the mutation is known from a previously affected offspring), mutation analysis can be performed from cells obtained using chorionic villous sampling at approximately 10 to 12 weeks gestation, or amniocentesis at approximately 15 to 38 weeks gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/24,74,79\">",
"     24,74,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preimplantation diagnosis using single cell molecular methodologies has been accomplished successfully in one of two families evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of aspartoacylase deficiency includes other progressive white matter diseases of infancy, particularly the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Krabbe disease (galactosylceramide lipidosis) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4038?source=see_link\">",
"       \"Krabbe disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Metachromatic leukodystrophy (sulfatide lipidosis) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42421?source=see_link\">",
"       \"Metachromatic leukodystrophy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Early-onset adrenoleukodystrophy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=see_link\">",
"       \"Adrenoleukodystrophy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Alexander disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40872?source=see_link\">",
"       \"Alexander disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Demyelinating disorders such as acute demyelinating encephalomyelitis and multiple sclerosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1352?source=see_link\">",
"       \"Differential diagnosis of acute central nervous system demyelination in children\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Spongiform degeneration of the brain is a nonspecific pathology shared by a number of other unrelated conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/50\">",
"     50",
"    </a>",
"    ]. These include certain mitochondrial disorders (eg, Leigh syndrome), metabolic diseases (eg, glycine encephalopathy), and viral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The subsequent clinical course, cranial imaging abnormalities, and biochemical studies should differentiate aspartoacylase deficiency from the others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effective treatment is available for aspartoacylase deficiency. Management is supportive and aimed at maintaining nutrition and hydration, protecting the airway, preventing seizures, minimizing contractures, and treating infections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/24\">",
"     24",
"    </a>",
"    ]. Assessment of nutritional and developmental status is recommended to guide management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A feeding gastrostomy tube is typically needed to maintain adequate nutrition and hydration in the presence of dysphagia. A gastrostomy tube can also reduce the risk of aspiration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/16/30985?source=see_link&amp;anchor=H12#H12\">",
"       \"Management of failure to thrive (undernutrition) in children younger than two years\", section on 'Nutritional therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Seizures are treated with standard antiepileptic drugs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=see_link\">",
"       \"Overview of the treatment of seizures and epileptic syndromes in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exercise (physical therapy) and position changes are helpful to reduce the risk of contractures and decubitus ulcers, and to improve sitting posture.",
"     </li>",
"     <li>",
"      Special education programs and interventions to enhance communication skills may be helpful, particularly for those with a less severe clinical course.",
"     </li>",
"     <li>",
"      Botulinum toxin injections can be used to treat spasticity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Investigational therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene transfer, enzyme replacement therapy, acetate supplementation, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    are being studied as possible treatments for aspartoacylase deficiency.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of preliminary studies have evaluated gene transfer:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The combined delivery of liposome enclosed enzyme and viral vector-mediated gene transduction was employed in two children [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]. While successful delivery could be demonstrated, the results did not demonstrate substantial efficacy.",
"     </li>",
"     <li>",
"      Adeno-associated viral vector mediated gene transfer of ASPA was studied in 10 children with aspartoacylase deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/83,84\">",
"       83,84",
"      </a>",
"      ]. No significant adverse immune response was noted, and no statement on efficacy was available.",
"     </li>",
"     <li>",
"      A knock-out mouse model has been developed, paving the way for additional gene therapy studies [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/67,85-90\">",
"       67,85-90",
"      </a>",
"      ], and a spontaneously arising rat model with aspartoacylase deficiency also has been developed [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/91\">",
"       91",
"      </a>",
"      ]. Effective gene transfer using an adeno-associated viral vector has been demonstrated in each model [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/92,93\">",
"       92,93",
"      </a>",
"      ]. Further, neural progenitor cells have been transplanted successfully in the mouse knock-out model and have differentiated into myelin forming oligodendrocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Modified aspartoacylase has been shown to reach the central nervous system following intraperitoneal injection, resulting in a reduction of N-acetylaspartic acid (NAA) levels [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/95\">",
"       95",
"      </a>",
"      ]. This finding suggests that enzyme replacement approaches may be examined in this model.",
"     </li>",
"     <li>",
"      Acetate supplementation has been proposed as potentially beneficial for myelin formation by oligodendrocytes based upon the presumption that aspartoacylase deficiency and resultant acetate deficiency in these cells could be responsible for abnormal myelination [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/41\">",
"       41",
"      </a>",
"      ]. As noted earlier (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above), given the multiple metabolic sources of acetate, this hypothesis seems unlikely. Nonetheless, the acetate precursor glyceryl triacetate was evaluated in low doses (up to 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily) in two children with aspartoacylase deficiency and in higher doses (up to 5.8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily) in an animal model [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/96\">",
"       96",
"      </a>",
"      ]. No evidence of toxicity was noted with either dosing schedule. In addition, the two children demonstrated no further clinical deterioration, providing a rationale for evaluating a larger dose in affected children. In an earlier study, acetate supplementation in normal mice did increase acetate levels in brain [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intraperitoneal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      chloride injection produced reduction, albeit modest, of brain NAA levels in the spontaneous rat model of aspartoacylase deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/97\">",
"       97",
"      </a>",
"      ]. In a study of six children with Canavan disease, lithium citrate administration was associated with a small but statistically significant decline in brain NAA detected by magnetic resonance spectroscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12873/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aspartoacylase deficiency (Canavan disease; MIM #271900) is an autosomal recessive spongiform leukodystrophy that is prevalent in the Ashkenazi Jewish population. The disease typically begins in infancy and is marked by relentless progression. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aspartoacylase deficiency is caused by mutations in the ASPA gene that encodes the enzyme aspartoacylase. The resulting deficiency of aspartoacylase leads to accumulation of N-acetylaspartic acid (NAA) in brain and to oligodendrocyte dysfunction, spongiform changes, and absence of myelin. However, the precise mechanisms causing to spongiform degeneration are uncertain. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aspartoacylase deficiency is highly prevalent among Ashkenazi Jewish individuals, but is much less common in other populations (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Epidemiology'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Aspartoacylase deficiency typically presents at about age three months with lethargy and listlessness, weak cry and suck, poor head control, and hypotonia with a paucity of extremity movement. Macrocephaly becomes prominent by three to six months. Thereafter hypotonia progresses to spasticity and tonic extensor spasms. By age six months, neurologic abnormalities are invariant. Little subsequent development is noted. Blindness from optic atrophy occurs between 6 and 18 months. Seizures are noted in about 50 percent of patients. Pseudobulbar signs and decerebrate posturing dominate the end stage. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of variant forms of aspartoacylase deficiency is controversial. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Variant forms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain imaging by CT and MRI reveals diffuse and symmetrical white matter involvement. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The gross pathologic findings are dominated by spongy degeneration of deep cortex, subcortical white matter, and cerebellum. The spongiform changes reflect vacuolated astrocytes in deeper cortical layers and in adjacent subcortical white matter. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Neuropathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In symptomatic infants with compatible clinical features (eg, hypotonia, poor head control, macrocephaly) and neuroimaging findings, the diagnosis of aspartoacylase deficiency is supported by elevated levels of urine N-acetylaspartic acid (NAA) and deficient aspartoacylase activity in cultured skin fibroblasts. Genetic testing may be obtained for purposes of genetic counseling. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of aspartoacylase deficiency includes other progressive white matter diseases of infancy, particularly Krabbe disease, metachromatic leukodystrophy, early-onset adrenoleukodystrophy, Alexander disease, and demyelinating disorders (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      No effective treatment is available for aspartoacylase deficiency. Management is supportive and aimed at maintaining nutrition and hydration, protecting the airway, preventing seizures, minimizing contractures, and treating infections. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/1\">",
"      Matalon R, Kaul R, Casanova J, et al. SSIEM Award. Aspartoacylase deficiency: the enzyme defect in Canavan disease. J Inherit Metab Dis 1989; 12 Suppl 2:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/2\">",
"      Hagenfeldt L, Bollgren I, Venizelos N. N-acetylaspartic aciduria due to aspartoacylase deficiency--a new aetiology of childhood leukodystrophy. J Inherit Metab Dis 1987; 10:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/3\">",
"      Kaul R, Gao GP, Balamurugan K, Matalon R. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat Genet 1993; 5:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/4\">",
"      Kaul R, Balamurugan K, Gao GP, Matalon R. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution. Genomics 1994; 21:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/5\">",
"      Kaul R, Gao GP, Balamurugan K, Matalon R. Canavan disease: molecular basis of aspartoacylase deficiency. J Inherit Metab Dis 1994; 17:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/6\">",
"      Matalon R, Michals-Matalon K. Biochemistry and molecular biology of Canavan disease. Neurochem Res 1999; 24:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/7\">",
"      Elpeleg ON, Anikster Y, Barash V, et al. The frequency of the C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel. Am J Hum Genet 1994; 55:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/8\">",
"      Kaul R, Gao GP, Aloya M, et al. Canavan disease: mutations among Jewish and non-Jewish patients. Am J Hum Genet 1994; 55:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/9\">",
"      Shaag A, Anikster Y, Christensen E, et al. The molecular basis of canavan (aspartoacylase deficiency) disease in European non-Jewish patients. Am J Hum Genet 1995; 57:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/10\">",
"      Elpeleg ON, Shaag A. The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-Jewish patients. J Inherit Metab Dis 1999; 22:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/11\">",
"      Kaul R, Gao GP, Matalon R, et al. Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. Am J Hum Genet 1996; 59:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/12\">",
"      Sistermans EA, de Coo RF, van Beerendonk HM, et al. Mutation detection in the aspartoacylase gene in 17 patients with Canavan disease: four new mutations in the non-Jewish population. Eur J Hum Genet 2000; 8:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/13\">",
"      Zeng BJ, Wang ZH, Ribeiro LA, et al. Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease. J Inherit Metab Dis 2002; 25:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/14\">",
"      Zeng BJ, Wang ZH, Torres PA, et al. Rapid detection of three large novel deletions of the aspartoacylase gene in non-Jewish patients with Canavan disease. Mol Genet Metab 2006; 89:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/15\">",
"      Zeng BJ, Pastores GM, Leone P, et al. Mutation analysis of the aspartoacylase gene in non-Jewish patients with Canavan disease. Adv Exp Med Biol 2006; 576:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/16\">",
"      Kobayashi K, Tsujino S, Ezoe T, et al. Missense mutation (I143T) in a Japanese patient with Canavan disease. Hum Mutat 1998; Suppl 1:S308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/17\">",
"      Olsen TR, Tranebjaerg L, Kvittingen EA, et al. Two novel aspartoacylase gene (ASPA) missense mutations specific to Norwegian and Swedish patients with Canavan disease. J Med Genet 2002; 39:e55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/18\">",
"      Moreno A, Ross BD, Bl&uuml;ml S. Direct determination of the N-acetyl-L-aspartate synthesis rate in the human brain by (13)C MRS and [1-(13)C]glucose infusion. J Neurochem 2001; 77:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/19\">",
"      Baslow MH. N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem Res 2003; 28:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/20\">",
"      Baslow MH, Suckow RF, Sapirstein V, Hungund BL. Expression of aspartoacylase activity in cultured rat macroglial cells is limited to oligodendrocytes. J Mol Neurosci 1999; 13:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/21\">",
"      Kirmani BF, Jacobowitz DM, Kallarakal AT, Namboodiri MA. Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease. Brain Res Mol Brain Res 2002; 107:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/22\">",
"      Chakraborty G, Mekala P, Yahya D, et al. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J Neurochem 2001; 78:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/23\">",
"      Kirmani BF, Jacobowitz DM, Namboodiri MA. Developmental increase of aspartoacylase in oligodendrocytes parallels CNS myelination. Brain Res Dev Brain Res 2003; 140:105.",
"     </a>",
"    </li>",
"    <li>",
"     Matalon R, Michals-Matalon K. Canavan Disease. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1234/ (Accessed on May 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/25\">",
"      Burlina AP, Corazza A, Ferrari V, et al. Detection of increased urinary N-acetylaspartylglutamate in Canavan disease. Eur J Pediatr 1994; 153:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/26\">",
"      Hershfield JR, Pattabiraman N, Madhavarao CN, Namboodiri MA. Mutational analysis of aspartoacylase: implications for Canavan disease. Brain Res 2007; 1148:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/27\">",
"      Zano S, Wijayasinghe YS, Malik R, et al. Relationship between enzyme properties and disease progression in Canavan disease. J Inherit Metab Dis 2013; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/28\">",
"      Kumar S, Mattan NS, de Vellis J. Canavan disease: a white matter disorder. Ment Retard Dev Disabil Res Rev 2006; 12:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/29\">",
"      Baslow MH. Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease. J Mol Neurosci 2000; 15:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/30\">",
"      Moffett JR, Ross B, Arun P, et al. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/31\">",
"      Baslow MH, Resnik TR. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms. J Mol Neurosci 1997; 9:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/32\">",
"      Kolodziejczyk K, Hamilton NB, Wade A, et al. The effect of N-acetyl-aspartyl-glutamate and N-acetyl-aspartate on white matter oligodendrocytes. Brain 2009; 132:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/33\">",
"      Kumar S, Biancotti JC, Matalon R, de Vellis J. Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease. J Neurosci Res 2009; 87:3415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/34\">",
"      Namboodiri AM, Peethambaran A, Mathew R, et al. Canavan disease and the role of N-acetylaspartate in myelin synthesis. Mol Cell Endocrinol 2006; 252:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/35\">",
"      Namboodiri AM, Moffett JR, Arun P, et al. Defective myelin lipid synthesis as a pathogenic mechanism of Canavan disease. Adv Exp Med Biol 2006; 576:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/36\">",
"      Kumar S, Sowmyalakshmi R, Daniels SL, et al. Does ASPA gene mutation in Canavan disease alter oligodendrocyte development? A tissue culture study of ASPA KO mice brain. Adv Exp Med Biol 2006; 576:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/37\">",
"      Mattan NS, Ghiani CA, Lloyd M, et al. Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination. Neurobiol Dis 2010; 40:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/38\">",
"      Baslow MH. Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation. J Mol Neurosci 2003; 21:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/39\">",
"      Baslow MH, Guilfoyle DN. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease? Neurochem Res 2009; 34:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/40\">",
"      Burlina AP, Ferrari V, Divry P, et al. N-acetylaspartylglutamate in Canavan disease: an adverse effector? Eur J Pediatr 1999; 158:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/41\">",
"      Mathew R, Arun P, Madhavarao CN, et al. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain. J Pharmacol Exp Ther 2005; 315:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/42\">",
"      Madhavarao CN, Arun P, Moffett JR, et al. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc Natl Acad Sci U S A 2005; 102:5221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/43\">",
"      Pederzolli CD, Mescka CP, Scapin F, et al. N-acetylaspartic acid promotes oxidative stress in cerebral cortex of rats. Int J Dev Neurosci 2007; 25:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/44\">",
"      Pederzolli CD, Rockenbach FJ, Zanin FR, et al. Intracerebroventricular administration of N-acetylaspartic acid impairs antioxidant defenses and promotes protein oxidation in cerebral cortex of rats. Metab Brain Dis 2009; 24:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/45\">",
"      Gascon GG, Ozand PT, Mahdi A, et al. Infantile CNS spongy degeneration--14 cases: clinical update. Neurology 1990; 40:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/46\">",
"      Kronn D, Oddoux C, Phillips J, Ostrer H. Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population. Am J Hum Genet 1995; 57:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/47\">",
"      Feigenbaum A, Moore R, Clarke J, et al. Canavan disease: carrier-frequency determination in the Ashkenazi Jewish population and development of a novel molecular diagnostic assay. Am J Med Genet A 2004; 124A:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/48\">",
"      Traeger EC, Rapin I. The clinical course of Canavan disease. Pediatr Neurol 1998; 18:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/49\">",
"      Adachi M, Schneck L, Cara J, Volk BW. Spongy degeneration of the central nervous system (van Bogaert and Bertrand type; Canavan's disease). A review. Hum Pathol 1973; 4:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/50\">",
"      Zelnik N, Luder AS, Elpeleg ON, et al. Protracted clinical course for patients with Canavan disease. Dev Med Child Neurol 1993; 35:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/51\">",
"      Zafeiriou DI, Kleijer WJ, Maroupoulos G, et al. Protracted course of N-acetylaspartic aciduria in two non-Jewish siblings: identical clinical and magnetic resonance imaging findings. Brain Dev 1999; 21:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/52\">",
"      Tacke U, Olbrich H, Sass JO, et al. Possible genotype-phenotype correlations in children with mild clinical course of Canavan disease. Neuropediatrics 2005; 36:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/53\">",
"      Janson CG, Kolodny EH, Zeng BJ, et al. Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene. Ann Neurol 2006; 59:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/54\">",
"      Rushton AR, Shaywitz BA, Duncan CC, et al. Computed tomography in the diagnosis of Canavan's disease. Ann Neurol 1981; 10:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/55\">",
"      McAdams HP, Geyer CA, Done SL, et al. CT and MR imaging of Canavan disease. AJNR Am J Neuroradiol 1990; 11:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/56\">",
"      Brismar J, Brismar G, Gascon G, Ozand P. Canavan disease: CT and MR imaging of the brain. AJNR Am J Neuroradiol 1990; 11:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/57\">",
"      Marks HG, Caro PA, Wang ZY, et al. Use of computed tomography, magnetic resonance imaging, and localized 1H magnetic resonance spectroscopy in Canavan's disease: a case report. Ann Neurol 1991; 30:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/58\">",
"      Michel SJ, Given CA 2nd. Case 99: Canavan disease. Radiology 2006; 241:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/59\">",
"      Srikanth SG, Chandrashekar HS, Nagarajan K, Jayakumar PN. Restricted diffusion in Canavan disease. Childs Nerv Syst 2007; 23:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/60\">",
"      Toft PB, Geiss-Holtorff R, Rolland MO, et al. Magnetic resonance imaging in juvenile Canavan disease. Eur J Pediatr 1993; 152:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/61\">",
"      Yalcinkaya C, Benbir G, Salomons GS, et al. Atypical MRI findings in Canavan disease: a patient with a mild course. Neuropediatrics 2005; 36:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/62\">",
"      Wittsack HJ, Kugel H, Roth B, Heindel W. Quantitative measurements with localized 1H MR spectroscopy in children with Canavan's disease. J Magn Reson Imaging 1996; 6:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/63\">",
"      Galanaud D, Nicoli F, Confort-Gouny S, et al. [Brain magnetic resonance spectroscopy]. J Radiol 2007; 88:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/64\">",
"      Janson CG, McPhee SW, Francis J, et al. Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI. Neuropediatrics 2006; 37:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/65\">",
"      Barker PB, Bryan RN, Kumar AJ, Naidu S. Proton NMR spectroscopy of Canavan's disease. Neuropediatrics 1992; 23:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/66\">",
"      Suzuki K. Peripheral nerve lesion in spongy degeneration of the central nervous system. Acta Neuropathol 1968; 10:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/67\">",
"      Surendran S, Ezell EL, Quast MJ, et al. Aspartoacylase deficiency does not affect N-acetylaspartylglutamate level or glutamate carboxypeptidase II activity in the knockout mouse brain. Brain Res 2004; 1016:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/68\">",
"      Inoue Y, Kuhara T. Rapid and sensitive screening for and chemical diagnosis of Canavan disease by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 806:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/69\">",
"      Matalon R, Michals K, Sebesta D, et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 1988; 29:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/70\">",
"      Matalon R, Kaul R, Michals K. Canavan disease: biochemical and molecular studies. J Inherit Metab Dis 1993; 16:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/71\">",
"      Ozand PT, Gascon GG, Dhalla M. Aspartoacylase deficiency and Canavan disease in Saudi Arabia. Am J Med Genet 1990; 35:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/72\">",
"      Kaya N, Imtiaz F, Colak D, et al. Genome-wide gene expression profiling and mutation analysis of Saudi patients with Canavan disease. Genet Med 2008; 10:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/73\">",
"      Matalon R, Michals K, Gashkoff P, Kaul R. Prenatal diagnosis of Canavan disease. J Inherit Metab Dis 1992; 15:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/74\">",
"      Matalon R, Kaul R, Gao GP, et al. Prenatal diagnosis for Canavan disease: the use of DNA markers. J Inherit Metab Dis 1995; 18:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/75\">",
"      Besley GT, Elpeleg ON, Shaag A, et al. Prenatal diagnosis of Canavan disease--problems and dilemmas. J Inherit Metab Dis 1999; 22:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/76\">",
"      Rolland MO, Divry P, Mandon G, et al. First-trimester prenatal diagnosis of Canavan disease. J Inherit Metab Dis 1993; 16:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/77\">",
"      Rolland MO, Mandon G, Bernard A, et al. Unreliable verification of prenatal diagnosis of Canavan disease: aspartoacylase activity in deficient and normal fetal skin fibroblasts. J Inherit Metab Dis 1994; 17:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/78\">",
"      Al-Dirbashi OY, Kurdi W, Imtiaz F, et al. Reliable prenatal diagnosis of Canavan disease by measuring N-acetylaspartate in amniotic fluid using liquid chromatography tandem mass spectrometry. Prenat Diagn 2009; 29:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/79\">",
"      Elpeleg ON, Shaag A, Anikster Y, Jakobs C. Prenatal detection of Canavan disease (aspartoacylase deficiency) by DNA analysis. J Inherit Metab Dis 1994; 17:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/80\">",
"      Yaron Y, Schwartz T, Mey-Raz N, et al. Preimplantation genetic diagnosis of Canavan disease. Fetal Diagn Ther 2005; 20:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/81\">",
"      Leone P, Janson CG, McPhee SJ, During MJ. Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease. Curr Opin Mol Ther 1999; 1:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/82\">",
"      Leone P, Janson CG, Bilaniuk L, et al. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol 2000; 48:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/83\">",
"      Janson C, McPhee S, Bilaniuk L, et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 2002; 13:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/84\">",
"      McPhee SW, Janson CG, Li C, et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 2006; 8:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/85\">",
"      Matalon R, Rady PL, Platt KA, et al. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. J Gene Med 2000; 2:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/86\">",
"      Surendran S, Rady PL, Michals-Matalon K, et al. Expression of glutamate transporter, GABRA6, serine proteinase inhibitor 2 and low levels of glutamate and GABA in the brain of knock-out mouse for Canavan disease. Brain Res Bull 2003; 61:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/87\">",
"      Surendran S, Matalon KM, Szucs S, et al. Metabolic changes in the knockout mouse for Canavan's disease: implications for patients with Canavan's disease. J Child Neurol 2003; 18:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/88\">",
"      Surendran S, Ezell EL, Quast MJ, et al. Mental retardation and hypotonia seen in the knock out mouse for Canavan disease is not due to succinate semialdehyde dehydrogenase deficiency. Neurosci Lett 2004; 358:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/89\">",
"      Surendran S, Szucs S, Tyring SK, Matalon R. Aspartoacylase gene knockout in the mouse: impact on reproduction. Reprod Toxicol 2005; 20:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/90\">",
"      Matalon R, Michals-Matalon K, Surendran S, Tyring SK. Canavan disease: studies on the knockout mouse. Adv Exp Med Biol 2006; 576:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/91\">",
"      Kitada K, Akimitsu T, Shigematsu Y, et al. Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system. J Neurochem 2000; 74:2512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/92\">",
"      Matalon R, Surendran S, Rady PL, et al. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. Mol Ther 2003; 7:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/93\">",
"      McPhee SW, Francis J, Janson CG, et al. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease. Brain Res Mol Brain Res 2005; 135:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/94\">",
"      Surendran S, Shihabuddin LS, Clarke J, et al. Mouse neural progenitor cells differentiate into oligodendrocytes in the brain of a knockout mouse model of Canavan disease. Brain Res Dev Brain Res 2004; 153:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/95\">",
"      Zano S, Malik R, Szucs S, et al. Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease. Mol Genet Metab 2011; 102:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/96\">",
"      Madhavarao CN, Arun P, Anikster Y, et al. Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model. J Inherit Metab Dis 2009; 32:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/97\">",
"      Baslow MH, Kitada K, Suckow RF, et al. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats. Neurochem Res 2002; 27:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12873/abstract/98\">",
"      Assadi M, Janson C, Wang DJ, et al. Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease. Eur J Paediatr Neurol 2010; 14:354.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1702 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-537ACF1ECA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12873=[""].join("\n");
var outline_f12_36_12873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Biochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Variant forms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neuropathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Molecular genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1702\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1702|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/52/41807\" title=\"diagnostic image 1\">",
"      T2-weighted MRI Canavan disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/36/10824\" title=\"diagnostic image 2\">",
"      Brain MRI 1-year-old girl Canavan disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/51/32562\" title=\"diagnostic image 3\">",
"      Magnetic resonance spectroscopy Canavan disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=related_link\">",
"      Adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40872?source=related_link\">",
"      Alexander disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1352?source=related_link\">",
"      Differential diagnosis of acute central nervous system demyelination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4038?source=related_link\">",
"      Krabbe disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/16/30985?source=related_link\">",
"      Management of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42421?source=related_link\">",
"      Metachromatic leukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_36_12874="Clinical manifestations and diagnosis of sphincter of Oddi dysfunction";
var content_f12_36_12874=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of sphincter of Oddi dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12874/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12874/contributors\">",
"     Lyndon V Hernandez, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12874/contributors\">",
"     Marc F Catalano, MD, FACP, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12874/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12874/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/36/12874/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/36/12874/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/36/12874/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sphincter of Oddi is a muscular structure that encompasses the confluence of the distal common bile duct and the pancreatic duct as they penetrate the wall of the duodenum (",
"    <a class=\"graphic graphic_figure graphicRef78786 \" href=\"UTD.htm?27/17/27924\">",
"     figure 1",
"    </a>",
"    ). The term sphincter of Oddi dysfunction (SOD) has been used to describe a clinical syndrome of biliary or pancreatic obstruction related to mechanical or functional abnormalities of the sphincter of Oddi.",
"   </p>",
"   <p>",
"    The literature regarding SOD is often difficult to interpret because of differences in nomenclature [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/1\">",
"     1",
"    </a>",
"    ]. The terms papillary stenosis, sclerosing papillitis, biliary spasm, biliary dyskinesia, and postcholecystectomy syndrome have been used synonymously with SOD. Despite this source of confusion, two separate pathologic entities are widely recognized based upon their distinct pathogenic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sphincter of Oddi stenosis",
"     </li>",
"     <li>",
"      Sphincter of Oddi dyskinesia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The term sphincter of Oddi dysfunction encompasses both sphincter of Oddi stenosis and sphincter of Oddi dyskinesia.",
"   </p>",
"   <p>",
"    SOD has been associated with two clinical syndromes: biliary pain and idiopathic recurrent acute pancreatitis. Idiopathic recurrent acute pancreatitis is defined as two or more attacks of well documented acute pancreatitis of unclear cause despite an exhaustive work-up (laboratory and noninvasive imaging) with complete resolution of clinical and laboratory findings between attacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence that SOD can cause acute pancreatitis was suggested in an animal model in which transient sphincter contraction induced by application of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/52/30531?source=see_link\">",
"     carbachol",
"    </a>",
"    abolished trans-sphincteric flow and increased pancreatic exocrine secretion and pancreatic duct pressure to levels comparable with those seen in pancreatic duct ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/4\">",
"     4",
"    </a>",
"    ]. The addition of",
"    <span class=\"nowrap\">",
"     cholecystokinin/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"      secretin",
"     </a>",
"    </span>",
"    stimulation of pancreatic secretion plus carbachol application caused pancreatic tissue damage and an increase in serum amylase levels.",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations and diagnosis of sphincter of Oddi dysfunction. The treatment of sphincter of Oddi dysfunction, other causes of postcholecystectomy syndrome, and functional gallbladder disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29126?source=see_link\">",
"     \"Treatment of sphincter of Oddi dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=see_link&amp;anchor=H689178094#H689178094\">",
"     \"Laparoscopic cholecystectomy: Techniques\", section on 'Postcholecystectomy syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sphincter of Oddi is composed of small circular and longitudinal muscular segments that are approximately 6 to 10 mm in total length and are contained mostly within the wall of the duodenum (",
"    <a class=\"graphic graphic_figure graphicRef78786 \" href=\"UTD.htm?27/17/27924\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/5\">",
"     5",
"    </a>",
"    ]. The muscle fibers surround the intraduodenal segment of the common bile duct and the ampulla of Vater (",
"    <a class=\"graphic graphic_picture graphicRef63728 \" href=\"UTD.htm?23/44/24257\">",
"     picture 1",
"    </a>",
"    ). A circular aggregate of muscle fibers known as the sphincter choledochus (or sphincter of Boyden) maintains resistance to bile flow and thereby permits filling of the gallbladder during fasting and prevents retrograde reflux of duodenal contents into the biliary tree. A separate structure, the sphincter pancreaticus, encircles the distal pancreatic duct. The muscle fibers of the sphincter pancreaticus are interlocked with those of the sphincter choledochus in a figure eight pattern. Although the pancreatic and biliary sphincter portions of the sphincter of Oddi can be distinguished anatomically, their manometric features are similar, and a direct anatomic and manometric correlation has not been established.",
"   </p>",
"   <p>",
"    The muscle fibers of the sphincter of Oddi function independently from those of the duodenal musculature. The motility of the sphincter of Oddi is complex and not completely understood, but it is known to vary in the fasting and fed states.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During fasting, sphincter of Oddi motility is integrated with the migrating motor complex (MMC), permitting coordinated release of bile into the duodenum. The MMC is the pattern of gastrointestinal motor activity present during fasting [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/6\">",
"       6",
"      </a>",
"      ]. It is divided into three phases: phase I is a quiescent period and lasts 45 to 60 minutes; phase II is comprised of random intermittent contractions and lasts approximately 30 minutes; phase III is a period of bursts of rapid, evenly-paced, uninterrupted peristaltic contractions and lasts for 5 to 15 minutes. Myoelectrical potentials within the sphincter of Oddi increase during phase I of the MMC, reach a maximum during phase III, and then decrease rapidly.",
"     </li>",
"     <li>",
"      During the fed state, myoelectrical potentials within the sphincter of Oddi vary depending upon the type and quantity of nutrients ingested and may be influenced by endogenous hormones such as cholecystokinin [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63642734\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sphincter of Oddi stenosis is an anatomic abnormality associated with narrowing of the sphincter of Oddi. It can result from any process leading to inflammation or scarring, such as pancreatitis, passage of a gallstone through the papilla, intraoperative trauma, infection, and adenomyosis. Sphincter of Oddi stenosis is associated with abnormal sphincter of Oddi motility and elevated basal pressure.",
"   </p>",
"   <p>",
"    Sphincter of Oddi dyskinesia refers to a functional disturbance of the sphincter of Oddi, leading to intermittent biliary obstruction. The cause of sphincter of Oddi dyskinesia is not well understood. Spasm and relaxation of the sphincter of Oddi can be induced pharmacologically with agents known to affect smooth muscle function (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    ), suggesting that the spasm may be influenced by local hormonal or neurologic disturbance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16563228\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of sphincter of Oddi dysfunction (SOD) among patients with biliary pain or idiopathic recurrent pancreatitis is difficult to estimate because of several potential sources of bias among studies evaluating SOD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The amount of investigation for other causes of symptoms differed",
"     </li>",
"     <li>",
"      The diagnostic \"gold-standard\" for SOD varied",
"     </li>",
"     <li>",
"      The use of different manometry systems, which may lead to variable results [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lack of adequate control groups in many studies because the diagnosis of SOD usually involves invasive testing",
"     </li>",
"     <li>",
"      The studies were performed in tertiary medical centers and are thus potentially vulnerable to referral bias",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, available data suggest that both biliary and pancreatic SOD occur more often in women than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a survey of 5430 participants from randomly sampled US households, women were significantly more likely to have functional biliary pain than men (2.3 versus 0.6 percent, odds ratio 3.3) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study of 49 patients with sphincter of Oddi stenosis and recurrent pancreatitis, 43 of the patients (88 percent) were female [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/11\">",
"       11",
"      </a>",
"      ]. The median age of the patients was 43 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16563417\">",
"    <span class=\"h2\">",
"     Epidemiology of biliary SOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary SOD is most commonly recognized in patients who have undergone cholecystectomy (hence the name postcholecystectomy syndrome). The reasons for this are not well understood, but may be related to unmasking of pre-existing SOD due to removal of the gallbladder, which may have served as a reservoir to accommodate increased pressure in the biliary system occurring during sphincter spasm [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/12\">",
"     12",
"    </a>",
"    ]. Another possible explanation is that there is alteration of sphincter of Oddi motility because of the severing of nerve fibers that pass between the gallbladder and the sphincter of Oddi via the cystic duct [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/13\">",
"     13",
"    </a>",
"    ]. However, SOD also occurs in patients whose gallbladders are intact, suggesting that other pathophysiologic mechanisms are involved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the association of SOD with cholecystectomy, SOD is an uncommon occurrence following cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/15\">",
"     15",
"    </a>",
"    ]. In one series of 454 patients who had undergone cholecystectomy, the prevalence of SOD was estimated to be less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/16\">",
"     16",
"    </a>",
"    ]. However, among patients complaining of symptoms following cholecystectomy, the prevalence was 14 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16563424\">",
"    <span class=\"h2\">",
"     Epidemiology of pancreatic SOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;SOD is one of the most common diagnoses found in patients with idiopathic recurrent acute pancreatitis. In an illustrative report, SOD was noted in 41 of 126 patients (33 percent) who underwent endoscopic retrograde pancreatography with sphincter of Oddi manometry and bile crystal analysis for microlithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/17\">",
"     17",
"    </a>",
"    ]. Similar findings were noted in a series of 90 patients with unexplained acute pancreatitis, in which 28 patients (31 percent) had elevated pancreatic basal sphincter pressures (",
"    <a class=\"graphic graphic_table graphicRef65380 \" href=\"UTD.htm?0/47/763\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations of biliary SOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sphincter of Oddi dysfunction (SOD) is suspected in patients who have biliary-type pain without other apparent causes. Typically the pain is located in the right upper quadrant or epigastrium and lasts from 30 minutes to several hours [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/19\">",
"     19",
"    </a>",
"    ]. Characteristics that are",
"    <strong>",
"     not",
"    </strong>",
"    suggestive of biliary SOD include lancinating pain that lasts for seconds, constant pain that lasts all day, pain that is exacerbated by eating, pain that is relieved by defecation, or pain that is associated with diarrhea. In addition, the pain is not relieved by anticholinergic antispasmodics, antacids, H2-blockers, or proton pump inhibitors.",
"   </p>",
"   <p>",
"    Laboratory abnormalities may include elevations in the alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase that normalize between attacks. Patients with biliary SOD have normal amylase and lipase levels.",
"   </p>",
"   <p>",
"    On imaging such as ultrasound, the common bile duct may appear dilated (&gt;8 mm in diameter).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations of pancreatic SOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pancreatic SOD present with recurrent episodes of pancreatitis. The episodes typically occur months apart and are associated with elevations in the amylase and lipase. Liver transaminases and bilirubin may also be elevated, and there may be dilation of the pancreatic duct. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16563928\">",
"    <span class=\"h1\">",
"     CLINICAL CRITERIA AND CLASSIFICATION SYSTEMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51500670\">",
"    <span class=\"h2\">",
"     Rome III criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical criteria for diagnosis of functional gallbladder and sphincter of Oddi disorders have been proposed, based mainly upon expert consensus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/20\">",
"     20",
"    </a>",
"    ]. These criteria (known as the Rome III criteria) specify three subsets of functional gallbladder and sphincter of Oddi disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Functional gallbladder disorder",
"     </li>",
"     <li>",
"      Functional biliary sphincter of Oddi disorder",
"     </li>",
"     <li>",
"      Functional pancreatic sphincter of Oddi disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines stress that patients with upper abdominal pain who do not meet the Rome III symptom-based criteria should not be submitted to sphincter of Oddi manometry. Those who fulfill the criteria should undergo further evaluation with liver and pancreatic enzymes, ultrasound, and, for selected patients, sphincter of Oddi manometry. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Diagnostic approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following are the Rome III criteria for functional gallbladder and sphincter of Oddi disorders. In order to fulfill the Rome III criteria,",
"    <strong>",
"     all",
"    </strong>",
"    of the following conditions must be met:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain located in the epigastrium",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      right upper quadrant",
"     </li>",
"     <li>",
"      Episodes lasting 30 minutes or longer",
"     </li>",
"     <li>",
"      Recurrent symptoms occurring at different intervals (not daily)",
"     </li>",
"     <li>",
"      The pain builds up to a steady level",
"     </li>",
"     <li>",
"      The pain is moderate to severe enough to interrupt the patient's daily activities or lead to an emergency department visit",
"     </li>",
"     <li>",
"      The pain is not relieved by bowel movements",
"     </li>",
"     <li>",
"      The pain is not relieved by postural change",
"     </li>",
"     <li>",
"      The pain is not relieved by antacids",
"     </li>",
"     <li>",
"      Exclusion of other structural disease that would explain the symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supportive criteria include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain associated with nausea and vomiting",
"     </li>",
"     <li>",
"      Pain radiating to the back",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      right infrascapular region",
"     </li>",
"     <li>",
"      Pain awakening the patient from sleep in the middle of the night",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once a patient has met the criteria for functional gallbladder and sphincter of Oddi disorders, the patient's subtype (ie, functional gallbladder disorder, functional biliary sphincter of Oddi disorder, or functional pancreatic sphincter of Oddi disorder) is determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16563965\">",
"    <span class=\"h3\">",
"     Functional gallbladder disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are the Rome III criteria for functional gallbladder disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Criteria for functional gallbladder and sphincter of Oddi disorders are fulfilled",
"     </li>",
"     <li>",
"      Gallbladder is present",
"     </li>",
"     <li>",
"      Normal liver enzymes, conjugated bilirubin, and",
"      <span class=\"nowrap\">",
"       amylase/lipase",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16563972\">",
"    <span class=\"h3\">",
"     Functional biliary sphincter of Oddi disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are the Rome III criteria for functional biliary sphincter of Oddi disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Criteria for functional gallbladder and sphincter of Oddi disorder are fulfilled",
"     </li>",
"     <li>",
"      Normal",
"      <span class=\"nowrap\">",
"       amylase/lipase",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supportive criteria include elevated serum aminotransferases, alkaline phosphatase, or conjugated bilirubin (&gt;twice the upper limit of normal) temporally related to at least two pain episodes and a dilated common bile duct (&gt;8 mm).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16563979\">",
"    <span class=\"h3\">",
"     Functional pancreatic sphincter of Oddi disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are the Rome III criteria for functional pancreatic sphincter of Oddi disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Criteria for functional gallbladder and sphincter of Oddi disorder are fulfilled",
"     </li>",
"     <li>",
"      Elevated",
"      <span class=\"nowrap\">",
"       amylase/lipase",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16565707\">",
"    <span class=\"h2\">",
"     Classification systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the criteria used in the diagnosis of SOD, several investigators have developed classification systems that predict the likelihood of finding SOD and its response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51500108\">",
"    <span class=\"h3\">",
"     Classification of biliary SOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Rome III revision of the Milwaukee Biliary Group classification is often used to determine which patients with suspected biliary SOD should undergo invasive testing, such as sphincter of Oddi manometry (SOM), and which are likely to respond to treatment with endoscopic sphincterotomy. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Diagnosis of biliary SOD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16565729\">",
"    <span class=\"h4\">",
"     Milwaukee Biliary Group classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best studied classification system for biliary SOD (known as the Milwaukee Biliary Group Classification) is based upon the number of laboratory, clinical, and radiologic features suggesting SOD in an individual patient. These have been revised in the Rome III statement as described below. The original Milwaukee classification recognizes three groups of patients who have biliary type pain without an identifiable cause prior to manometry [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I patients fulfill all of three criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pain associated with abnormal serum aminotransferases (alanine aminotransferase and aspartate aminotransferase more than two times normal on at least two occasions)",
"     </li>",
"     <li>",
"      A dilated common bile duct more than 10 mm on ultrasound or 12 mm on endoscopic retrograde cholangiopancreatography (ERCP)",
"     </li>",
"     <li>",
"      Delayed drainage of contrast from the common bile duct after more than 45 minutes in the supine position",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type II patients have one or two of the above criteria",
"     </li>",
"     <li>",
"      Type III patients have none of the above criteria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria have been evaluated in a number of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/12,22-25\">",
"     12,22-25",
"    </a>",
"    ]. In one report, 213 patients with pancreaticobiliary pain were evaluated by SOM and ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/22\">",
"     22",
"    </a>",
"    ]. Abnormal SOM was found in 86, 55, and 28 percent of patients classified as Milwaukee types I, II, and III, respectively.",
"   </p>",
"   <p>",
"    However, the ability of these criteria to predict a favorable outcome in patients treated by sphincterotomy has varied among studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/23-27\">",
"     23-27",
"    </a>",
"    ], and their role in management has been criticized [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/19\">",
"     19",
"    </a>",
"    ]. In most series, patients with type I benefit from endoscopic biliary sphincterotomy without the need for prior SOM. Optimal therapy and the value of the Milwaukee criteria are less clear for patients who have type II and III. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29126?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of sphincter of Oddi dysfunction\", section on 'Endoscopic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16565736\">",
"    <span class=\"h4\">",
"     Rome III revision of the Milwaukee classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Rome III consensus statement revised the Milwaukee Biliary Group classification to make it more applicable to clinical practice and, whenever possible, to avoid invasive procedures such as ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, the revised system emphasizes noninvasive methods to evaluate common bile duct diameter instead of contrast drainage times.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I patients present with biliary-type pain, abnormal aminotransferases, bilirubin or alkaline phosphatase (&gt;2 times normal values) documented on two or more occasions, and a dilated bile duct (&gt;8 mm on ultrasound). Approximately 65 to 95 percent of these patients have manometric evidence of biliary SOD.",
"     </li>",
"     <li>",
"      Type II patients present with biliary-type pain and one of the previously mentioned laboratory or imaging abnormalities. Approximately 50 to 63 percent of these patients have manometric evidence of biliary SOD.",
"     </li>",
"     <li>",
"      Type III patients complain only of recurrent biliary-type pain and have none of the previously mentioned laboratory or imaging criteria. Approximately 12 to 59 percent of these patients have manometric evidence of biliary SOD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51500136\">",
"    <span class=\"h3\">",
"     Classification of pancreatic SOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;A classification system similar to the Milwaukee Biliary Group classification has been developed for pancreatic SOD, although it is not as widely used as the classification system for biliary SOD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. This classification for presumptive pancreatic SOD recognizes three groups of patients who have recurrent pancreatitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    typical pancreatic pain of uncertain etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I patients have all three of the following criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pain",
"     </li>",
"     <li>",
"      A dilated pancreatic duct (&gt;6 mm in the head and &gt;5 mm in the body)",
"     </li>",
"     <li>",
"      Serum amylase or lipase level &gt;1.5 times the upper limit of normal on at least one occasion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type II patients have pain plus one other criterion",
"     </li>",
"     <li>",
"      Type III patients only have pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51500858\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary and pancreatic sphincter of Oddi dysfunction (SOD) both present with pain in the right upper quadrant or epigastrium, a symptom that is common to multiple disorders, most of which are more common than SOD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/20\">",
"     20",
"    </a>",
"    ]. The differential diagnosis of right upper quadrant or epigastric pain includes gastroesophageal reflux disease, irritable bowel syndrome, functional dyspepsia, cholelithiasis, cholecystitis, and pancreatitis due to other causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link&amp;anchor=H6#H6\">",
"     \"Differential diagnosis of abdominal pain in adults\", section on 'Upper abdominal pain syndromes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation for alternate diagnoses may include studies such as transabdominal ultrasound, abdominal computed tomography, magnetic resonance cholangiopancreatography, upper endoscopy, endoscopic ultrasound, and endoscopic retrograde cholangiopancreatography (ERCP). Which tests to pursue will depend upon their availability and the patient's clinical presentation. In addition, therapeutic trials of medications such as antispasmodics or proton pump inhibitors should be considered in patients with symptoms suggestive of possible irritable bowel syndrome or gastroesophageal",
"    <span class=\"nowrap\">",
"     reflux/functional",
"    </span>",
"    dyspepsia, respectively, prior to invasive testing for SOD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnostic approach to abdominal pain in adults\", section on 'Right upper quadrant pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnostic approach to abdominal pain in adults\", section on 'Epigastric pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to a patient with suspected sphincter of Oddi dysfunction (SOD) depends upon the patient's clinical presentation as well as the results of laboratory testing and abdominal imaging. In general, only patients fulfilling the Rome III criteria should undergo invasive evaluation for SOD. This decreases the chance of patients being inappropriately subjected to invasive testing for SOD that is associated significant complications (primarily pancreatitis). (See",
"    <a class=\"local\" href=\"#H51500670\">",
"     'Rome III criteria'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H24\">",
"     'Sphincter of Oddi manometry'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    To determine if patients fulfill the Rome III criteria, liver tests (transaminases, alkaline phosphatase, bilirubin) and pancreatic enzymes (amylase, lipase) should be checked, and structural abnormalities need to be excluded. Transabdominal ultrasound is typically the initial imaging study obtained for suspected biliary SOD. It can look for structural abnormalities such as gallstones while also providing an estimate of the common bile duct diameter. However, transabdominal ultrasound may not adequately visualize the pancreas because of overlying bowel gas, so alternate imaging techniques, such as magnetic resonance cholangiopancreatography (MRCP), may be required for evaluation of the pancreatic duct. Additional testing that may help to rule out structural abnormalities includes abdominal computed tomography, endoscopic ultrasound, and endoscopic retrograde cholangiopancreatography (ERCP).",
"   </p>",
"   <p>",
"    In appropriately selected patients, the diagnosis of SOD is established by sphincter of Oddi manometry (SOM), which is performed during ERCP. Several less invasive methods have also been evaluated for establishing the diagnosis, but none has been shown to approach the diagnostic accuracy of SOM [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Sphincter of Oddi manometry'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnosis of biliary SOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary SOD may be suspected based upon the presence of biliary-type pain, abnormal liver tests (aminotransferases, bilirubin or alkaline phosphatase &gt;2 times normal values) that normalize between attacks, and dilation of the common bile duct. The diagnosis may be supported by provocation tests or hepatobiliary scintigraphy, but definitive diagnosis requires SOM. (See",
"    <a class=\"local\" href=\"#H51499802\">",
"     'Specific diagnostic tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The Rome III consensus conference statement suggests that in patients who have had a cholecystectomy, a reasonable approach is to start with liver and pancreatic biochemical tests, followed by ultrasound, MRCP, and then ERCP with SOM in appropriate patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/20\">",
"     20",
"    </a>",
"    ]. It also notes that hepatobiliary scintigraphy (HIDA scan) may be a valuable noninvasive test before making the decision to undertake SOM. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Hepatobiliary scintigraphy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Whether to purse SOM depends upon whether the patient has type I SOD (biliary-type pain, abnormal liver tests, and a dilated common bile duct), type II SOD (biliary-type pain and either abnormal liver tests or a dilated common bile duct), or type III SOD (biliary-type pain but normal liver tests and common bile duct diameter) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16565736\">",
"     'Rome III revision of the Milwaukee classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63641987\">",
"    <span class=\"h3\">",
"     Type I SOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with type I do not require additional testing and can be referred directly for ERCP with endoscopic sphincterotomy because of the high likelihood of manometric abnormalities. (See",
"    <a class=\"local\" href=\"#H16565736\">",
"     'Rome III revision of the Milwaukee classification'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29126?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of sphincter of Oddi dysfunction\", section on 'Endoscopic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63642032\">",
"    <span class=\"h3\">",
"     Type II SOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with type II are less likely to have abnormal SOM than patients with type I SOD. In addition, patients with normal manometry are unlikely to respond to sphincterotomy. As a result, patients with type II SOD should undergo SOM to confirm the diagnosis and to select patients likely to respond to treatment. However, some authorities recommend empiric sphincterotomy in such patients, a strategy that was supported by a cost-effectiveness analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/31\">",
"     31",
"    </a>",
"    ]. Our approach is to proceed with SOM in such patients, which is consistent with the Rome III consensus statement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Sphincter of Oddi manometry'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29126?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of sphincter of Oddi dysfunction\", section on 'Biliary pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a provider with significant experience in SOM is not available, hepatobiliary scintigraphy (in patients whose gallbladder is intact) or a fatty meal ultrasound study (in patients with or without a gallbladder) is a reasonable alternative, provided that local standards for these tests have been established. However, these tests are inferior to SOM, and when possible, patients should be referred to centers experienced in performing SOM. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Biliary provocation tests'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Correlation of noninvasive tests with sphincter of Oddi manometry for biliary SOD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63642039\">",
"    <span class=\"h3\">",
"     Type III SOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with type III SOD are less likely than patients with type I or II SOD to have manometrically confirmed SOD, and there is poor correlation between the results of SOM and response to sphincterotomy in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/19\">",
"     19",
"    </a>",
"    ]. Such patients are commonly encountered and represent a difficult diagnostic and management challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/32\">",
"     32",
"    </a>",
"    ]. Symptoms in these patients may be due to SOD or to functional bowel diseases, such as dyspepsia or irritable bowel syndrome. To further complicate matters, these conditions may coexist and may result from generalized smooth muscle dysfunction, duodenal hyperalgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/33\">",
"     33",
"    </a>",
"    ], or somatosensory hypersensitivity following cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/34\">",
"     34",
"    </a>",
"    ]. For type III patients, pharmacologic trials should be tried (eg, proton pump inhibitors, spasmolytic drugs, calcium channel blockers [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ], and psychotropic agents) before performing ERCP and SOM.",
"   </p>",
"   <p>",
"    While SOM is generally not recommended in type III patients, it can be considered in patients who have been carefully assessed by a clinician who has significant experience in the evaluation of SOD and who believes the potential benefits exceed the risk of complications (primarily pancreatitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our approach begins with and evaluation focused on detecting clinical features associated with irritable bowel syndrome or functional dyspepsia (",
"    <a class=\"graphic graphic_algorithm graphicRef60587 \" href=\"UTD.htm?40/11/41150\">",
"     algorithm 1",
"    </a>",
"    ). Patients whose clinical features are more consistent with one of these diagnoses are treated accordingly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link\">",
"     \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For other patients, we proceed based upon whether or not the gallbladder is intact. In patients who have",
"    <strong>",
"     not",
"    </strong>",
"    undergone cholecystectomy, we obtain a gallbladder ejection fraction to determine whether the gallbladder may be the source of symptoms. For those who have an ejection fraction &lt;40 percent or reproduction of symptoms during intravenous cholecystokinin administration, we suggest laparoscopic cholecystectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51500222\">",
"    <span class=\"h2\">",
"     Diagnosis of pancreatic SOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients fulfilling the Rome III criteria for suspected pancreatic sphincter of Oddi disorders will typically require manometric evaluation of the sphincter of Oddi. In particular, recordings from the pancreatic portion of the sphincter should be obtained. (See",
"    <a class=\"local\" href=\"#H16563979\">",
"     'Functional pancreatic sphincter of Oddi disorder'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H24\">",
"     'Sphincter of Oddi manometry'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51499802\">",
"    <span class=\"h1\">",
"     SPECIFIC DIAGNOSTIC TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51500283\">",
"    <span class=\"h2\">",
"     Noninvasive tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Transabdominal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otherwise unexplained dilation of the common bile duct on ultrasound is associated with sphincter of Oddi dysfunction (SOD) and may predict a favorable response to sphincterotomy in patients with other clinical evidence of biliary obstruction (eg, pain, abnormal liver function tests) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/35\">",
"     35",
"    </a>",
"    ]. However, common bile duct dilation (&gt;6 mm) may be observed in up to one-third of patients after cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Furthermore, the size of the common bile duct increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/39\">",
"     39",
"    </a>",
"    ]. As a result, dilation of the common bile duct alone is insufficient evidence for establishing the diagnosis of SOD. It should be considered in the context of symptoms, liver and pancreatic biochemical tests, and a history of multiple gallbladder stones or past removal of common bile duct stones. In most instances, mild dilation is an incidental finding warranting only observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Biliary provocation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;To increase the specificity of common bile duct diameter measurement for determining SOD, several provocation tests have been developed that use either a fatty meal (fatty meal ultrasonography) or cholecystokinin (CCK) to increase bile flow [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In patients who have normal sphincter of Oddi function, the bile duct diameter remains constant or decreases following stimulation; an increase of more than 2 mm is considered to be abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Correlation of these provocation tests with sphincter of Oddi manometry is poor, and abnormal findings may be seen in non-biliary diseases. As an example, an abnormal response of the sphincter of Oddi to CCK stimulation or the Nardi test (a provocative test using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    and prostigmin) has been observed in patients with irritable bowel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Thus, provocation tests are not performed routinely in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63642869\">",
"    <span class=\"h3\">",
"     Magnetic resonance cholangiopancreatography",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     Secretin",
"    </a>",
"    stimulated magnetic resonance cholangiopancreatography (MRCP) has also been used for the diagnosis of biliary SOD.",
"   </p>",
"   <p>",
"    One prospective study included 47 patients with suspected type II or III SOD who underwent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    MRCP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/44\">",
"     44",
"    </a>",
"    ]. Results were compared with conventional manometry where the diagnosis was based upon a mean basal pressure of &gt;40 mmHg (",
"    <a class=\"graphic graphic_table graphicRef65380 \" href=\"UTD.htm?0/47/763\">",
"     table 1",
"    </a>",
"    ). Results were also correlated with long-term outcomes with or without endoscopic sphincterotomy.",
"    <br/>",
"    <br/>",
"    Of the 47 patients, 27 (57 percent) were considered to have SOD based upon manometry and underwent biliary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pancreatic sphincterotomy. Secretin MRCP was abnormal in 10 of 16 (63 percent) of type II and 0 of 11 type III cases. The overall diagnostic accuracy was estimated to be 73 and 46 percent for types II and III, respectively.",
"    <br/>",
"    <br/>",
"    During a mean follow-up of 32 months, 9 of 13 patients with normal manometry (and thus no sphincterotomy) and 14 of 16 patients with type II SOD treated with sphincterotomy experienced a significant reduction in symptoms. By contrast, only 2 of 11 patients with type III SOD treated with sphincterotomy had a reduction in symptoms. All patients with SOD by manometry and an abnormal secretin MRCP (n = 12) had long-term symptom improvement following sphincterotomy. The authors concluded that secretin MRCP was useful in predicting abnormal manometry and a response to endotherapy in patients with suspected type II SOD, but it was insensitive for predicting abnormal manometry in patients with suspected type III SOD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Hepatobiliary scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatobiliary scintigraphy using technetium-99m labeled dyes can provide a standardized, semiquantitative assessment of delayed biliary drainage in patients whose gallbladder is absent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/12,45-47\">",
"     12,45-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link&amp;anchor=H19#H19\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Cholescintigraphy (HIDA scan)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies on the utility of hepatobiliary scintigraphy have had variable results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 26 consecutive patients underwent hepatobiliary imaging, ERCP, and SOM [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/45\">",
"       45",
"      </a>",
"      ]. A scintigraphic score (referred to as the Hopkins score) was constructed from quantitative and visual criteria that successfully discriminated all patients with SOD.",
"     </li>",
"     <li>",
"      Substantially different conclusions were reached in another report in which scintigraphy results were compared with sphincter of Oddi manometry in 27 patients with suspected SOD following cholecystectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/48\">",
"       48",
"      </a>",
"      ]. Scintigraphy with CCK infusion was performed within one month of manometry. Scoring of the scans and measurement of the transit time from the hepatic hilum to the duodenum (HDTT) was performed by independent, blinded observers.",
"      <br/>",
"      <br/>",
"      Eight patients had abnormal SOM (basal sphincter of Oddi pressure &gt;40 mmHg). Scintigraphy scoring had a sensitivity of 25 to 38 percent, a specificity of 86 to 89 percent, a positive predictive value of 40 to 60 percent, and a negative predictive value of 75 to 79 percent. The coefficient of variation between observers was 0.72 (ie, moderately good correlation). The sensitivity, specificity, positive, and negative predictive values of the HDTT were 13, 95, 50, and 74 percent, respectively. The authors concluded that scintigraphy correlated poorly with manometry in postcholecystectomy patients with suspected SOD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A problem with hepatobiliary scintigraphy is that clearance rates in patients with SOD overlap with those in a normal population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, scintigraphy may be falsely positive in patients who have extrahepatic biliary obstruction from a variety of causes, or it may be falsely negative in patients who have sphincter of Oddi dyskinesia in whom the obstruction to bile flow may be intermittent. Furthermore, hepatobiliary scintigraphy cannot detect obstruction to flow arising from the pancreatic portion of the SO. Thus, scintigraphy should have only a supportive role in the evaluation of suspected SOD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Correlation of noninvasive tests with sphincter of Oddi manometry for biliary SOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, several studies have compared the accuracy of the noninvasive tests for SOD with manometry. One of the largest studies comparing the most commonly used methods involved 304 patients with suspected SOD who underwent manometry, fatty meal ultrasonography, and hepatobiliary scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/49\">",
"     49",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      73 patients (24 percent) were diagnosed with SOD by manometry.",
"     </li>",
"     <li>",
"      Compared with SOM as the gold-standard, the sensitivity and specificity of fatty meal ultrasonography were 21 and 97 percent, respectively.",
"     </li>",
"     <li>",
"      The sensitivity and specificity of hepatobiliary scintigraphy were 49 and 78 percent, respectively.",
"     </li>",
"     <li>",
"      Hepatobiliary scintigraphy and fatty meal ultrasonography (either one or both) were abnormal in 91, 50, and 44 percent of patients with type I, II, and III SOD dysfunction, respectively.",
"     </li>",
"     <li>",
"      A durable clinical response was observed in 40 of 73 patients (55 percent) who underwent sphincterotomy. Of those with SOD, 11 of 13 (85 percent) with both abnormal hepatobiliary scintigraphy and fatty meal ultrasonography had a good long-term response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that the correlation of fatty meal ultrasonography and hepatobiliary scintigraphy with sphincter of Oddi manometry is poor, though the combined use of hepatobiliary scintigraphy and fatty meal ultrasonography increases sensitivity compared with either alone. In addition, the accuracy of these tests appears to decrease in relation to the probability of SOD as determined by the Milwaukee Biliary Group classification. The authors suggest that despite the poor test characteristics, fatty meal ultrasonography and hepatobiliary scintigraphy may provide assistance in predicting the long-term response to sphincterotomy in patients with manometrically proven SOD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Pancreatic provocation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Provocation tests for evaluating pancreatic SOD are based upon a similar principle as provocation tests for biliary SOD. An increase in pancreatic duct diameter following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    stimulation of &gt;1.5 mm (assessed by ultrasound, computed tomography, or magnetic resonance cholangiopancreatography [MRCP]) lasting for &gt;30 minutes is considered to be pathologic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report evaluating this technique, a positive test was associated with good operative outcomes in 90 percent of patients with suspected SOD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/51\">",
"     51",
"    </a>",
"    ]. However, these results have not been duplicated in other centers. In another study, the accuracy of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    ultrasound test was compared with manometry as the gold standard in 47 patients with acute pancreatitis. Ultrasound findings in 35 healthy patients were used as controls [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/52\">",
"     52",
"    </a>",
"    ]. The sensitivity and specificity of the secretin ultrasound were 88 and 82 percent, respectively.",
"   </p>",
"   <p>",
"    The addition of endoscopic ultrasound to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    stimulation test has been attempted to improve accuracy. In one report, 20 patients underwent dynamic imaging of the pancreas using real-time endoscopic ultrasonography with secretin stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/53\">",
"     53",
"    </a>",
"    ]. Of the seven patients who had SOD based upon manometric results, only four (57 percent) had an abnormal endoscopic ultrasound measurement. Only 1 of 13 patients with normal SOM had an abnormal endoscopic ultrasound study. The results suggested excellent negative and positive predictive values but poor overall sensitivity for this test (",
"    <a class=\"graphic graphic_table graphicRef77832 \" href=\"UTD.htm?7/50/7979\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link\">",
"     \"Glossary of common biostatistical and epidemiological terms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    stimulation test has also been performed with MRCP with similar results. In two studies, the sensitivities of secretin stimulated MRCP for diagnosing pancreatic SOD ranged from 57 to 67 percent, with specificities of 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51500319\">",
"    <span class=\"h2\">",
"     Invasive tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Sphincter of Oddi manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sphincter of Oddi manometry (SOM) remains the gold standard for diagnosing of SOD. Basal pressure and phasic wave contractions are routinely recorded from the common bile duct and pancreatic duct segments of the sphincter of Oddi. The mechanical and electrical activity is similar between the two segments (",
"    <a class=\"graphic graphic_figure graphicRef57960 graphicRef54223 \" href=\"UTD.htm?1/16/1286\">",
"     figure 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/56\">",
"     56",
"    </a>",
"    ]. Measurement of basal pressures from either the biliary or pancreatic duct alone may miss up to one-quarter of patients with abnormal sphincter pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/57\">",
"     57",
"    </a>",
"    ]. Because of this, we recommend that patients undergoing SOM have measurements taken from both the biliary and pancreatic ducts.",
"   </p>",
"   <p>",
"    Patients with SOD have been divided into two groups based upon manometric findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with structural alterations of the sphincter of Oddi (stenosis)",
"     </li>",
"     <li>",
"      Patients with functional abnormalities (dyskinesia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with stenosis are identified by an abnormally elevated basal sphincter of Oddi pressure (&gt;40 mmHg), which is the most widely clinically accepted diagnostic finding for SOD (",
"    <a class=\"graphic graphic_figure graphicRef80705 graphicRef57715 \" href=\"UTD.htm?33/18/34081\">",
"     figure 3A-B",
"    </a>",
"    ). This finding is reproducible, and the elevated sphincter of Oddi pressure does not relax following administration of smooth muscle relaxants. Other abnormalities have also been described (",
"    <a class=\"graphic graphic_table graphicRef65380 \" href=\"UTD.htm?0/47/763\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with sphincter of Oddi dyskinesia may also have elevated basal sphincter of Oddi pressure. However, in contrast to sphincter of Oddi stenosis, the elevated pressure decreases dramatically following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/1/33813?source=see_link\">",
"     amyl nitrite",
"    </a>",
"    inhalation or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    bolus injection, which relaxes smooth muscle. Other manometric characteristics of this group are: rapid sphincter of Oddi contraction frequency",
"    <span class=\"nowrap\">",
"     (&gt;7/min)",
"    </span>",
"    or tachyoddia, an excess in retrograde phasic contractions (&gt;50 percent), and a substantial basal sphincter of Oddi pressure increase (paradoxical response) following administration of cholecystokinin-octapeptide (CCK-8) (",
"    <a class=\"graphic graphic_waveform graphicRef61411 \" href=\"UTD.htm?19/19/19761\">",
"     waveform 1",
"    </a>",
"    ). Manometric findings in patients with sphincter of Oddi dyskinesia are less well reproduced upon repeat measurement compared with patients with sphincter of Oddi stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h4\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although SOM remains the gold standard for diagnosis of SOD, it is invasive, technically demanding, and has several limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cut-off point for what is considered elevated basal pressure for biliary and pancreatic sphincters was based upon a single study of 50 South American subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The procedure has been associated with an increased risk of pancreatitis.",
"     </li>",
"     <li>",
"      The technique, equipment, and method of sedation used can affect the results.",
"     </li>",
"     <li>",
"      The interpretation of results can vary among observers depending in part upon experience [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most series have suggested that SOM is associated with an increased risk of pancreatitis compared with ERCP for other indications, which carries with it a risk of approximately 5 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=see_link\">",
"     \"Post-ERCP pancreatitis\"",
"    </a>",
"    .) In an illustrative series of 100 consecutive patients who underwent sphincter of Oddi manometry, the overall incidence of pancreatitis (defined as upper abdominal pain associated with an elevation in serum amylase or lipase 24 hours after manometry) was 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/60\">",
"     60",
"    </a>",
"    ]. Pancreatitis developed in 6 of 38 patients with type II SOD (16 percent) and in 11 of 62 patients with type III SOD (18 percent). Among the 54 patients with normal SOM, the rate of pancreatitis was 13 percent, and among the 46 patients with abnormal SOM, the rate was 22 percent. The incidence was significantly increased in patients who had manometry plus ERCP during one session compared with those who had manometry alone (26 versus 9 percent). On multivariable analysis, only the performance of ERCP was associated with pancreatitis.",
"   </p>",
"   <p>",
"    . Placement of a pancreatic stent following biliary sphincterotomy may reduce the incidence of pancreatitis in patients with pancreatic sphincter hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/61\">",
"     61",
"    </a>",
"    ]. In one report in which stenting was used, the level of the serum amylase obtained two hours after SOM predicted the development of pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29126?source=see_link\">",
"     \"Treatment of sphincter of Oddi dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=see_link\">",
"     \"Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, some reports suggest that the risk is related to the SOD itself and that patients undergoing SOM and ERCP are not at higher risk for pancreatitis than patients undergoing ERCP alone. A retrospective study of 268 patients who underwent elective ERCP categorized patients into two major groups: those with suspected SOD (cases), and those with a bile duct stone (controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/63\">",
"     63",
"    </a>",
"    ]. The case group was further subclassified into two groups: those who underwent sphincter of Oddi manometry followed by immediate ERCP, and those who had an ERCP without manometry. Similar to other reports, the rate of pancreatitis was much higher in the group with suspected SOD (27 versus 3.2 percent). However, there was no significant difference in the rate of pancreatitis in those with SOD who underwent manometry and ERCP compared with those who had ERCP without manometry (OR 0.72, 95% CI 0.08 to 9.2). On multivariable analysis, biliary sphincterotomy and pancreatography were independent predictors of pancreatitis. Thus, the authors concluded that the higher risk of pancreatitis was not due to the manometry, but rather to the underlying presence of SOD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to subjecting patients to invasive testing for sphincter of Oddi dysfunction, it is important to ensure that they have been adequately evaluated for alternative explanations for their pain. In addition, the evaluation of patients with suspected SOD should consider the availability of local expertise, since the accuracy of the various diagnostic tests is operator dependent. (See",
"    <a class=\"local\" href=\"#H51500858\">",
"     'Differential diagnosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Diagnostic approach'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H51499802\">",
"     'Specific diagnostic tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Evaluation of suspected biliary SOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary SOD may be suspected based upon the presence of biliary-type pain, abnormal liver tests, and dilation of the common bile duct. The diagnosis may be supported by provocation tests or hepatobiliary scintigraphy, but definitive diagnosis requires sphincter of Oddi manometry (SOM). Patients who fulfill the Rome III clinical criteria for functional biliary sphincter of Oddi disorders are candidates for further evaluation. (See",
"    <a class=\"local\" href=\"#H51500670\">",
"     'Rome III criteria'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H51499802\">",
"     'Specific diagnostic tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with type I SOD (biliary-type pain, abnormal liver tests, and a dilated common bile duct) do not require additional testing and can be referred directly for endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic sphincterotomy because of the high likelihood that they will have manometric confirmation of the diagnosis. (See",
"      <a class=\"local\" href=\"#H63641987\">",
"       'Type I SOD'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16565707\">",
"       'Classification systems'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29126?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of sphincter of Oddi dysfunction\", section on 'Endoscopic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with type II SOD (biliary-type pain and either abnormal liver tests or a dilated common bile duct) are less likely to have abnormal SOM than patients with type I SOD. In addition, patients with normal manometry are unlikely to respond to sphincterotomy. As a result, patients with type II SOD should undergo SOM to confirm the diagnosis and to select patients likely to respond to treatment. (See",
"      <a class=\"local\" href=\"#H63642032\">",
"       'Type II SOD'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Sphincter of Oddi manometry'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29126?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of sphincter of Oddi dysfunction\", section on 'Biliary pain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with type III SOD (biliary-type pain but normal liver tests and common bile duct diameter) are less likely than patients with type I or II SOD to have manometrically confirmed SOD, and there is poor correlation between the results of SOM and response to sphincterotomy in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/19\">",
"       19",
"      </a>",
"      ]. As such, SOM is generally not recommended in these patients, though it can be considered in patients who have been carefully assessed by a clinician who has significant experience in the evaluation of suspected SOD and who believes the potential benefits exceed the risk of complications (primarily pancreatitis) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/36/12874/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H63642039\">",
"       'Type III SOD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Evaluation of suspected pancreatic SOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pancreatic SOD present with recurrent episodes of pancreatitis and have a negative evaluation for alternate causes. Patients fulfilling the Rome III criteria for suspected pancreatic sphincter of Oddi disorders will typically require manometric evaluation of the sphincter of Oddi. In particular, recordings from the pancreatic portion of the sphincter should be obtained. (See",
"    <a class=\"local\" href=\"#H16563979\">",
"     'Functional pancreatic sphincter of Oddi disorder'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H51500222\">",
"     'Diagnosis of pancreatic SOD'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/1\">",
"      Tzovaras G, Rowlands BJ. Diagnosis and treatment of sphincter of Oddi dysfunction. Br J Surg 1998; 85:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/2\">",
"      Chuttani R, Carr-Locke DL. Pathophysiology of the sphincter of Oddi. Surg Clin North Am 1993; 73:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/3\">",
"      Toouli J. Sphincter of Oddi. Gastroenterologist 1996; 4:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/4\">",
"      Chen JW, Thomas A, Woods CM, et al. Sphincter of Oddi dysfunction produces acute pancreatitis in the possum. Gut 2000; 47:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/5\">",
"      BOYDEN EA. The anatomy of the choledochoduodenal junction in man. Surg Gynecol Obstet 1957; 104:641.",
"     </a>",
"    </li>",
"    <li>",
"     Chan WW, Burakoff R. Disorders of gastric &amp; small bowel motility. In: Current diagnosis &amp; treatment: Gastroenterology, hepatology, &amp; endoscopy, second edition, Greenberger NJ, Blumberg RS, Burakoff R.  (Eds), McGraw-Hill, New York 2012. p.215.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/7\">",
"      Coelho JC, Wiederkehr JC. Motility of Oddi's sphincter: recent developments and clinical applications. Am J Surg 1996; 172:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/8\">",
"      Grider JR. Role of cholecystokinin in the regulation of gastrointestinal motility. J Nutr 1994; 124:1334S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/9\">",
"      Wehrmann T, Schmitt T, Sch&ouml;nfeld A, et al. Endoscopic sphincter of Oddi manometry with a portable electronic microtransducer system: comparison with the perfusion manometry method and routine clinical application. Endoscopy 2000; 32:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/10\">",
"      Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/11\">",
"      Toouli J. The sphincter of Oddi and acute pancreatitis--revisited. HPB (Oxford) 2003; 5:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/12\">",
"      Lisbona R. The scintigraphic evaluation of sphincter of Oddi dysfunction. J Nucl Med 1992; 33:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/13\">",
"      Luman W, Williams AJ, Pryde A, et al. Influence of cholecystectomy on sphincter of Oddi motility. Gut 1997; 41:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/14\">",
"      Choudhry U, Ruffolo T, Jamidar P, et al. Sphincter of Oddi dysfunction in patients with intact gallbladder: therapeutic response to endoscopic sphincterotomy. Gastrointest Endosc 1993; 39:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/15\">",
"      Middelfart HV, Kristensen JU, Laursen CN, et al. Pain and dyspepsia after elective and acute cholecystectomy. Scand J Gastroenterol 1998; 33:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/16\">",
"      Bar-Meir S, Halpern Z, Bardan E, Gilat T. Frequency of papillary dysfunction among cholecystectomized patients. Hepatology 1984; 4:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/17\">",
"      Kaw M, Brodmerkel GJ Jr. ERCP, biliary crystal analysis, and sphincter of Oddi manometry in idiopathic recurrent pancreatitis. Gastrointest Endosc 2002; 55:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/18\">",
"      Coyle WJ, Pineau BC, Tarnasky PR, et al. Evaluation of unexplained acute and acute recurrent pancreatitis using endoscopic retrograde cholangiopancreatography, sphincter of Oddi manometry and endoscopic ultrasound. Endoscopy 2002; 34:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/19\">",
"      Baillie J. Sphincter of Oddi dysfunction: overdue for an overhaul. Am J Gastroenterol 2005; 100:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/20\">",
"      Behar J, Corazziari E, Guelrud M, et al. Functional gallbladder and sphincter of oddi disorders. Gastroenterology 2006; 130:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/21\">",
"      Hogan WJ, Geenen JE. Biliary dyskinesia. Endoscopy 1988; 20 Suppl 1:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/22\">",
"      Sherman S, Troiano FP, Hawes RH, et al. Frequency of abnormal sphincter of Oddi manometry compared with the clinical suspicion of sphincter of Oddi dysfunction. Am J Gastroenterol 1991; 86:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/23\">",
"      Geenen JE, Hogan WJ, Dodds WJ, et al. The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction. N Engl J Med 1989; 320:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/24\">",
"      Botoman VA, Kozarek RA, Novell LA, et al. Long-term outcome after endoscopic sphincterotomy in patients with biliary colic and suspected sphincter of Oddi dysfunction. Gastrointest Endosc 1994; 40:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/25\">",
"      Bozkurt T, Orth KH, Butsch B, Lux G. Long-term clinical outcome of post-cholecystectomy patients with biliary-type pain: results of manometry, non-invasive techniques and endoscopic sphincterotomy. Eur J Gastroenterol Hepatol 1996; 8:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/26\">",
"      Wehrmann T, Wiemer K, Lembcke B, et al. Do patients with sphincter of Oddi dysfunction benefit from endoscopic sphincterotomy? A 5-year prospective trial. Eur J Gastroenterol Hepatol 1996; 8:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/27\">",
"      Lin OS, Soetikno RM, Young HS. The utility of liver function test abnormalities concomitant with biliary symptoms in predicting a favorable response to endoscopic sphincterotomy in patients with presumed sphincter of Oddi dysfunction. Am J Gastroenterol 1998; 93:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/28\">",
"      Petersen BT. Sphincter of Oddi dysfunction, part 2: Evidence-based review of the presentations, with \"objective\" pancreatic findings (types I and II) and of presumptive type III. Gastrointest Endosc 2004; 59:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/29\">",
"      Elta GH. Sphincter of Oddi dysfunction and bile duct microlithiasis in acute idiopathic pancreatitis. World J Gastroenterol 2008; 14:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/30\">",
"      Petersen BT. An evidence-based review of sphincter of Oddi dysfunction: part I, presentations with \"objective\" biliary findings (types I and II). Gastrointest Endosc 2004; 59:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/31\">",
"      Arguedas MR, Linder JD, Wilcox CM. Suspected sphincter of Oddi dysfunction type II: empirical biliary sphincterotomy or manometry-guided therapy? Endoscopy 2004; 36:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/32\">",
"      Cohen S, Bacon BR, Berlin JA, et al. National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002. Gastrointest Endosc 2002; 56:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/33\">",
"      Desautels SG, Slivka A, Hutson WR, et al. Postcholecystectomy pain syndrome: pathophysiology of abdominal pain in sphincter of Oddi type III. Gastroenterology 1999; 116:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/34\">",
"      Kurucsai G, Jo&oacute; I, Fejes R, et al. Somatosensory hypersensitivity in the referred pain area in patients with chronic biliary pain and a sphincter of Oddi dysfunction: new aspects of an almost forgotten pathogenetic mechanism. Am J Gastroenterol 2008; 103:2717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/35\">",
"      Thatcher BS, Sivak MV Jr, Tedesco FJ, et al. Endoscopic sphincterotomy for suspected dysfunction of the sphincter of Oddi. Gastrointest Endosc 1987; 33:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/36\">",
"      Hunt DR, Scott AJ. Changes in bile duct diameter after cholecystectomy: a 5-year prospective study. Gastroenterology 1989; 97:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/37\">",
"      Feng B, Song Q. Does the common bile duct dilate after cholecystectomy? Sonographic evaluation in 234 patients. AJR Am J Roentgenol 1995; 165:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/38\">",
"      Chung SC, Leung JW, Li AK. Bile duct size after cholecystectomy: an endoscopic retrograde cholangiopancreatographic study. Br J Surg 1990; 77:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/39\">",
"      Kaim A, Steinke K, Frank M, et al. Diameter of the common bile duct in the elderly patient: measurement by ultrasound. Eur Radiol 1998; 8:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/40\">",
"      Fein AB, Rauch RF 2nd, Bowie JD, et al. Intravenous cholecystokinin octapeptide: its effect on the sonographic appearance of the file ducts in normal subjects. Radiology 1984; 153:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/41\">",
"      Simeone JF, Mueller PR, Ferrucci JT Jr, et al. Sonography of the bile ducts after a fatty meal: an aid in detection of obstruction. Radiology 1982; 143:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/42\">",
"      Evans PR, Dowsett JF, Bak YT, et al. Abnormal sphincter of Oddi response to cholecystokinin in postcholecystectomy syndrome patients with irritable bowel syndrome. The irritable sphincter. Dig Dis Sci 1995; 40:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/43\">",
"      Steinberg WM, Salvato RF, Toskes PP. The morphine-prostigmin provocative test--is it useful for making clinical decisions? Gastroenterology 1980; 78:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/44\">",
"      Pereira SP, Gillams A, Sgouros SN, et al. Prospective comparison of secretin-stimulated magnetic resonance cholangiopancreatography with manometry in the diagnosis of sphincter of Oddi dysfunction types II and III. Gut 2007; 56:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/45\">",
"      Sostre S, Kalloo AN, Spiegler EJ, et al. A noninvasive test of sphincter of Oddi dysfunction in postcholecystectomy patients: the scintigraphic score. J Nucl Med 1992; 33:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/46\">",
"      Persson B, Axelsson B, Jacobsson H. Cholescintigraphy in the diagnosis and assessment of benign papillary stenosis. Eur J Nucl Med 1993; 20:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/47\">",
"      Darweesh RM, Dodds WJ, Hogan WJ, et al. Efficacy of quantitative hepatobiliary scintigraphy and fatty-meal sonography for evaluating patients with suspected partial common duct obstruction. Gastroenterology 1988; 94:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/48\">",
"      Craig AG, Peter D, Saccone GT, et al. Scintigraphy versus manometry in patients with suspected biliary sphincter of Oddi dysfunction. Gut 2003; 52:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/49\">",
"      Rosenblatt ML, Catalano MF, Alcocer E, Geenen JE. Comparison of sphincter of Oddi manometry, fatty meal sonography, and hepatobiliary scintigraphy in the diagnosis of sphincter of Oddi dysfunction. Gastrointest Endosc 2001; 54:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/50\">",
"      Bolondi L, Gaiani S, Gullo L, Lab&ograve; G. Secretin administration induces a dilatation of main pancreatic duct. Dig Dis Sci 1984; 29:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/51\">",
"      Warshaw AL, Simeone J, Schapiro RH, et al. Objective evaluation of ampullary stenosis with ultrasonography and pancreatic stimulation. Am J Surg 1985; 149:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/52\">",
"      Di Francesco V, Brunori MP, Rigo L, et al. Comparison of ultrasound-secretin test and sphincter of Oddi manometry in patients with recurrent acute pancreatitis. Dig Dis Sci 1999; 44:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/53\">",
"      Catalano MF, Lahoti S, Alcocer E, et al. Dynamic imaging of the pancreas using real-time endoscopic ultrasonography with secretin stimulation. Gastrointest Endosc 1998; 48:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/54\">",
"      Mariani A, Curioni S, Zanello A, et al. Secretin MRCP and endoscopic pancreatic manometry in the evaluation of sphincter of Oddi function: a comparative pilot study in patients with idiopathic recurrent pancreatitis. Gastrointest Endosc 2003; 58:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/55\">",
"      Testoni PA, Mariani A, Curioni S, et al. MRCP-secretin test-guided management of idiopathic recurrent pancreatitis: long-term outcomes. Gastrointest Endosc 2008; 67:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/56\">",
"      Abell TL, Werkman RF, Familoni BO, et al. Biliary, pancreatic, and sphincter of Oddi electrical and mechanical signals recorded during ERCP. Dig Dis Sci 1998; 43:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/57\">",
"      Aymerich RR, Prakash C, Aliperti G. Sphincter of oddi manometry: is it necessary to measure both biliary and pancreatic sphincter pressures? Gastrointest Endosc 2000; 52:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/58\">",
"      Guelrud M, Mendoza S, Rossiter G, Villegas MI. Sphincter of Oddi manometry in healthy volunteers. Dig Dis Sci 1990; 35:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/59\">",
"      Smithline A, Hawes R, Lehman G. Sphincter of Oddi manometry: interobserver variability. Gastrointest Endosc 1993; 39:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/60\">",
"      Maldonado ME, Brady PG, Mamel JJ, Robinson B. Incidence of pancreatitis in patients undergoing sphincter of Oddi manometry (SOM). Am J Gastroenterol 1999; 94:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/61\">",
"      Tarnasky PR, Palesch YY, Cunningham JT, et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998; 115:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/62\">",
"      Sheehan SJ, Lee JH, Wells CK, Topazian M. Serum amylase, pancreatic stents, and pancreatitis after sphincter of Oddi manometry. Gastrointest Endosc 2005; 62:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/36/12874/abstract/63\">",
"      Singh P, Gurudu SR, Davidoff S, et al. Sphincter of Oddi manometry does not predispose to post-ERCP acute pancreatitis. Gastrointest Endosc 2004; 59:499.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5654 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12874=[""].join("\n");
var outline_f12_36_12874=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63642734\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16563228\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16563417\">",
"      Epidemiology of biliary SOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16563424\">",
"      Epidemiology of pancreatic SOD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations of biliary SOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations of pancreatic SOD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16563928\">",
"      CLINICAL CRITERIA AND CLASSIFICATION SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51500670\">",
"      Rome III criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16563965\">",
"      - Functional gallbladder disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16563972\">",
"      - Functional biliary sphincter of Oddi disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16563979\">",
"      - Functional pancreatic sphincter of Oddi disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16565707\">",
"      Classification systems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H51500108\">",
"      - Classification of biliary SOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16565729\">",
"      Milwaukee Biliary Group classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16565736\">",
"      Rome III revision of the Milwaukee classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H51500136\">",
"      - Classification of pancreatic SOD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51500858\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnosis of biliary SOD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63641987\">",
"      - Type I SOD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63642032\">",
"      - Type II SOD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63642039\">",
"      - Type III SOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51500222\">",
"      Diagnosis of pancreatic SOD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51499802\">",
"      SPECIFIC DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51500283\">",
"      Noninvasive tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Transabdominal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Biliary provocation tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63642869\">",
"      - Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Hepatobiliary scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Correlation of noninvasive tests with sphincter of Oddi manometry for biliary SOD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Pancreatic provocation tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51500319\">",
"      Invasive tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Sphincter of Oddi manometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Evaluation of suspected biliary SOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Evaluation of suspected pancreatic SOD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5654\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5654|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?40/11/41150\" title=\"algorithm 1\">",
"      Sphincter of Oddi algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5654|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/17/27924\" title=\"figure 1\">",
"      Sphincter of Oddi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/63/39921\" title=\"figure 2A\">",
"      CBD and PD pressures manometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/63/43007\" title=\"figure 2B\">",
"      SO phasic waves manometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/57/18320\" title=\"figure 3A\">",
"      Elevated PD pressure manometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/8/24717\" title=\"figure 3B\">",
"      PD pressure gradient manometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5654|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/44/24257\" title=\"picture 1\">",
"      Endoscopic view of the papilla of Vater",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5654|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/47/763\" title=\"table 1\">",
"      Abnormal pressure SOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/50/7979\" title=\"table 2\">",
"      Sensitivity specificity PPV NPV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5654|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?19/19/19761\" title=\"waveform 1\">",
"      CCK sphincter of Oddi manometry",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=related_link\">",
"      Laparoscopic cholecystectomy: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=related_link\">",
"      Post-ERCP pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=related_link\">",
"      Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29126?source=related_link\">",
"      Treatment of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_36_12875="Ann Arbor staging PI";
var content_f12_36_12875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F66845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F66845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ann Arbor staging classification for Hodgkin and non-Hodgkin lymphomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       Stage I",
"      </td>",
"      <td>",
"       Involvement of a single lymph node region (stage I)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       Stage II",
"      </td>",
"      <td>",
"       Involvement of two or more lymph node regions or lymphatic structures on the same side of the diaphragm alone (stage II)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       Stage III",
"      </td>",
"      <td>",
"       Involvement of lymph node regions on both sides of the diaphragm (stage III)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       Stage IV",
"      </td>",
"      <td>",
"       Involvement of one or more organs or tissues outside the lymphatic system, with or without involvement of nearby lymph nodes",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The letters A and B are used to indicate if certain symptoms occurred in the six months before diagnosis. A person is said to have \"B symptoms\" if he or she had: unexplained fever (higher than 100.4 F or 38 C), night sweats, or unexplained weight loss during the six months prior to diagnosis. For example a person with stage II disease who had B symptoms has stage IIB disease.",
"    <br>",
"     In contrast, a person without B symptoms has stage IIA disease.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Adapted from: Carbone, PP, et al, Cancer Res 1971; 31:1860 and Lister, TA, et al, J Clin Oncol 1989; 7:1630.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12875=[""].join("\n");
var outline_f12_36_12875=null;
var title_f12_36_12876="Causes anovulation oligoovulati";
var content_f12_36_12876=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of anovulation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Primary hypothalamic-pituitary dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kallman's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic hypogonadotropic hypogonadism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumors, trauma, or radiation of the hypothalamic or pituitary area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sheehan's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Empty sella syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pituitary adenoma or other pituitary tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphocytic hypophysitis (autoimmune diseases)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactational amenorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eating disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intense exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immaturity at onset of menarche or perimenopausal decline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polycystic ovary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthyroidism or hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hormone producing tumors (adrenal, ovarian)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic liver or renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cushing's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital adrenal hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Premature ovarian failure, which may be autoimmune, genetic, surgical idiopathic, or related to drugs or radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Turner syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Androgen insensitivity syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progestins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antidepressant and antipsychotic drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corticosteroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemotherapeutic agents",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12876=[""].join("\n");
var outline_f12_36_12876=null;
var title_f12_36_12877="Circadian lung function asthma";
var content_f12_36_12877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circadian lung function in asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 260px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Circadian alterations in lung function (as assessed by peak expiratory flow rate or FEV1) in normal subjects and asthmatics. The nadir occurs at approximately 4 AM in both groups, but the amplitude of the peak-to-trough swings is much larger in asthma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hetzel, MR, Clark, TJ, Thorax 1980; 35:732.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12877=[""].join("\n");
var outline_f12_36_12877=null;
var title_f12_36_12878="External rotation exercise for frozen shoulder";
var content_f12_36_12878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    External rotation exercise for frozen shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 235px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To stretch the anterior portion of the shoulder capsule, the patient stands in a door frame with their elbow bent at approximately 90 degrees and the inside of their distal forearm resting against the frame, and then externally rotates the shoulder by turning their body away from the forearm. The forearm is kept in place by the door frame.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tore Prestgaard, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12878=[""].join("\n");
var outline_f12_36_12878=null;
var title_f12_36_12879="RNS study MG";
var content_f12_36_12879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F75502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F75502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repetitive nerve stimulation (RNS) study in myasthenia gravis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 141px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Successive compound motor action potentials (CMAPs) from the abductor pollicis brevis muscle are displayed after six stimuli at 3 Hertz. A decremental response (ie, a decline in the response amplitude) is seen. It is maximal at 38 percent by the fourth response in this example. Sensitivity: 5 mV/div; Sweep speed: 5 msec/div.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_36_12879=[""].join("\n");
var outline_f12_36_12879=null;
